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Abstract 
Cancer a global epidemic is a major cause of morbidity and mortality affecting 
populations in all nations and regions. Breast cancer (BC) is the second most 
common cancer in the world and the most fatal malignancy affecting women both 
in the developed and developing countries. Even with the improvement in overall 
survival of BC patients due to early detection and advancement with systematic 
therapy, triple negative breast cancer (TNBC), an aggressive subtype of BC still 
remains a major challenge as it lacks targetable receptors. Chemotherapy is the 
main treatment for TNBC. However, de novo and acquired resistance to 
conventional anticancer drugs is a major limitation and cause of therapeutic 
failure.  
Cancer stem cells (CSCs) are believed to be responsible for chemoresistance 
and tumour relapse. My study demonstrates that hypoxia is involved in the 
development and maintenance of these CSCs traits in TNBC, as cells grown in 
hypoxia are significantly resistant to several first line anti-BC drugs. Hypoxia-
induced activation of nuclear factor kappa B (NFB) and hypoxia inducible factors 
(HIFs) also play pivotal roles in chemoresistance. Forced expression of NFB 
and HIFs by transfection with p65 subunits of NFB and HIF1α and 2α subunits 
induced CSCs characters and resistance to a range of anticancer drugs in TNBC 
cell lines. My study also indicated a positive loop between the activation of NFB 
and HIFs. Therefore development of novel medicine to interfere the pathways of 
hypoxia and NFB may efficaciously target CSCs and reverse chemoresistance 
which will be of clinical significance for TNBC treatment. 
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Disulfiram (DS) is a commercially available anti-alcoholism drug. Recent studies 
demonstrate that it is highly cytotoxic in a wide range of cancer types and 
potentially repurposed as an anticancer drug. The anticancer mechanisms of DS 
were investigated in this study. The results from my study indicate that the 
cytotoxicity of DS is copper (Cu) dependent with a biphasic manner. The instant 
cytotoxic phase is induced by the extracellular reactive oxygen species (ROS) 
generated by the reaction between DS and Cu. The delayed killing is caused by 
the complex diethyldithiocarbamate (DDC) and Cu (DDC-Cu), the final product of 
the reaction. The cytotoxicity of both phases needs the intact DS. However, due 
to the extremely short half-life of DS in the bloodstream, the anticancer efficacy 
of DS has been severely hampered in vivo and in patients. 
Nanotechnology-based drug delivery system is a rapidly evolving and expanding 
interdisciplinary field involving in an amalgamation of chemistry, engineering, 
biology and medicine. In the last part of my study, I have successfully 
encapsulated DS into polymeric micelle (PM) nanoparticles. The half-life of PM 
encapsulated DS (PM-DS) was extended to over 3 hours in horse serum. The 
PM-DS showed strong anticancer efficacy. Therefore this nano-enabled DS may 
be able to translate DS into cancer therapeutics in the future. 
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Chapter One 
1.0. Introduction 
1.1 . Brief background on Breast cancer   
Cancers, one of the leading causes of death worldwide, comes in many 
different types and forms in which uncontrolled cell growth can spread to other 
parts of the body. It is rapidly becoming a global pandemic with cancer-related 
death exceeding death caused by stroke and coronary heart diseases (Ferlay 
et al., 2014). It was predicted that the global cancer burden is anticipated to 
increase to 23.6 million cases and 13 million deaths by 2030 (IARC- World 
cancer report, 2014). The most frequently diagnosed carcinomas worldwide 
are lung, female breast cancer, colorectal and stomach cancers representing 
about 40% of cancer cases.  
Breast cancer (BC) is a heterogeneous malignant disease consisting of a 
cluster of breast diseases affecting the same anatomical organ and arising 
from the same anatomical structure; deferring in risk factors, clinical 
manifestations, histopathologies, genetic and genomic variations, therapeutic 
and clinical outcomes (Weigelt and Reis-Filho, 2009). BC is the second most 
common cancer in the world and the most fatal malignancy affecting women 
both in the developed and developing world. It is a major culprit associated 
with cancer-related deaths occurring in women worldwide (Kamangar, 2006).  
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1.2. Classification and Staging of breast cancer 
Breast cancer (BC) is not a single disease but represents a heterogeneous 
group of tumours with diverse morphologic and biological features, behaviour 
and responses to treatment (Weigelt and Reis-Filho, 2009). The treatment 
decisions of Breast cancer patients depend on variables such as the site of 
the primary tumour, the size and number of tumours, cell type and tumour 
characteristics and grade. BC Staging is based on the size of the tumour, 
nature of the tumour (invasive or non-invasive) and lymph node involvement 
(Sobin et al., 2009; Elston and Ellis 1993) (Table 1.1). 
BC can be histopathologically divided into invasive and non-invasive cancers. 
Invasive cancer is further subdivided into invasive ductal carcinoma (80%) 
arising from the breast ducts, invasive lobular carcinoma (10%) arising from 
the breast lobules and an inflammatory breast cancer (incidence 1-3%) an 
uncommon form of invasive breast cancer which has poorer prognosis. Using 
gene expression profiling BC is divided into three biological types according to 
the expression status of oestrogen receptor (ER), progesterone receptor  (PR) 
and human epidermal growth factor receptor -2 status (HER2) (Moulder et al., 
2008). BC can be also divided into luminal A (ER+ and/or PR+, HER2-, low 
Ki67), luminal B (ER+ and/or PR+, HER2+), HER2-enriched (ER-, PR2-, 
HER2+), and basal-like (ER-, PR-, and HER2-) BCs (Perou et al., 2000; Sorlie 
et al., 2003) (Table 1.2). 
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Table 1.1: Staging of Breast Cancer (Cancer Research UK, 2012) 
Stage Staging criteria 
 
Stage IA Tumour is 2cm or less and has not spread outside the breast 
Stage IB Tumour is 2cm or less and a few cancer cells in nearby lymph nodes 
Stage 2A  no tumour can be found in the breast, but cancer (larger than 2 mm) is found in 1 to 3 axillary lymph nodes or in the lymph nodes near the 
breast bone (found during a sentinel node biopsy) or 
 the tumour measures 2 cm or smaller and has spread to the axillary lymph nodes or 
 the tumour is larger than 2 cm but not larger than 5 cm and has not spread to the axillary lymph nodes 
   
Stage 2B  the tumour is larger than 2 cm but no larger than 5 cm; small groups of breast cancer cells -- larger than 0.2 mm but not larger than 2 mm -- 
are found in the lymph nodes OR 
 the tumour is larger than 2 cm but no larger than 5 cm; cancer has spread to 1 to 3 axillary lymph nodes or to lymph nodes near the 
breastbone (found during a sentinel node biopsy) OR 
 the tumour is larger than 5 cm but has not spread to the axillary lymph nodes 
 
Stage 3A  the tumour may be any size and has spread to the chest wall and/or skin of the breast and caused swelling or an ulcer AND may have 
spread to up to 9 axillary lymph nodes OR 
 may have spread to lymph nodes near the breastbone 
 
Stage 3B  the tumour may be any size and has spread to the chest wall and/or skin of the breast and caused swelling or an ulcer AND may have 
spread to up to 9 axillary lymph nodes OR 
 may have spread to lymph nodes near the breastbone 
 
Stage 3C  there may be no sign of cancer in the breast or, if there is a tumour, it may be any size and may have spread to the chest wall and/or the 
skin of the breast AND 
 the cancer has spread to 10 or more axillary lymph nodes OR 
 the cancer has spread to lymph nodes above or below the collarbone OR 
 the cancer has spread to axillary lymph nodes or to lymph nodes near the breastbone 
  
Stage 4 The tumour can be any size and has spread (metastasized) to other parts of the body such as the brain, bone, liver or lungs. 
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Table1.2: Commonly Recognized Molecular Subtypes of Breast 
Carcinoma (Schnitt, 2010; Tang, et al., 2009; Sorlie, et al., 2003) 
Molecular 
Subtype 
Representative 
Gene 
Expression 
Signature 
 
Representative 
Immuno 
phenotype 
Associated 
Histologic 
Features 
Associated Clinical Features 
Luminal A ESR1 (estrogen 
receptor 1) 
Estrogen 
receptor– 
associated 
transcription 
factors 
 
ER+ and/or 
PR+, HER2/ 
neu2, low Ki-67 
Usually low 
grade 
Tend to be sensitive to endocrine 
therapy, variable response to 
chemotherapy, overall good 
prognosis 
Luminal B ESR1 
Estrogen 
receptor– 
associated 
transcription 
factors 
 
ER+ and/or 
PR+, HER2/ 
neu+ 
Usually 
higher grade 
than 
luminal A 
subtype 
Tend to be sensitive to endocrine 
therapy, variable response to 
chemotherapy, prognosis 
poorer than that of luminal A 
subtype 
Basal-like KRT5 (keratin 5) 
KRT17 (keratin 
17) 
LAMC2 (laminin, 
g 2) 
 
ER2-, PR2-, 
HER2/neu2, 
CK 5/6+, and/or 
EGFR+ 
Often high 
grade 
 
Tend to be insensitive to 
endocrine therapy, variable 
response to chemotherapy, 
overall poor prognosis  
HER2/neu 
Enriched 
ERBB2 
(HER2/neu) 
ERBB2 
amplicon 
ER2-, PR2-, 
HER2/neu+ 
Often high 
grade 
Tend to respond to biologic 
therapy (trastuzumab), variable 
response to chemotherapy, 
overall poor prognosis 
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1.3. Triple Negative Breast Cancer 
Triple-negative breast cancer (TNBC) is defined as invasive carcinoma of the 
breast that does not express the genes for oestrogen receptor, progesterone 
receptor and Her2/neu (Sorlie et al., 2003; Lehmann et al., 2010). TNBC and 
basal-like breast cancer (BLBC) have significant similar characteristics; 
however these breast cancer subtypes are not identical (Oakman et al., 2010).   
1.3.1. Epidemiology and prevalence of triple negative breast cancer  
TNBC is diagnosed in approximately 15-20% of all breast cancer cases 
encountered and is usually of the invasive ductal carcinoma subtype (Carey 
et al., 2006). Globally, approximately 170,000 cases of TNBC (ER–/PR–
/HER2–) phenotype is detected in the estimated 1 million breast cancer 
incidences identified annually (Anders and Carey  2009).  The incidence and 
prevalence of TNBC also vary with race. African American and Hispanic 
premenopausal women have the highest incidence rate of TNBC (Carey et al., 
2006). Asian women have a TNBC prevalence of about 12% to 19% (Tsang 
et al., 2009), Hispanic women about 24% while black women have the highest 
prevalence of TNBC ranging from 26% in all ages which are elevated to about 
39% in premenopausal black females (Carey et al., 2006). Apart from 
premenopausal status and African ancestry, other associated risk factors 
linked with the development of TNBC include early menarche, higher parity, 
younger age at ﬁrst term birth, not breastfeeding, intake of pharmacological 
lactation suppression, and increased waist-to-hip ratio (Dolle et al., 2009).  
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1.3.2. Clinical and Pathological features of TNBC 
TNBC have been shown to present as an interval cancer in which detection 
occurs more frequently through clinical examination rather than with a 
mammogram or an ultrasound (Dent et al., 2007), which is suggestive of rapid 
growth and tissue density similar to that of normal tissue. Common clinical and 
pathologic features of TNBC are summarized in Table 1.3. 
Table 1.3: Clinical and Pathologic features in TNBC 
Prevalent in premenopausal African and Hispanic women Azim et al., 2012 
BRCA 1 mutations present Oakman et. al., 2010 
High grade invasive tumours Dent et al., 2007; Cheang et al., 2008 
High risk of early recurrence  Dent et al., 2007 
Rapid progression from the onset of metastasis to death Kim et al., 2006 
High prevalence of brain and lung metastasis Dent et al., 2007 
Chemoresistant tumours Liedtke et al., 2008 
High expression of Ki-67, Vimentin and p53 Han et. al., 2008 
Loss of PTEN  Hu et. al., 2009 
Copy number alteration and amplified NFkB expression Hu et. al., 2009 
Expression of epidermal growth factor receptor Collins et. al., 2009 
 
1.3.3. Classification of TNBC 
TNBC can be classified into two (2) major intrinsic subtypes 
 The basal-like subtype 
 
 
7 
 
 The claudin-low subtype 
However, the basal-like subtype constitutes the majority of TNBC incidence as 
it represents about 50-70% of TNBC encountered (Prat and Perou, 2011). The 
basal-like triple-negative breast cancer subtypes also have increased rates of 
p53 mutations (Sorlie, 2003). The claudin-low subtypes of TNBC are typically 
comprised of high grade invasive ductal carcinomas often having amplified 
frequency of metaplastic and medullary diﬀerentiation properties. The claudin-
low subtypes of TNBC have lower expression of proliferation-related genes, 
such as Ki67 (Prat et al., 2010) but are greatly enriched in mesenchymal 
features (ZEB1, twist, and snail) and stem cell-like biological processes 
epithelial–mesenchymal transition (EMT) (Prat and Perou, 2011; Prat et. al., 
2010) when compared to the basal-like subtypes. The claudin-low tumours 
lack cell-cell junction protein E-cadherin and are known to have intense 
immune cell infiltrations. The report by Prat et al., 2010 demonstrated that 
there was no difference in the survival rates between the basal-like and 
claudin-low subtypes of TNBCs however, the pathologic complete response 
(pCR) rates of the claudin-low subtype of TNBC was observed to be lower 
after preoperative anthracycline/ taxane-based chemotherapy in a cohort of 
133 patients. There is also the existence of other TNBC subtypes such as the 
mesenchymal-related, proliferation-related and immune-related subsets 
(Lehmann et al., 2010). 
1.3.4. Prognosis of TNBC 
Triple negative breast cancer (TNBC) patients generally have poorer 
prognosis when compared to other subtypes of breast cancers (Nofech-Mozes 
 
 
8 
 
et al., 2009). During diagnosis, TNBCs are often identified to be of larger 
tumour size, having high mitotic grade and are biologically more aggressive 
with low Bcl-2 but high p53 and Ki67 expressions (Tian et al. 2008). Altogether, 
these factors have been suggested to cause the poorer overall survival (OS), 
breast-cancer-speciﬁc survival (BCSS) and relapse-free survival (RFS) 
observed in patients with TNBC. Patients with TNBC have a greater risk of 
tumour recurrence and are more likely to die of cancer relapse when compared 
to patients with non-TNBC subtypes (Mersin et al., 2008). 
1.4. Treatment for Breast Cancer 
There are several treatment regimens available for breast cancer and the 
choice of treatment is dependent on certain factors such as the type of breast 
cancer, the size of the breast tumour, the stage and grade of the tumour, the 
menstrual status of the patient, expression of certain proteins and endocrine 
receptors and general health of the patient. Five treatment options available in 
clinics include surgical resection, radiotherapy, immunotherapy, molecular 
based therapy (endocrine and biological therapy) and chemotherapy.  
Surgery is usually the first type of treatment for breast cancer that has not 
spread to the axillary lymph nodes. Surgery also provides samples for further 
molecular and histological analysis to confirm diagnosis and may help in 
treatment and prognosis of cancer.  Radiotherapy is the use of high energy x-
ray radiation to kill cancer cells usually given in controlled doses. Hormone 
therapy involves the use of additional hormones to treat breast cancer to 
prevent relapse. Endocrine therapy is not effective against cancers that lack 
hormone receptors such as TNBC.  
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1.4.1. Chemotherapy  
Despite the advancement in early detection of breast cancer, a small 
proportion of women present with metastatic disease at the first time of 
presentation (Early Breast Cancer Trialists’ Collaborative Group, 2005) or are 
prone to develop distant metastasis even though their initial diagnosis was 
non-metastatic breast cancer. Metastatic breast cancer though not curable 
has improved in survival due to the introduction of new chemotherapeutic 
regimen (Gennari et al., 2005; Chia et al., 2007; Dafni et al., 2010). Normal 
cell growth is tightly controlled where cells undergo apoptosis to avert 
excessive growth, however cancer cells have lost this control mechanism and 
thus are usually antiapoptotic in nature. Chemotherapeutic drugs target cancer 
cells via circulation in blood by inhibiting cancer cell proliferation and inducing 
apoptosis in cancer cells.  
Chemotherapy is a treatment that involves the use of a drug or a combination 
of drugs that are cytotoxic to rapidly growing and dividing cells such as cancer 
cells. Rapidly dividing normal cells can also be affected by these cytotoxic 
drugs but are more likely to undergo repair. Anti-cancer drugs work by 
disrupting the growth of cancer cells. Chemotherapy is the standard care for 
patients with node-positive cancer and is of great benefit to patients with 
hormone receptor negative tumours (Goldhirsch et al., 2007).  Chemotherapy 
can be a neoadjuvant therapy given before surgery to shrink the tumour, 
adjuvant therapy given after surgery to prevent cancer spread or relapse or 
given to already relapsed tumour.  The use of chemotherapy is largely based 
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on the age, tumour size or grade, type of receptors and status, lymph node 
involvement and risk of spread of cancer (Howell et. al., 2005).  
Chemotherapy is not recommended for stage I BC except in case with 
unfavourable features or at high risk of recurrence due to the adverse effects 
of chemotherapy drugs. Anthracycline-based regime (doxorubicin and 
epirubicin) are usually the standard chemotherapy drug used for such patients 
(Takeda et. al., 2007). Stage II/III BCs are usually larger and involve spread to 
nearby lymph nodes, chemotherapy is either given before or after surgery to 
decrease the risk of recurrence. Standard chemotherapy treatment followed 
by paclitaxel (PTX) is usually recommended for such patients. In stage IV BC 
where spread is beyond the breast and lymph nodes to other parts of the body, 
patients are treated with a selection of chemotherapeutic drugs including the 
standard epirubicin or gemcitabine (dFdC), PTX or docetaxel, platinum 
agents, cyclophosphamide, vinorelbine, nucleotide analogue and ixabepilone 
(Ross and Cubby, 1994; McArthur and Hudis, 2007). Chemotherapy drugs can 
be classified into several groups based on the chemical structure, mechanism 
of action and interaction with other drugs. They can be grouped into alkylating 
agents, antimetabolites, Taxanes (mitotic inhibitors), antitumour antibiotics, 
monoclonal antibodies, topoisomerase inhibitors platinums and anthracyclines 
(Raina et al., 2007). Most of which can be used to treat advanced breast 
cancer.  
 
 
 
 
11 
 
Table 1.4: Some Commonly used Drugs in BC Chemotherapy (Chorawala, 
et al., 2012). 
Drugs Mechanism of action 
Docetaxel Stabiles polymerization of tubulins and inhibits the disassembly of 
microtubules  
 5-Fluorouracil Interferes with DNA synthesis 
Paclitaxel Stabilize microtubules and inhibition of cells in the anaphase stage 
Cisplatin/Carboplatin Reacts with proteins and nucleic acid, disrupts DNA synthesis by 
forming DNA adducts and cross-links 
Gemcitabine  Incorporates into DNA inducing steric hinderance and inhibits DNA 
synthesis 
Vincristine Binds to tubulin, disrupts mitotic spindle and arrest cell growth 
Doxorubicin Disrupts DNA helical structure, Inhibits DNA and RNA polymerases, 
generates ROS 
Vinorelbine Binds to tubulin, disrupts mitotic spindle and arrest cell growth 
 
1.4.1.1. Cisplatin  
Cisplatin (cis-diamminedichloroplatinum(II)) is a heavy metal complex 
containing a central atom of platinum surrounded by two chloride molecules 
and two ammonia molecules in the cis position (Figure 1.1). It was first 
synthesized by Peyrone in 1844 and its chemical structure elucidated by Alfred 
Werner in 1893. It was until the 1960s when Rosenberg et al., (1965) observed 
that cisplatin was capable of inhibiting cell division in Escherichia coli that it 
gained scientific interest as an anticancer agent. 
 
 
12 
 
    
Figure 1.1 Structure of Cisplatin 
Since its introduction in clinical trials cisplatin has changed the course of 
therapeutic management of several solid malignancies such as testicular, 
ovarian, bladder, head and neck and non-small cell lung cancers. Cisplatin 
predominantly targets the DNA by inducing DNA damage through inhibition of 
DNA synthesis, suppression of RNA transcription and induction of apoptosis. 
The cytotoxic effects of cisplatin occur after cisplatin undergoes hydrolysis 
within the cell producing a highly reactive platinum complex 
[Pt(NH3)2ClH2O]+ which combines with DNA forming adducts and DNA 
cross-linkages (DNA intra-strand and inter-strand links) which unwind the DNA 
helix and interferes with cell division and replication and triggers apoptosis if 
repair mechanisms are unsuccessful (Gonzalez et al., 2001; Fuertes et al., 
2002). Cisplatin is not routinely used in breast cancer treatment but can be 
used in TNBC especially BRCA 1 tumours which are particularly susceptible 
to cisplatin (Garbe et al.,2006; Byrski et al.,2009; Hastak et al., 2010; Silver et 
al.,2010). 
One major limitation associated with the use of cisplatin is the development of 
resistance. There are two types of resistance to cisplatin (intrinsic and 
acquired) however the molecular basis involved are not fully elucidated. 
Acquired resistance can develop in patients undergoing chemotherapy or in 
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cell lines after exposure to increasing dose of cisplatin after a high tolerance 
dose is reached. An initial response of up to 70% occurs with ovarian cancer, 
however, this response is not durable where the 5-year patient survival rate is 
only about 15 -20 % and the primary tumour becomes resistant to therapy 
(Ozols, 1991). Similar response also occurs in small cell lung cancer, where 
relapse rate is as high as 95% (Giaccone, 2000). Other analogs of platinum-
containing drugs used in clinic include carboplatin, oxaliplatin, ormaplatin and 
enloplatin. 
1.4.1.2. Gemcitabine  
Gemcitabine (2', 2'-difluoro 2'-deoxycytidine, Gemzar, dFdC) (Figure 1.2) is a 
deoxycytidine analogue with metabolic similarities to cytarabine (Ara-C) but 
differs structurally due to its fluorine substituents on position 2’ of the furanose 
ring. dFdC was synthesized in the 1980s at Lilly Research Laboratories (Eli 
Lilly and Co., Indianpolis, IN) as an antiviral agent because it was observed to 
inhibit DNA and RNA viruses (Bergman et al., 2005) but then developed as an 
anticancer agent because of its in vitro and in vivo antitumoural effects. 
Gemcitabine is a first-line treatment for advanced pancreatic cancers (Burris 
et al., 1997) and used in combination therapy in non-small cell lung cancer,  
ovarian, bladder, breast, and head and neck squamous cell cancers with 
response rates ranging from 13% to 29% (Sandler et al., 2000; Albain et al., 
2004;  Mini et al., 2006). 
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   Figure 1.2: Structure of Gemcitabine. 
dFdC is a prodrug which requires cellular uptake and intracellular 
phosphorylation for its activation. Being hydrophilic in nature, dFdC is 
transported across cell membrane via specialized carriers called human 
nucleoside transporters (hNT) which facilitate its uptake into cells. There are 
two hNTs; concentrative hNT (CNT) which is the sodium dependent and 
equilibrative hNT (ENT) sodium independent (Shah et al., 2007). dFdC has 
affinity for five hNTs, two of which are of the equilibrative type (hENT1 and 
Hent2) and three concentrative type (hCNT1, hCNT2 and hCNT3)(Ritzel et al., 
2001). Once inside the cell dFdC is phosphorylated by deoxycytidine kinase 
(dCK) to gemcitabine monophosphosphate (dFdCMP), which is further 
phosphorylated to active drug metabolites diphosphate (dFdCDP) and 
triphosphate (dFdCTP) by nucleoside monophosphate kinase and nucleoside 
diphosphate kinase respectively (Ueno et al., 2007; Galmarini et al., 2004). 
dFdC can also be phosphorylated by thymidine kinase 2 but has a low 
substrate affinity of only 5% to 10% (Wang et al., 1999).  
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The cytotoxic activity of dFdC is mediated by its phosphorylated derivatives 
which are inhibitors of DNA synthesis. dFdCTP competes with deoxycytidine 
triphosphate (dCTP) as an inhibitor of DNA polymerase (Gandhi and Plunkett,  
1990), once incorporated into the DNA and after the incorporation of one more 
nucleotide, dFdCTP leads to DNA polymerization termination and single 
strand breakage (Ross and Cuddy, 1994). The extra nucleotide is able to 
prevent dFdCTP from being recognized by DNA repair enzymes which induce 
apoptosis. dFdCDP is a potent inhibitor of ribonucleotide reductase and 
indirectly inhibit DNA synthesis by depletion of the deoxyribonucleotide pools 
and prevents the conversion of RNA nucleotides to DNA nucleotides. 
Resistance to dFdC is correlated with CdR kinase levels in tumours, increased 
ribonucleotide reductase expression as well as inhibition of nucleoside 
transporters which prevents influx dFdC into cells. 
1.4.1.3. Doxorubicin 
Doxorubicin (Dox) is a member of the anthracycline drug family isolated from 
a metabolite of Streptomyces peucetius in the 1960s (Woodruff et al., 1960) 
(Fig. 1.3). It is routinely used as treatment in a wide range of solid tumours, 
lymphomas and leukaemia (Kostrzewa-Nowak et al., 2005; Cortes-Funes and 
Coronado, 2007) and is considered as one of the potent therapeutics for breast 
cancer. Dox is a first-line therapy for metastatic breast cancer and has a 
response rate of about 29% to 43% with a median survival time of 2 years 
(Henderson, 1991). 
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Figure 1.3 Structure of Doxorubicin 
The two proposed mechanisms by which Dox carries out its anticancer effects 
are by intercalation to DNA which disrupts topoisomerase-II-mediated DNA 
repair and by the generation of free radicals which damage cellular membrane, 
DNA and proteins (Gewirtz, 1999). Dox is rapidly taken up into the nucleus of 
cells, once inside the cell, it binds with high affinity to DNA by classical 
intercalation between base pairs of the super-coiled double helix which impairs 
topoisomerase II activity resulting in uncoiling of the helix and DNA breakage. 
(Gewirtz, 1999). Topoisomerase II is a DNA superhelix control enzyme that 
controls the supercoiled structure of DNA by making a nick and rejoining the 
two adjacent DNA strands (D’Arpa and Liu,1989). Once its activity is disrupted 
DNA replication and RNA transcription are compromised leading to permanent 
DNA cleavage (D’Arpa and Liu,1989). Dox can also undergo a one-electron 
reduction by oxidoreductases such as mitochondrial NADH dehydrogenase, 
cytoplasmic NAD(P)H dehydogenases, xanthine oxidase and endothelial nitric 
oxide synthase to form a Dox-semiquinone radical, an unstable metabolite 
which can be reoxidized back to Dox by same enzymes and in the process 
releases reactive oxygen species (ROS) which leads to lipid peroxidation, 
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membrane damage, DNA damage, oxidative stress, and triggers apoptotic 
pathways of cell death (Adama et al., 2003). Although a potent antineoplastic 
drug, resistance to Dox is a problem limiting its use. Mechanisms of Dox 
resistance involves transporters such as ATP-Binding Cassette Sub-Family B 
-1 (ABCB1) an ATP-dependent drug efflux pump and ATP-Binding Cassette 
Sub-Family C -1 (ABCC1). 
1.4.1.4. Vincristine  
Vincristine (VCR) is a naturally occurring alkaloid isolated from the leaves  
of the plant Catharanthus roseus also known as Madagascar periwinkle 
(formerly classified as Vinca rosea) (Kufe et al., 2003). This plant was first 
used for the treatment of diabetes and high blood pressure and later used in 
cancer treatment due to its cytotoxic effects (Gidding et al., 1999).  
 
Figure 1.4 Structure of Vincristine. 
VCR is one of the vinca alkaloids used in clinic. VCR is effective against a wide 
spectrum of cancers (Gascoigne and Taylor, 2009) and made up of two multi-
ring structures: vindoline and catherantne (Figure 1.4). The exact mechanisms 
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of action of vincristine is not fully understood, its cytotoxicity is due to 
interactions with tubulin and disruption of microtubule function, particularly of 
microtubules (hollow rigid dynamic structures that play a vital role in cell shape 
and cell movements) comprising the mitotic spindle apparatus which directly 
causes metaphase arrest (Himes, 1991). VCR binds to β-tubulin dimers at the 
vinca domain site located adjacent to the Guanosine-5'-triphosphate (GTP) 
binding site in tubulin forming a paracrystalline aggregate tubulin–drug 
complex which reduces the dimer and causes shrinkage of the microtubules.  
This shrinkage alters the alignment and movement of chromosomes during 
mitosis disrupting spindle fibre generations.  
1.4.1.5. Paclitaxel 
In 1967 Monroe E. Wall and Mansukh C. Wani isolated a mitotic inhibitor from 
the bark of Taxus brevifolia (northwest Pacific Yew Tree) which they called 
taxol. Paclitaxel (PTX) a taxol drug was first isolated from extracts of the bark 
of Taxus Brevifolia the Pacific yew or the English yew and in 1971 was 
discovered to have anti-leukemic effects (Wani et al., 1971). PTX is now a first 
line anticancer drug for several cancers such as ovarian, liver, metastatic 
breast and non-small cell lung carcinomas (Rowinsky et al., 1992; Yen et al., 
2004). PTX obtained from a non-renewable source the bark of Taxus tree was 
not widely used for patients until scientists developed a semisynthetic 
derivative based on the molecular structure of paclitaxel (Figure 1.5).  
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Figure 1.5 Structure of paclitaxel. 
The main cytotoxic mechanism of PTX is its ability to stabilize microtubules 
and inhibition of cells in the anaphase stage. The microtubules are cylindrical 
assembly of tubulin dimers composed of α and β tubulin subunits (Chretien et 
al. 1992). The main function of microtubules is the formation of mitotic spindles 
during cell division. It also maintains cell structure, mobility and cytoplasmic 
movement and is in a state of dynamic equilibrium with the α and β subunits 
arranged in a head to tail pattern. The β-subunit of microtubule has a binding 
site for PTX, binding of PTX to the β-unit of tubulin forms structurally abnormal 
microtubules which do not depolymerize and cells are arrested in the 
anaphase (G2/M) stage and inevitably undergo cell death (Ganguly et al., 
2010).  
1.5. Chemoresistance 
Chemotherapy is one of the main strategies for breast cancer treatment. Even 
with the advancement in treatment and outcome of patients in recent times, 
drug resistance of tumour cells is a major factor limiting the effectiveness of 
chemotherapeutic treatment in most human tumours. There are two 
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categories of drug resistance, e.g. intrinsic (innate) and acquired resistance 
which may be applicable to a single agent or a group of agents with similar 
mechanisms of action (Longley et al., 2005). Intrinsic chemoresistance is the 
de novo resistance of cancer cells prior to the commencement of treatment 
regimen which originates in cells capable of limiting drug uptake by enhanced 
efflux and activation of detoxification of the drugs (Gottesman, 2002). Acquired 
resistance occurs when tumour cells are initially sensitive to anticancer drugs 
but undergo genetic and epigenetic alteration that make them resistant. 
Chemoresistance is a multifactorial process involving numerous interrelated 
and independent mechanisms. Relevant mechanisms that contribute to 
cellular resistance in cancer cells include high expression of defence factors 
reducing intracellular drug concentrations, the involvement of cancer stem 
cells, modifications in drug-target interactions, defects in apoptotic pathways 
and increased cellular ability for DNA repair damage and increase tolerance 
to unfavourable cellular environment (Longley et al., 2005). 
1.5.1. Drug efflux mechanisms 
1.5.1.1. P-glycoprotein 
P-glycoprotein (P-gp) is an active, efflux, membrane bound transport protein 
pump discovered in 1976 (Juliano and Ling, 1976).  P-gp also known as 
multidrug resistance protein 1 (MDR1) is a 170 kDA membrane protein 
encoded by the ATP binding cassette B1 (ABCB1) gene and belongs to the 
ATP binding cassette super family (ABC) transporters. P-gp is a physiological 
barrier protecting susceptible tissues from toxic compounds, preventing entry 
into the cytosol and extruding them to the exterior (Fortuna et al., 2011). P-gp 
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is predominantly found in epithelial cells with excretory function such as the 
apical surface of epithelial cells lining the colon, small intestine, adrenal gland, 
bile ductules, pancreatic ductules and proximal kidney tubules (Melaine et al., 
2002; Edwards et al., 2005). It is also found in the endothelial cells of the blood 
brain barrier (Ma et al., 2010). Many solid tumours overexpress P-gp (Thomas 
and Coley, 2003). The efflux action of P-gp requires an ATP active process, 
where hydrolysis of ATP releases the energy needed for the extrusion 
process. This efflux occurs unidirectionally with the transfer of one molecule 
per time out of the cell to the extracellular space. A second hydrolysis of the 
ADP bound P-gp takes place to the bound ADP from P-gp which then returns 
to its original state. Substrates for P-gp transporter include cationic, 
hydrophobic cytotoxic drugs and amphipathic natural products such as 
taxanes, doxorubicin, paclitaxel, vinca alkaloids, anthracyclines and mitomycin 
C (Krishna and Mayer, 2000). P-gp overexpressed on the surface of cancer 
cells precludes the accumulation of anticancer drugs in the tumour preventing 
them from reaching their intended targets through the efflux pump. There are 
conflicting results on the influence on P-gp on breast cancer therapeutics, 
some studies showed a positive correlation between reduced P-gp 
expressions and improvement in response rate while others did not find such 
relationship (Verrelle et al., 1991; Chevillard et al., 1996). 
1.5.1.2. Multidrug resistance associated protein (MRP) 
Multidrug resistance associated proteins (MRPs) are members of the ATP-
binding cassette (ABC) superfamily of transmembrane transporters found in 
many mammalian tissues. They are 180 to 195 kDa membrane proteins 
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associated with resistance of tumours to anticancer drugs. They primarily 
transport anionic drugs such as methrotrexate and neutral drugs conjugated 
with acidic ligands (glutathione (GSH), glucoronate, or sulphate). 9 MRPs have 
been characterized in human tumours (MRP 1-9). MRPs 1-3 have also been 
found to confer resistance to neutral organic drugs not bound to acidic ligand 
by transporting drugs with free glutathione. MRP 1 is overexpressed in breast 
carcinoma (Zaman et al., 1994) but their clinical relevance is still not fully 
understood.  Anticancer drug resistance to anthracyclines (Doxorubicin), 
antifolates and vinca alkaloids are associated with MRP1 (Zhou et al., 2001). 
The relevance of other members of the MRP family have not been linked to 
breast cancer.  
1.5.1.3. Breast Cancer Resistance Protein (BCRP) 
Breast cancer resistance protein (BCRP) is a 72kDa 655 amino acid peptide 
transporter encoded by the ATP-binding cassette ABCG2 gene with 
similarities to both P-gp and MRP but contain only one transmembrane domain 
and one nucleotide binding domain. BCRP overexpression confers resistance 
to cisplatin, paclitaxel and vinca alkaloids in BC cell lines (Brinkhuis et al., 
1999). 
1.5.2. Drug activation/inactivation mechanisms 
Drug resistance can occur due to decreased drug activation. For instance, the 
antifolate drug methotrexate is first polyglutamated by folypolyglutamate 
synthase to increase cellular retention and elevate substrate binding activity. 
Several studies have noted positive correlation between decrease 
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polyglutamation and antifolate resistance in cell line models (Barnes et al., 
1999; Wang et al., 2003). 
1.5.3. Defects in DNA damage repair 
The anticancer mechanism of many chemotherapeutic agents is by induction 
of DNA damage which leads to cell cycle arrest, DNA damage repair and 
eventually death. Mutation in DNA mismatch repair (MMR) mechanisms has 
been associated with drug resistance. The MMR are important for the 
maintenance of the stability of the genome by scanning newly produced DNA 
to correct replication errors, excising single-base mismatches and inserting 
deletion loops (Fink et al., 1998). Deficiency of MMR gene has been linked to 
resistance to DNA damaging agents. A research by Plumb et al., 2000 
demonstrated that resistance to cisplatin was attributed to hypermethylation of 
the hMLH1 promoter which resulted in defects in the mutation in DNA 
mismatch repair.    .  
1.5.4. Defects in apoptotic mechanisms 
During normal development and maturation cycle, cell death is a relevant 
aspect and a balance between the rate of proliferation and cell death is 
important for maintenance of normal physiological processes (Jacobson et al., 
1997). Apoptosis is a physiological programmed cell death characterized by 
cell shrinkage, blebbing of plasma membrane, condensation and 
fragmentation of the DNA control cell number during development and in 
disease states. Apoptosis is via the extrinsic or intrinsic pathway, the extrinsic 
pathway is a receptor mediated killing while the intrinsic pathway is regulated 
by the mitochondria mediated killing. Impairment of the apoptotic pathway 
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results in chemoresistance. Disruptions in mechanisms such as loss of p53 
function, overexpression of Bcl2 or Bcl-XL and upregulation of epidermal 
growth factor receptor (EGFR) dysregulates the apoptotic pathway 
(Blagosklonny, 2001). 
Table 1.5: Resistance Mechanisms to some Anticancer Drugs 
Drug Efflux mechanism  Anti-cancer drugs 
P-gp overexpression doxorubicin, paclitaxel, docetaxel, 
vinca alkaloids, anthracyclines 
Impair DNA repair mechanisms Cisplatin  
Multidrug resistance associated 
proteins (MRPs) 
Doxorubicin, antifolates and vinca 
alkaloids 
 
1.6. Cancer Stem cells 
Stem cells are a small and distinct population of undifferentiated cells capable 
of differentiating into specialized cells and also divide through mitosis to 
produce more stem cells. Stem cells have major characteristics namely the 
ability for self-renewal and production of progenitor cells which differentiate 
into more mature and specialized cells. Cancer stem cells (CSCs) are defined 
as a rare group of cells within the tumour population capable of self-renewal 
and differentiation to produce diverse cells that drive tumourigenesis (Jordan, 
2004). CSCs are also known as tumour initiating cells or tumourigenic cells. 
Normal stem and cancer stem cells share certain similar characteristics such 
as the ability to self-renew, differentiate to progenitor cells and utilize common 
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pathways (Jordan, 2004). Evidence for the concept of cancer stem cell was 
first documented in haematological malignancies, where a small population of 
cancer cells were able to generate tumours in in vivo mice models after 
transplantation of human acute myeloid leukaemia cells in immunodeficient 
mice (Bonnet and Dick, 1997). In recent years, there has been growing interest 
in the role of stem cells in cancer biology. CSCs have been identified in 
numerous solid tumours such as the breast, brain, colon, liver and pancreatic 
cancers (Li et al., 2007; O’Brien et al., 2007; Prince et al., 2007). CSCs are 
believed to play crucial roles in tumour initiation, relapse, metastasis and 
resistance to therapy (Coker and Allan, 2008). 
1.6.1. Breast cancer stem cells 
Two cell types make up the breast epithelium: the luminal epithelial and the 
myoepithelial cells. Mammary stem cell population are located in the luminal 
but not in the myoepithelial compartment of the breast (Gudjonsson and 
Magnusson, 2005). CSCs in human BC were first identified in 2003 (Al-Hajj 
et al., 2003) when a CD44+/highCD24-/low lineage subpopulation of tumours from 
human patients initiated tumour growth in immunodeficient mice. Injections of 
few cells (100 tumourigenic cells) resulted in palpable tumours within 12 
weeks, serial passaging from these cells gave similar results, while CD 44- 
cells were non-tumourigenic even after injection of 10,000 cells. The exact 
origin of breast CSCs though not clearly identified is suggested to occur from 
accumulation of oncogenic insults on normal breast stem/progenitor cells 
inducing mutations.  
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1.6.2. Cancer stem cell markers 
Cancer stem cells (CSCs) have been isolated from several tumours such as 
the breast, brain, blood (leukemia), skin (melanoma), head and neck, thyroid, 
cervix, lung, organs of the gastrointestinal and reproductive tract (Mimeault et 
al., 2007). Selective markers found on the cell surface can be used for 
detection and identification of CSCs. Specific surface markers used for 
identification of breast CSCs includes CD44, CD24, CD133 and Aldehyde 
Dehydrogenase (ALDH).  
Table 1.6 CSC markers in solid tumours (Medema et al., 2013) 
Breast Glioma Colon Liver Lungs Ovarian Prostate Pancreatic 
ALDH CD15 CD24 CD13 ABCG2 CD24 ALDH ALDH 
CD24 CD90 CD26 CD24 ALDH CD44 CD44 CD24 
CD44 CD133 CD29 CD44 CD90 CD117 CD133 CD44 
CD133 Nestin  CD44 CD90 CD117 CD133 CD166 CD133 
CD90  CD133 CD133 CD133  Trop2 Nestin 
ESA  CD166     ABCG2 
  LGR5     C-met 
  ABCB5      
  ALDH      
Aldehyde Dehydrogenase (ALDH), a family of enzymes involved in the 
oxidation of aldehydes into their corresponding carboxylic acids is a functional 
marker of CSCs (Ginestier et al., 2007). Nineteen isoforms of ALDH have been 
identified in humans, important for physiological and toxicological functions. 
High ALDH activity is seen in normal stem cells particularly the human 
haemopoietic stem cells. Increase in ALDH activity has also been reported in 
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many solid tumours such as breast, lung, pancreas, liver and head and neck 
cancers (Clay et al., 2010; Hellsten et al., 2011).  The role of ALDH in 
chemoresistance was identified by Hilton et al., (1984) in cyclophosphamide-
resistant L1210 leukemic cell line. They observed that in early passage colon 
cancer xenograft tumours more, ESA+, CD44+, ALDH positive cell 
populations survived after exposure to cyclophosphamide. When these 
surviving ESA+, CD44+, ALDH positive cell CSCs were treated with ALDH 
inhibitors, sensitivity to cyclophosphamide was induced (Dylla et al., 2008). 
Aldefluor a BIODIPY flurochrome attached to an aminoacetaldehyde moiety 
(a substrate of ALDH) when cleaved, fluoresces and remains within the cell 
and can therefore be used in the measurement of ALDH activity (Storms et al., 
1999). CSCs in breast, lung, liver, head and neck tumours and in cell lines 
have been identified using Aldefluor (Jiang et al., 2009; Chen et al., 2009). 
CD 44 is an 85 to 90 kDa transmembrane glycoprotein containing 10 standard 
exons. CD44 plays vital role in adhesion, motility, proliferation and cell survival 
(Marhaba and Zoller, 2004; Afify et al., 2008). The exact function of CD44 in 
breast CSCs is not fully understood, it is postulated to be involved in the 
metastasis characteristics of CSCs (Charafe-Jauffret et al., 2009) and play 
protective roles against apoptosis (Bourguignon et al., 2009). 
CD24 is a 30 to 70 kDa glycosylated protein first identified on the surface of 
B-cell. It is expressed in a range of epithelial cancers and is an indicator for 
metastasis. In vitro assay and in vivo studies show that CD24 play important 
roles in the migration and invasion of cancer cells (Lim, 2004; Sano et al., 
2009). CD24- expressing cells show increase growth and cell adhesion by 
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enhanced interactions between integrins and fibronectin proteins. CD24 
expression also represents mesenchymal phenotypes in breast cancer by 
regulation of the chemokine receptor type 4 (CXCR4) response. CSC 
population in breast cancer cells have been well defined by CD44+(high)/CD24-
(low) expression (Al-Hajj et al., 2003). Cells with High ALDH expression in 
combination with CD44+(high)/CD24-(low) expression in primary breast cancer 
xenografts had enhanced ability to induce tumours in immunodeficient  mice 
(Al-Hajj et al., 2003). 
CD133 is a 120kDa glycosylated protein consisting of five transmembrane 
domains with two large extracellular loops, was first discovered in 
haemopoietic stem cell (Miraglia et al., 1997). CD133 positive phenotype was 
used in the identification and isolation of stem cells in brain tumour, it has been 
used to identify CSC populations in other tumours such as breast, liver and 
prostate cancers (Singh et al., 2004). D133+ cells are expressed in tumour-
initiating population of brain cancers as well as in CSC populations of the lung, 
pancreatic, liver, prostate, gastric, colorectal, and head and neck cancers 
(Singh et al., 2004). High CD133 expression in in vivo and in vitro studies 
shows resistance to treatment with cisplatin, etoposide, doxorubicin, and 
paclitaxel (Chen et al., 2008; Zhang et al., 2009). Stemness genes Nestin, 
Olig2, and Nanog are upregulated in CD133+ population in the brain, lung, 
liver, and prostate tumours (Miki et al., 2007; Ma et al., 2008). 
1.6.3. Cancer stem cell in tumorigenesis 
Cancer stem cells (CSCs) have been implicated in the initiation and formation 
of cancer. Carcinogenesis, a multistep process depends on sequential 
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accumulation of mutation within tissue cells over a long period of time. 
However, only a subset of cells is vital for tumour initiation (Reya et al., 2001; 
Al-Hajj and Clarke, 2004). These tumourigenic cells are believed to be the 
driving force in tumour progression and heterogeneity of breast cancer (Pardal 
and Clarke, 2003). CSCs therefore provides the cellular mechanism for 
genetic and epigenetic changes with resultant cancer initiation, progression, 
invasion, and metastasis. 
1.6.4. Cancer stem cell and chemoresistance 
Even with the improvement in Breast cancer (BC) treatment in recent times, 
the relapsed advanced/metastatic breast cancer has very poor prognosis and 
survival rate because it is usually pan-resistant to an ample range of 
anticancer drugs. Understanding the mechanisms of resistance is crucial for 
the development of new therapeutic approaches for BC management. BC 
contains a very small fraction (1%) of CSC population with stem cell characters 
e.g. self-renewal, development into the original tumors in immune deficient 
mice, differentiation into several linages of progenies (Dalerba et al., 2007). 
Evidence show that these CSCs play a vital role in resistance to chemotherapy 
and radiotherapy in several cancers (Phillips et al., 2006; Tang et al., 2007; 
Kakarala and Wicha, 2008). Most anticancer drugs target rapidly proliferative 
cells, CSCs are often quiescent and remain in the G0 phase and are able to 
evade killing by chemotherapeutic agents (Ishikawa et al., 2007). Others 
resistant mechanisms of breast CSCs include the expression of cell surface 
drug pump such as ATP-binding cassette G2/ Breast cancer resistance 
protein1 (ABCG2/BCRP1), which increases the expulsion of 
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chemotherapeutic drugs from cancer cells (Engelmann et al., 2008). The high 
ALDH expression in breast cancer cells metabolizes cytotoxic agents (Moreb, 
2008) and overexpression of antiapoptotic molecules such as BCL2 and 
survivin can prevent cell death (Madjd et al., 2009).  
1.6.5. Cancer stem cell and hypoxia 
Stem cell ‘‘niche’’ is a specialized microenvironment within tumours which 
maintains self-renewal and multi-potency. The stem cell niche contains cellular 
and non-cellular components. The stem cell niche contains a distinct 
population of cells that maintain stemness, these cells are anchored to the 
niche by adhesion molecules which interacts with the extracellular matrix. The 
niche also generates extrinsic factors that regulate that proliferative and 
differentiated rate of cell growth. The cells within the stem niche are in a 
hypoxic state. Both normal stem cell and CSC are quiescent in the niches 
which protect them from chemotherapy. CSCs in the niche have been 
implicated in tumour formation (Simsek et al., 2010). Hypoxia has also been 
implicated in the development and maintenance of CSCs within the niche 
(Panchision, 2009). Hypoxia also triggers cancer stemness genes such as 
(sex determining region Y)-box 2 (Sox2), octamer-binding transcription factor 
4 (Oct4) and Nanog resulting in tumour aggressiveness. The HIF proteins 
regulate the hypoxia-medicated phenotype and functions of CSCs by 
upregulation of HIF targeting genes such as Oct4, Nanog, c-Myc, Notch-1, and 
CD133 (Li and Rich, 2010; Bar et al., 2011). 
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1.7. Hypoxia 
Hypoxia, a reduction of oxygen levels insufficient to meet the metabolic 
requirement is a common feature of solid tumours (Vaupel and Mayer, 2007).  
The physiological oxygen concentration in normal tissue is maintained at 3-
9%, tumours with an oxygen concentration at or below 1% are considered to 
be hypoxic. Tissue hypoxia occurs where there is an imbalance between 
oxygen supply and consumption. Cancer characterized by dysregulation in 
growth pattern with increased cell division and reduced cell death results in 
decreased O2 availability.  Oxygen supply to the respiring neoplastic and 
stromal cells are frequently compromised due to structural abnormalities of the 
tumour microvasculature and disturbed microcirculation (Vaupel et al., 1989). 
Hypoxic areas within tumours are heterogeneously distributed with oxygen 
diffusion being greater in cells closer to the vessels (Vaupel et al., 2004). 
Tumour hypoxic response could be acute, intermediate or chronic. Acute 
response to hypoxia induces disturbances in ionic homeostasis with decrease 
in intracellular adenosine triphosphate/adenosine diphosphate (ATP/ADP) 
ratios causing enhanced K+ efflux and Na+ and Ca2+ influx (Hammarstrom 
and Gage, 2002). To ensure survival and maintenance of oxygen homeostasis 
in tumours during chronic hypoxic conditions, several cellular responses are 
triggered such as metabolic reprogramming, de novo synthesis of new blood 
vessels or the activation of epithelial to mesenchymal transition (EMT) to 
escape the hostile hypoxic environment and metastasis to colonize a different 
environment. Hypoxia (1% or less O2) or anoxia (<0.01% or no detectable O2) 
is a predominant feature in more than 60% of locally advanced solid tumours 
which clinically contributes to high risk of metastasis, tumour recurrence, 
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reduced overall survival rate and high mortality (Harris, 2002; Vaupel et al., 
2004; Sullivan and Graham 2007). 
 
Figure 1.6: HIF pathway in normoxic and hypoxic conditions. Under normoxia 
hypoxia-inducible factor alpha (HIFα) subunits are hydroxylated by propyl 
hydrogenase domain (PHD) enzymes leading to their degradation. In hypoxic 
conditions, HIFα is accumulated and translocated to the nucleus where combines with 
its β subunit inducing transcription of downstream target genes (Ohh et al., 2000). 
1.7.1. Hypoxia-inducible factors (HIFs) 
Neoplastic cells respond to hypoxic microenvironments through the activation 
of hypoxia-inducible factors (HIFs). HIFs are DNA-binding transcription factors 
that respond to changes in oxygen levels specifically during hypoxia. They are 
the key regulator of hypoxia-inducible genes implicated in many different 
cellular functions such as cell survival, cell proliferation, apoptosis, glucose 
metabolism, and angiogenesis. HIF is a heterodimer consisting of an oxygen-
labile α-subunit (HIFα) closely regulated by PHDs (prolyl-hydroxylases) and a 
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constitutively expressed β-subunit (HIFβ or ARNT) (Gordan et al., 2008). 
Three HIF alphas isoforms (HIF1α, HIF2α and HIF3α) have been identified in 
humans with HIF1α been the most established of the HIF family. HIF1α protein 
levels are low in normoxic conditions, HIF1α is hydroxylated by an oxygen 
sensitive prolyl-hydroxylase (PDH) in one or both conserved proline residue 
sites: a carboxyl terminal (CODDD) and amino terminal oxygen-dependent 
degradation domains (NODDD) (Ivan et al., 2001). The hydroxyl-HIF1α 
complex binds to the β-domain of von Hippel-Lindau tumour suppressor 
protein (pVHL) and is subsequently ubiquitylated by the breast 
cancer/Cul2/pVHL ubiquitin–ligase complex assembled via the pVHLα 
domain, where it is then degraded by 26S proteasomes (Ohh et al., 2000). 
Under hypoxia, HIF1α is stabilized and accumulates, it is then translocated to 
the nucleus, binds to HIFβ and the co-activators p300/CBP to induce gene 
expression by binding to the conserved [A/G]CGTG hypoxia-responsive 
element (HRE) (Semenza, 2010) including PHD2 (Metzen et al., 2005) and 
PHD3 (Pescador et al., 2005). 
HIF2α is structurally similar to HIF1α and is also rapidly induced by hypoxia. It 
is a heterodimer composed of HIF2α and HIF2β subunits. Expression of HIF2α 
is cell-type specific and expressed in endothelial cells particularly important in 
renal cancer and vascular system (Bertout et al., 2008). HIF2α share 
numerous transcriptional targets with HIF1α such as vascular endothelial 
growth factor (VEGF), Tie-1, Tie-2, Ang-2 and Flt-1 (Raval et al., 2005; Carroll 
and Ashcroft, 2006). HIF2α has recently been found to play vital roles in 
tumourigenesis and maintaining CSC phenotype in certain cancers. 
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Not much is known about the biology and function of HIF3α. Several splice 
variants of HIF3α has been identified (Maynard et al., 2003). A non-functional 
complex is formed when pro-apoptotic activity Per/Arnt/Sim domain proteins 
bind to HIF1α in the nucleus thus disrupting the expression of HIF1 target 
genes under hypoxia (Makino et al., 2001).   
1.7.2. HIF and cancer 
Solid tumour has areas of limited oxygen availability due to structural and 
functional abnormalities in newly formed vessels resulting in poor perfusion. 
Hypoxia-inducible factors (HIFs) proteins are overexpressed in several solid 
tumours (Talks et al., 2000). Tumour hypoxia is a common feature of many 
cancers and essentially occurs when the growth of the tumour outstrips the 
accompanying angiogenesis. The HIF proteins are activated by hypoxia which 
upregulates expression of proteins that promote angiogenesis, anaerobic 
metabolism, and antiapoptotic cell proliferation survival pathways. Many 
tumours including BC have high expression of HIF proteins which has been 
associated with poorer prognosis due to the aggressive, invasive and resistant 
phenotype of such cancer (Talks et al., 2000). 
1.8. Nuclear Factor kappa B (NFB) 
NFB comprises a family of structure-related transcription factors that regulate 
a large number of normal cellular processes such as the immune and 
inflammatory responses, developmental processes, cellular growth and 
apoptosis. It is persistently activated in several disease states such as cancer, 
arthritis, chronic inflammation, asthma, neurodegenerative and heart 
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diseases. NFB was first discovered in the nucleus of activated B cells as 
having a DNA-binding activity with strong affinity for the transcriptional 
enhancer of kappa (light-chain gene of immunoglobulin (Sen and Baltimore, 
1986). NFB is ubiquitously expressed in almost all cell types and tissues and 
is a stimulus-responsive pleiotropic regulator of gene control which regulates 
several genes that have NFB binding sites in their promoters or enhancer 
regions (Oeckinghaus et al., 2009) thus is important in several physiological 
and biological processes.  
1.8.1. NFB Family members 
The NFB family consists of five closely related transcription proteins namely 
RelA (p65), RelB, c-Rel, NFB1 (p50/p105), and NFB2 (p52/p100) which 
share a 300 amino acid N-terminal DNA binding domain called the Rel 
homology domain (RHD) (Moynagh, 2005; Hoffmann et al., 2006). The RHD 
is the basis by which NFB family members can form homodimers and 
heterodimers allowing them to bind to promoters and enhancer gene regions 
which control their expression. The C-terminal transcriptional domain (TADs) 
located in RelA, cRel and RelB activates target gene expression while p50 and 
p52 lack C-terminal TADs and are suppressed unless they are bound to 
proteins containing TADs. NFB proteins are not produced de novo but are 
activated by signals that trigger Nuclear factor NF-kappa B inhibitor kinase 
(IKK) which cause the kappa light polypeptide gene (I- of nuclear factor to 
undergo phosphorylation which degrades and releases NFB from its dimer 
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form which then translocated to the nucleus to activate target genes (Liang et 
al., 2004). The nuclear–cytoplasmic localization of NFB is tightly controlled. 
 
Figure 1.7. Members of the Rel/NFB and IB families of proteins. 
The red boxes indicate the endoproteolytic cleavage sites of p105 and p100 which give 
rise to p50 and p52, respectively. Purple boxes indicate the PEST domains (polypeptide 
sequences enriched in proline, glutamic acid, serine, and threonine). Abbreviations: RHD, 
Rel homology domain; ANK, ankyrin repeat; SS, signal-induced phosphorylation sites. N, 
nuclear localization sequence. 
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1.8.2. Activation of NFB Pathways 
NFB is usually bound to its co-repressor molecule Iin the cytosol in normal 
resting conditions. Degradation of Iproteinoccurs through specific 
phosphorylation mediated by Ikinase (IKK) (Ghosh and Karin, 2002). The 
IKK complex plays vital roles in upstream NFB signal transduction cascade. 
Ikinase (IKK) enzyme complex comprises of two catalytic kinase subunits 
I(IKK1) and or Iβ (IKK1)  and a nonenzymatic regulatory scaffold 
protein NFB essential modulator (I Two primary signalling pathways 
(Figure 1.8) are involved in the activation of NFB namely the classical 
(canonical) and the alternative (non-canonical) pathways (Tergaonkar, 2006; 
Scheidereit, 2006). The canonical pathway activates NFB dimers RelA, c-
Rel, RelB and p50 while the noncanonical pathway activates p100/RelB 
complexes. The classical NFB pathway is triggered when cells are stimulated 
by TNFα, T-cell receptors (TCR), B-cell receptors (BCR), Toll-like receptor 
(TLR) or interleukin-1 receptors (IL-1R) (Karin and Ben-Neriah, 2000). Iβis 
important for the phosphorylation of I at Ser32 and Ser36. Phosphorylation 
of IκBα triggers rapid polyubiquitination at Lys21 and Lys22 sites of IκBα and 
stimulates subsequent degradation of this cytoplasmic inhibitor by 26S 
proteasome complex, that liberates NFB (RelA/p50) and unveils the nuclear 
localization signal present on RelA promoting the nuclear translocation of 
NFB dimers to the nucleus (Karin and Ben-Neriah, 2000). The alternative 
pathway is largely dependent on IKKα subunits and is responsible for the 
activation of p100/RelB complexes. Signals from NFB inducers such 
lymphotoxin B and B cell activating factor (BAFF) initiate the activation of 
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NFB inducing kinase (NIK), which phosphorylates and activates the IKKα 
complex that in turn phosphorylates p100 by 26S proteasome liberating 
p52/RelB active heterodimer. This generates RelB/p52 heterodimers that are 
translocated into the nucleus as transcription factors (Bonizzi et al., 2004).  
 
Figure 1.8: Classical and alterative pathway of NFB activation. The classical 
pathway is mediated by IKKβ leading to the phosphorylation of IB. Activators of classical 
pathway include TNFR1/2, TCR and BCR and TLR/IL-1R. The alterative pathway involves 
NIK activation of IKKα and leads to the phosphorylation p100 liberating of p52/RelB 
heterodimer (Abbreviations NEMO: Nuclear factor kappa B essential modulator, NIK: 
Nuclear factor kappa B inducing Kinase, TNFR:, TCR:, IKKβ: IκB kinase, IB: Inhibitors 
of NFB) (Scheidereit, 2006). 
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1.8.3. NFB and Breast Cancer 
Breast cancer (BC) is affiliated with dysregulated expression of growth factors, 
kinases and transcription factors. NFB activation is strongly associated with 
oncogenesis, its activation induces proliferation, inflammation, cell invasion 
and suppression of apoptosis (Basseres and Baldwin, 2006; Karin, 2006). 
Several reports have shown that NFB is activated in human breast cancer 
cell lines as well as in primary breast tumours (Cogswell et al., 2000; Nakshatri 
and Goulet, 2002; Biswas et al., 2004). NFB is an upstream regulator of many 
cellular signalling pathways involved in BC promotion, Its activation up-
regulates antiapoptotic genes in BC cells resulting in cell survival mechanisms 
and resistance to therapeutic regimens. Constitutive activation of NFB in BC 
cells occurs through abnormal signalling of the epidermal growth factor 
receptor, cytokines (interleukin-1) or the heregulin pathways (Bhat-Nakshatri 
et al., 2002). Mechanisms involved in NFB activation in mammary tumours is 
not  fully understood, cyclin D1 a regulator of the cell cycle is activated by 
NFB gene. Cyclin D1 promoter has an NFB binding site, and experiments 
done on mice models reported that overexpression of cyclin D1 in the 
mammary gland of mice increased the incidence of mammary carcinoma and 
knock out of the cyclin D1 gene protected development of BC by the induction 
of mouse mammary tumour virus MMTV-neu or MMTV-v-Ha-ras (Wang et al., 
1994; Yu et al., 2001). The basal-like subtype, a subgroup of TNBC, exhibits 
high levels of constitutively active NFκB signalling. There is a cross-link 
between NFB and the oestrogen receptor pathway, according to the reports 
by Biswas and colleagues NFB activation is predominantly in oestrogen 
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receptor-negative breast tumours, thus TNBC patients have poorer prognosis 
(Biswas et al., 2000). 
1.8.4. NFB and Chemoresistance  
NFB a ubiquitous transcription factor represents a class of dimeric proteins 
regulating over 400 genes involved in immunoregulation, growth regulation, 
inflammation, carcinogenesis, apoptosis and cell survival pathway. Activation 
of the NFB pathway protects tumour cells from apoptosis through the 
expression of antiapoptotic proteins as well as the suppression of proapoptotic 
protein expression in many tumours (Kato et al., 2003; Panta et al., 2004). 
Several studies have reported that NFB plays vital role in preventing 
apoptosis induced by radiation and chemotherapeutic agents. Most solid 
tumours including BC have high expression of NFB which can be further 
increased by exposure to cytotoxic agents resulting in cell growth, survival and 
resistance to therapeutic agents (Karin et al., 2002; Arlt et al., 2003).  
Chemotherapeutic agents result in NFB-induced expression of antiapoptotic 
genes such as IAP, IEX-1L, FLICE, cFLIP, Bcl-XL, Bfl-1, TNF receptor (TNFR) 
associated factor TRAF1 and TRAF2. IAPs (c-IAP1, c-IAP2, and XIAP) inhibits 
caspases which suppress the extrinsic and intrinsic apoptotic pathways. Anti-
apoptotic members of the Bcl-2 family (Bcl-XL, A1) prevents the release of 
cytochrome-c and inhibit caspase-9 activity (Wu et al., 1998; Wang et al., 
1998). Genes for tumour growth and survival, including cyclin D1 and c-Myc, 
are also regulated by NFB and contribute to the chemoresistance. 
Furthermore, multidrug resistance genes such as multidrug resistance 
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associated protein, P-gp, and breast cancer resistance protein have NFB 
binding sites within their promoter regions (Bentires-Alj et al., 2003), therefore 
activation of NFB induces these resistance gene. Thus regulation of the 
NFB signalling pathway could be a potent target for improving the 
chemosensitivity of tumour cells. Down regulation of constitutive activation of 
NFB by curcumin sensitize human multiple myeloma cells to vincristine and 
melpahan (Bharti et al., 2003). Triptolide a potent inhibitor of NFB also 
enhance the chemosensitivity to doxorubicin (Yinjun et al., 2005).  
1.8.5. NFB and hypoxia 
Hypoxia, a decrease in O2 availability triggers several cellular and molecular 
responses required for adaptation of cells to the low oxygen conditions. 
Activation of a number of genes occurs during hypoxia, such as the hypoxia-
inducible factor (HIF), an oxygen dependent transcription factor responsible 
for the upregulation of genes involved in different cellular functions such as 
cell survival, cell proliferation, apoptosis, glucose metabolism and 
angiogenesis (Semenza, 2009).  
NFB is another important transcription factor activated during hypoxia. It 
consists of a 5 membered family of proteins namely (RelA (p65), RelB, c-Rel, 
NFB1 (p50/p105), and NFB2 (p52/p100). Studies have demonstrated that a 
cross-talk exists between NFB and HIF signalling pathways (Figure 1.9). 
Human HIF1α promoter has a NFB binding site at -197/-188 base pairs 
upstream of the transcriptional start site, the mutation of which leads to a loss 
of hypoxic HIF1α up-regulation. Studies showed that NFB stimulates the 
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transcription of HIF1, and HIF1 expression regulates the activation of NFB 
(Scortegagna et al., 2008). Therefore, inhibition of NFB may influence the 
activity of HIF1α and vice versa.  
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Figure 1.9 Cross-talk between HIF and NFB in hypoxia. Under normoxic conditions, 
activated HIF1α binds to pVHL and is followed by proteasomal degradation. Hypoxia leads to 
phosphorylation of IκB, releasing NFκB to the nucleus, where it binds to a distinct element at 
HIF1α promoter site. (Abbreviations; HIF: hypoxia-inducible factor, NFκB: Nuclear factor 
κappa B, HRE: Hypoxia-response element, pVHL: von Hippel-Lindau, TNF: tumour necrosis 
factor,H2O2: Hydrogen perioxide) (Scortegagna et al., 2008). 
   
 
 
 
 
 
 
Figure 1.9B Cross-talk between HIF and NFκB. Figure displays some common stimulators 
and targets genes of  HIF and NFproteins.  
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1.9. Disulfiram 
Disulfiram (DS) also known as tetraethylthiuram disulfide was developed in 
1881 by M. Grodzki a German chemist (Grodzki et al., 1881). He synthesized 
DS from thiocarbamide with a stoichiometric formula of C10H20N2S4. This new 
formulation did not get much attention until some twenty years later when it 
was introduced in the rubber industry to accelerate the vulcanization of natural 
and synthetic rubber (Twiss et al, 1992; Eneanya et al, 1981). In the early 
1940s, DS was also used as a scabicide. Two British physicians discovered 
that DS was an effective treatment against scabies in domestic animals 
(Gordon and Seaton, 1942). In 1945, two Danish physicians Hald and 
Jacobsen while testing the effects of DS as a vermicide observed that 
ingestion of alcohol after treatment with DS lead to the development of 
extreme unpleasant reactions which paved the way for the use of DS as an 
antialcoholism drug (Eneanyn et al, 1981). The clinical use of DS over a long 
period of time has shown it to be a very safe drug with minimal and 
manageable toxic effects, even when fairly high doses of 300 to 500 milligrams 
per day are administered. DS also has a high bioavailability of more than 80% 
with 20% still detected in the body after two weeks administration (Sauna et 
al., 2005). DS is also found to have potent anticancer effects after it was 
observed that alcoholic patients with cancer being treated with DS had 
regression in cancer growth, this lead to further investigations on the use of 
DS as a potential anticancer agent (Wang et al., 2003).    
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1.9.1. Metabolism of Disulfiram 
DS is made up of made of two molecules of diethyldithiocarbamate molecules 
attached together by a disulfide bridge with a molecular weight of 296.54 
Dalton (Figure 1.10). 
    
Figure 1.10: Structure of disulfiram. 
During the metabolism of DS (Figure 1.11), rapid reduction reaction of the 
disulfide bridge converts it into its thiol group diethyldithiocarbamate (DDC). If 
orally ingested, 80% of DS is readily absorbed from the gastrointestinal tract 
and a small amount is reduced to DDC in the acidic environment of the 
stomach. DDC is highly unstable in acidic conditions and is rapidly 
disintegrated to carbon disulphide (CS2) and diethylamine (DEA). However, 
DDC is a strong metal chelating agent especially with heavy metal ions such 
as cupric ions and rapidly forms a DDC-Cu complex 
bis(diethyldithiocarbamato)copper complex (Cu(DDC)2). Cu(DDC)2 is more 
hydrophobic and stable in the acidic environment of the stomach which favours 
its absorption along the entire length of the upper gastrointestinal tract (GIT). 
After absorption of the parent drug DS or its Cu-complex DDC-Cu across the 
GIT mucosa into the blood stream, where DS rapidly disappears below its limit 
of detection (Stromme, 1965) by being reduced to DDC by endogenous thiols 
and glutathione reductase in the erythrocytes. In vivo studies showed that DS 
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was quickly reduced to its thiols within 4 minutes (Cobby et al., 1977). The 
DDC formed is a substrate for phase II metabolism and is further metabolised 
by four different reactions namely glucuronidation, nonenzymatic degradation, 
methylation, and oxidation.  
Glucuronidation: This is the major detoxification mechanism of DS which 
involves the conjugation of DDC with glucuronic acid in mammals. 50% of the 
given dose of DS is excreted in urine as a glucuronide metabolite (III) 
(Eneanyn et al., 1981). 
Nonenzymatic degradation: The decomposition of DDC is pH dependent 
where DDC is rapidly converted to diethylamine (IV) and carbon disulfide (V) 
in an acidic environment (Stromme et al., 1966). Diethylamine undergoes 
further degradation to ammonium and acetaldehyde. Carbon disulfide is 
oxidatively desulfurated to carbonyl sulfide (VII) and sulphur by NADPH and 
cytochrome P450 (Dematteis, 1974). Carbonyl sulfide undergoes further 
oxidization to carbon dioxide and sulphur, which can be metabolized to sulfate 
by the sulfoxidases (Faiman et al., 1978). 
Methylation:  A small amount about 0.05% of DS and its DDC form can be 
methylated forming methyl ester of DDC (MeDDC) (X). DDC can also be 
methylated by S-methylation accounting for about 27% of the given dose 
(Gessner and Jakubowski, 1972). The MeDDC derivative can be targeted by 
esterases which generate mercaptan which is further oxidized to sulfate and 
formaldehyde. 
Oxidation: oxidation of DS is an uncommon process where DDC is reoxidized 
back to DS under atmospheric oxygen conditions. This process accounts for 
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only 4% of DDC and is mostly affected by oxidases in the body (Strume et al., 
1965). 
 
Figure 1.11: Metabolism of disulfiram. Tetraethylthiuram disulfide (disulfiram), II. 
Diethyldithiocarbamic acid, III. Glucuronide of diethyldithiocarbamate, IV. 
Diethylamine, V. carbonyl disulfide, VI. Sulfur, VII. Carbonyl sulfide, VIII. Carbon 
dioxide, IX. Sulfate, X. methyl ester of diethyldithiocarbamate, XI. Methyl mercaptan, 
XII. Formaldehyde, XIII. thiocarboxylic acid. (a) Glutathione reductase, (b) 
conjugation, (c) nonenzymatic degradation, (d) oxidative desulfuration (C-P450), (e) 
oxidation, (f) sulfoxidase, (g) esterases, (h) S-methylation: S-adenosyl methionine 
transmethylase (Eneanyn et al, 1981). 
1.9.2. Disulfiram and Disease Treatment 
1.9.2.1. Anti-alcoholism 
Ethanol is metabolised by the liver by alcohol dehydrogenase (ADH) into 
acetaldehyde. Acetaldehyde is highly toxic and is promptly converted to 
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acetate a less toxic compound by acetaldehyde dehydrogenase (ALDH) 
(Deitrich et al., 2007) (Figure 1.12), which then enters the citric acid cycle. 
 
Figure 1.12: Disulfiram as an antialcoholism agent. 
DS and many of its metabolites (S-Methyl-N,N-diethylthiocarbamate sulfoxide 
(MeDTC-SO), S-Methyl-N,N-diethyldithiocarbamate sulfoxide (MeDDC-SO) 
and S-Methyl-N,N-diethyldithiocarbamate sulfine (MeDDC-sulfine) irreversibly 
inhibits ALDH by oxidation of sulfhydryl groups to form irreversible internal S-
S bonds leading to the accumulation of acetaldehyde in the blood (Johansson, 
1992; Pike et al., 2001). Alcohol consumption after taking DS intake drastically 
increase the acetaldehyde levels in plasma manifestating in a condition called 
disulfiram-alcohol reaction (DER).  
1.9.2.2. Anticancer treatment 
The use of DS as a potential anticancer agent has been studied (Brar et al., 
2004). DS has been shown to inhibit the growth of several cancers including 
breast cancer cell lines in vitro. The use of DS as an anticancer treatment drew 
some attention after a case report by Lewison in 1977 reported that a breast 
cancer patient with multiple bone metastasis had been treated for alcohol 
dependence by the Antabuse-DS showed spontaneous cancer regression. In 
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vivo animal studies also demonstrated the anticancer activity of DS. Neoplasia 
induced on the forestomach of female mice by Benzo[]pyrene administration, 
after a 30 week period more than 90% of treated animals developed tumours 
while in the group with 1% Antabuse in their diet, no tumour was developed at 
this site (Borchert and Wattenberg, 1976). Another animal study reported 
similar findings; urinary bladder cancer was distinctly inhibited when Wistar 
rats were fed with Antabuse in their diet of N-n-butyl-N-(4-hydroxybutyl) 
nitrosamine (BHBN) (Irving et al., 1979; Irving et al., 1983). In a patient with 
stage IV metastatic ocular melanoma being treated for alcoholism, reduction 
in hepatic metastasis was observed after an oral combination of DS and zinc 
gluconate was given continuously for a 53 month period, the patient 
experienced negligible side effects from the drug (Brar et al, 2004). 
1.9.3. Cytotoxic mechanism of disulfiram 
The exact mechanism by which DS exerts its anticancer effects has not been 
elucidated. However, studies have shown that DS and its metabolites target 
several cellular pathways in the human body such as inhibition of DNA 
topoisomerase preventing DNA transcription and replication, inhibition of 
matrix metalloproteinases (MMPs) leading to the inhibition of tumour cell 
metastasis, inhibition of the proteasome leading to inhibition of the NFB 
signalling pathway and downstream expression of cancer survival genes, 
inhibition of superoxide dismutase (SOD) and increasing intracellular copper 
(Cu) levels leading to toxic build-up of reactive oxygen species (ROS) (Sauna 
et al., 2005). A recent paper showed that DS in association with Cu mediates 
its cytotoxic action by the generation of ROS (in short term) and formation of 
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DDC-Cu which has a longer term toxic effect on cancer cells (Tawari et al., 
2015). A Randomized phase 2 trial of advanced non-small cell lung carcinoma 
with/without disulfiram and cisplatin; Navelbine showed that DS increased the 
tumour response disease free survival in many patients (Nechushtan et al., 
2015) 
1.9.3.1. Generation of Reactive Oxygen Species (ROS) 
Reactive oxygen species (ROS) are chemically reactive molecules containing 
oxygen. They usually have a single unpaired electron in their outermost shell 
of electrons thus are highly reactive. ROS include free oxygen radicals as 
superoxide (O2•−), hydroxyl radical (•OH), nitric oxide (NO•) and non-radical 
derivatives of oxygen such as hydrogen peroxide (H2O2) and singlet oxygen 
(1O2). ROS is generated through normal cellular metabolism processes and 
from activation of membrane bound enzymes system such as NADPH oxidase 
complexes. The mitochondrial electron-transport chain, a complex system 
involved in a series of oxidation-reduction reactions through the transfer of 
electrons from reductant to oxidant results in the generation of intracellular 
ROS when some electrons leak out of the respiratory chain and react directly 
with oxygen forming superoxide which can also be converted to other ROS. 
ROS can also be generated by reactions involving NADPH oxidase complexes 
or from biochemical reactions in peroxisomes and cytochromes (Bokoch and 
Knaus, 2003). A mild increase in ROS favours cell proliferation and 
differentiation, however a substantial increase results in irreversible damage 
to lipids, proteins and DNA, leading to cell death (Schafer and Buettner, 2001; 
Boonstra and Post, 2004). Therefore, maintaining the level of ROS is important 
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for cell growth and survival. Antioxidants and ROS-scavenging enzymes 
tightly regulate the ROS generated. These antioxidants and ROS-scavenging 
enzymes include superoxide dismutases (SOD1, SOD2, and SOD3), 
glutathione peroxidase, peroxiredoxins, glutaredoxin, thioredoxin and catalase 
(Boonstra and Post, 2004).  
Cancer cells being metabolically active and under high oxidative stress have 
elevated ROS level due to increase in peroxisome activity, mitochondrial 
dysfunction, oncogenic activity, infiltration of immune cells and increased 
cellular receptor signals (Storz, 2005). The cancer cells adapt to the high ROS 
generated by increasing the expression of cell survival proteins, modification 
of protein structures, enhancing transcription factors and activate genes that 
control cell growth and differentiation (Davies, 1999). Cancer cells also 
express high levels of antioxidant enzymes such as the superoxide dismutase 
(SOD), catalase, peroxidases and activation of the glutathione system 
(GSSG/2GSH) and thioredoxin system which maintain cellular redox balance 
(Schafer and Buettner, 2001). Transcription factors such as NFB, HIF1α, 
HIF2α and signalling molecules MAPK and JNK are activated in cancer cells 
which favour their growth and survival (Martindale and Holbrook, 2002). 
Therefore, further increment in ROS level after exposure to anticancer drugs 
might be an ‘‘Achilles heel’’ for cancer cells leading to their death.   
Copper (Cu) an essential trace element plays pivotal role in the biology of 
humans (Harris and Gitlin, 1996). Its unique electronic structure enables it to 
act as cofactors in a number of redox reactions of enzymes required for normal 
growth and development (Tapiero et al., 2003). Cu generates ROS with 
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oxidizing agent through the Fenton’s reaction damaging cellular components 
such as lipids, protein and DNA inducing apoptosis. The transport of Cu within 
cells is tightly regulated by copper transporters such as the human copper 
transporter (hCtr1). DS is a strong chelator of divalent metallic ions such as 
Cu, zinc (Zn), gold (Au) and iron (Fe) (Morrison et al., 2010). The binding of 
DS with Cu increases the cellular uptake of Cu, which causes ROS 
accumulation and induces apoptosis. Elevated levels of Cu has been 
documented in a number of tumours such as breast (Kuo et al., 2002), lungs 
(Diez et al., 1989), cervix (Chan et al., 1993) and ovaries (Chan et al., 1993).  
Exposure of cancer cells to DS/Cu complex increase the Cu load in the cells 
inducing the generation of more ROS within the cell. The ROS activates NFB 
activity triggering antiapoptotic factors which diminish this effect. However DS 
is also a potent inhibitor of NFB and ALDH which acts as ROS-scavengers. 
This overall effect, inhibition of NFB and ALDH by DS/Cu complex and the 
induction of excess ROS by Cu causes cell damage or sensitize the cancer 
cells to chemotherapeutic drugs (Guo et al., 2010; Liu et al., 2012; Yip et al., 
2011). This selective target mechanism of DS/Cu complex on inducing death 
of cancer cells (elevated Cu, NFB and ALDH inhibition) may be why DS is 
not toxic to normal cell.    
1.9.3.2. ALDH inhibition 
Aldehyde dehydrogenases (ALDHs) are a superfamily of enzymes important 
for endogenous and exogenous metabolism of aldehydes. There are 19 
isozymes in humans which perform important physiological and toxicological 
functions. ALDH1A play crucial role in embryogenesis and mediation of 
 
 
53 
 
retinoic acid signalling. ALDH2 is the main enzyme involved in the metabolism 
of aldehyde for alcohol metabolism; the other ALDH isozymes maintain cellular 
homeostasis by oxidizing reactive aldehydes from lipid peroxidation. High 
ALDH activity is used as a functional marker for CSCs (Ginestier et al., 2007) 
and is a factor involved in chemoresistance and radiotherapy resistance in 
several human cancer and in BC cell lines MDA-MB-231 and MDA-MB-468 
(Croker and Allan, 2012). ALDH is also a scavenger of ROS thereby reducing 
the drug or radiation induced oxidative stress which could explain the high 
amounts of ALDH in CSCs and their resistant nature (Croker and Allan, 2012).  
DS is a potent inhibitor of ALDH where it inhibits the ALDH enzyme activity. 
DS and its metabolites irreversibly inhibits ALDH. The molecular mechanism 
by which DS inhibits ALDH is through the reduction DS to DDC which is an 
inhibitor of ALDH in vivo but not in vitro (Lipsky et al., 2001). DDC is converted 
to methyltransferases to S-methyl-N,N-diethyldithiocarbamate and S-methyl-
N,N-diethyldithiocarbamate by hepatic thiols which are potent inhibitors of 
mitochondrial ALDH2 in vivo.  
1.9.3.3. Proteasome / NF-B inhibition 
Proteasomes are protein complexes inside cells that degrade damaged or 
unwanted protein by proteolysis.  Enzymes called proteases located in the 
proteasome carry out this degradation reaction after the proteins are tagged 
with ubiquitin. The proteasome degradation pathway is vital for several cellular 
processes such as cell cycle, regulation of gene expression and responses to 
oxidative stress (Lodish et al., 2004). The ubiquitin–proteasome system (UPS) 
is a complex and dynamic intracellular proteases, responsible for the 
degradation of about 90% of proteins in the cell and plays a crucial role in 
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maintaining normal cellular homeostasis. The proteasome pathway plays a 
vital role in the activation of NFB which is a predominant transcription factor 
activated in many malignant tumours. NFB is constitutively active and 
overexpressed in breast cancer cells and drives cancer cell survival, 
development and metastasis (Sovak et al., 1997). Therefore, inhibition of 
NFB would result in the inhibition of cancer cell survival, development and 
metastasis. DS/Cu complex is a potent inhibitor of NFB pathway via the 
inhibition of E3 ubiquitin ligase of the proteasome pathway which prevents 
phosphorylation and degradation of IB (NFB inhibitor), thus NFB release 
and nuclei translocation is hindered (Cvek and Dvorak, 2007; Matsuno et al., 
2012). This would lead to the accumulation of proapoptotic target proteins and 
induces cell death (Rae et al., 2013). 
1.9.3.4. Overriding resistance mechanisms 
P-gp an active drug efflux pump is overexpressed in many solid tumours 
(Krishna and Mayer, 2000; Thomas and Coley, 2003). DS was found to 
decrease the P-gp mediated drug resistance of vinblastine and colchicine in 
vitro by targeting the thiol groups in cysteine residues of P-glycoprotein (Loo 
and Clarke, 2000). DS and its metabolites DDC, MeDDC-sufoxide and 
MeDDC-sulfone were also found to inhibit the stimulated ATPAse activity of 
P-gp in verapamil treated cells (Loo et al., 2004).  
Due to the unrestricted and uncontrollable growth of breast cancer cells, 
angiogenesis the formation of new blood vessels to meet the demand of the 
growing cells occurs. DS was found to inhibit angiogenesis in glioma and lung 
carcinoma tumours (Marikovsky et al., 2002). Other research also showed that  
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DS suppressed angiogenesis in 10 day old chicken embryos. The authors 
demonstrated that DS directly interacts with matrix metalloproteinase MMP-2 
and MMP-9 in vitro, inhibiting their proteolytic activity through zinc chelating 
mechanisms (Shiah et al., 2003).  
1.10. Encapsulation of Chemotherapeutic drugs 
1.10.1. Nanoencapsulation 
Nanomedicine the use of nanotechnology (manipulation of matter in an atomic 
or molecular scale) to diagnose, treat or prevent diseases in humans is an 
evolving discipline that has the potential to radically change medical science. 
Nanoparticles are particles in the nanometer size range. Nanoencapsulation 
can therefore be defined as technology involved in the packaging of molecules 
of solid, liquid or gas in a core-shell complex where the active compound is 
protected within the core of the nanoparticles. The nanoparticles acts as a 
reservoir that encapsulates an active substance protecting and isolating it from 
the surrounding environment and the properties of the nanoparticles can be 
adjusted to meet specific requirements. The principal aims of nanoparticles 
are for the provision of formulations with prolonged activity, protection against 
unfavourable conditions and to control the release of the active ingredient. 
Nanotechnology has been extensively used in the preparation of medicine, 
food stuff and cosmetics in the pharmaceuticals (Farokhzad and Langer, 2009; 
Shimoni, 2009), food (Fathi and Mohebbi, 2010; Neethirajan and Jayas, 2011) 
and cosmetic industries. 
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1.10.2. Nanocarriers for anticancer drug delivery 
Chemotherapy is usually accompanied by severe adverse effects limiting the 
amount of drug given to patients, consequently tumours may not be sufficiently 
exposed to lethal doses of drugs. Nanocarriers have improved the treatment 
and management of breast cancer patients by increasing the efficacy, 
specificity and targeting ability of chemotherapeutic agents (Soppimath et al., 
2001). Nano vehicles used for encapsulation of anticancer drugs include 
liposomes, micelles, carbon nanotubes and dendrimers. 
Liposomes: Liposomes are spherical nanocarriers composed of an aqueous 
core surrounded by one or more concentric lipid bilayers with size ranging from 
50 nm to several micrometers (Figure 1.13). A Major limitation of liposomes is 
their short half-life due to unspecific interactions with macromolecules and 
cellular surfaces. Macrophages in the liver and spleen rapidly clear 
conventional liposomes.   
 
Figure 1.13 Structure of a multilaminar liposome 
Polymeric micelles (PM): Polymeric micelles are nanoscopic amphiphilic 
block polymers formed from self-aggregation of amphiphilic polymers with the 
hydrophobic part of the polymer on the inside (core) and the hydrophilic part 
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on the outside (shell). Many anticancer drugs have been successfully 
encapsulated in micelles, Dox a very toxic anticancer drug when encapsulated 
in micelle, systemic uptake by normal tissue was reduced two fold compared 
to free drug (Marin et al., 2002), the cytotoxic effect of PTX was greatly 
enhanced by encapsulation in amphiphilic block copolymers (Park et al., 
2005). Oxaliplatin loaded into poly(ethylene glycol)-β-poly(glutamic acid) 
polymeric micelles demonstrated enhanced antitumour activity (Cabral et al., 
2007). Surface modification of micelles such as conjugation with PEG 
increased blood circulation time by preventing opsonin adsorption and 
clearance by the mononuclear phagocytic system (Kwon, 2003). 
 
Figure 1.14 Structure of Polymeric Micelle. 
Carbon nanotubes are graphite sheets rolled into cylinders with a hexagonal 
latticework. Anticancer drugs DOX and PTX have been successfully 
encapsulated in PEG-carbon nanotubes (Niu et al., 2013) 
Dendrimers are highly branched nanoscale molecules. They are the new 
class of polymeric molecules characterized by an extensively branched 3D 
structure composed of a central core, an interior dendritic structure and an 
exterior surface with functional groups. The core of dendrimers is suitable for 
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encapsulation of anticancer drugs while modifications to the surface groups 
affect solubility and chelating ability of dendrimers. Dendrimers have been 
used as delivery vehicles for Dox and PTX (Lai et al., 2007). 
1.10.3. Targeting Strategies for effective drug delivery 
For effective delivery of chemotherapeutic drugs by nanocarriers, the drugs 
should be able to reach the desired tumour sites at optimal doses after 
administration, remain biologically active with minimal loss during blood 
circulation and exhibit selective killing of tumour tissues with minimal harmful 
effects to normal tissues (Sinha et al., 2006). Two targeting strategies namely 
passive and active drug targeting are involved. The compromised lymphatic 
drainage system of tumour cells together with the ‘leaky’ vasculature of tumour 
vessels results in the enhanced permeability and retention (EPR) effects 
enabling macromolecules as low as 400nm to migrate into surrounding tumour 
tissues. The passive targeting takes advantage of the pathophysiological 
characteristics of tumour vessels (Smith et al., 2008). However, not all tumours 
exhibit this EPR effect and different tumours cells have varying vessel 
permeability so the active targeting approach which involves the conjugation 
of ligands such as antibodies, peptides or small molecules to the surface of 
the nanodrug may overcome these limitations (Leamon and Reddy, 2004; Wu 
et al., 2010). The conjugated nanodrug can then bind through ligand-receptor 
interactions to receptors or epitopes overexpressed on tumour cells but not on 
normal cells enabling accumulation of the nanodrugs inside the tumour cells. 
pH-sensitive delivery systems are stimulus responsive carriers that respond to 
pH changes in the body.  The pH of solid tumour cells is acidic (4-6) unlike 
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blood pH which is alkaline 7.4. This pathophysiology of tumours serves as a 
trigger for delivery of pH sensitive nanocarriers (Rofstad et al., 2006). 
1.10.4. Nanoencapsulation, a solution for chemotherapy delivery 
The efficacy of most chemotherapeutic agents in clinics are hindered by 
barriers such as severe adverse effects due to nonspecific killing of both 
cancerous and normal cells, poor solubility, macrophage uptake and the 
multidrug resistance. Nanocarriers can improve the solubility of hydrophobic 
anticancer drug enhancing their efficacy. Macrophages detect, capture and 
digest foreign materials circulating in the blood and transfer them to the liver, 
polyethylene glycol nanocarriers enables anticancer drug to escape 
phagocytosis by macrophages increasing cellular uptake and prevents liver 
damage (van Vlerken et al., 2007).  
1.11. Aim of the research 
The goal of this study was to develop and examine a novel drug delivery 
system for treatment of drug-resistant breast cancer cells with disulfiram. This 
project was designed to achieve the following aims.  
1.   To examine the roles of hypoxia and hypoxia-induced transcription factors 
in stemness and chemoresistance of triple negative breast cancer cell lines.   
(Chapters 3, 4 and 5). 
2.  To characterise the resistant in vitro cell systems for similarity to breast 
cancer cells (Chapter 6). 
3.  To develop a disulfiram loaded polymeric micelle nanoparticle and examine 
its in vitro efficacy in the resistant cell systems (Chapter 7).  
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Chapter Two 
2.0. Material and Methods 
2.1.  Materials  
2.1.1. General reagents, enzymes, kits, lab wares and equipment. 
Enhanced Chemiluminescence Western Blot Signal Detection Kit (Amersham 
Biosciences, Buckinghamshire, UK). 
BD FACSCalibur™ Flow Cytometer, CellQuest™ Pro (BD Biosciences, 
Oxford, UK).  
Stuart® 3 block heater (Bibby Scientific Ltd., Straffordshire, UK).  
EZ-ECL chemiluminescence detection kit for horse radish peroxidise Solution 
A and B (Biological Industries Beit Haemek Ltd., Isreal).  
Bio-Rad protein assay kit II (Bio-Rad Laboratories, Hertfordshire, UK)  
Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose, Foetal Calf 
Serum (FCS), L-Glutamate (200 mM) (BioWhittaker® Lonza, Walkersville, 
USA).  
Penicillin-streptomycin mixture (10,000U/ml penicillin and 10,000U/ml 
Streptomycin) (BioWhittaker® Lonza, Walkersville, USA). 
Sterile Phosphate Buffer Saline (PBS) (0.0067M PO4) (BioWhittaker® Lonza, 
Walkersville, USA). 
Trypsin-EDTA (10x) (BioWhittaker® Lonza, Walkersville, USA).  
Microscope slide (ERIE SCIENTICFIC Company Portmouth.N.H., USA).  
 
 
61 
 
Fuji Medical X-Ray Film Super RX (13x18) (Fujifilm UK Ltd., Bedfordshire, 
UK).  
Amersham Hybond ™ - P (PVDF membrane), Amersham Hybond TM - N+ 
(GE Healthcare, Buckinghamshire, UK).  
30% acrylamide:bis-acrylamide (37.5:1) (GeneFlow Ltd, Staffordshire, UK)  
10× Transfer buffer (GeneFlow Ltd, Staffordshire, UK). 
10× Electrophoresis buffer (GeneFlow Ltd, Staffordshire, UK).  
Semi-dry transfer unit (Hoefer, Inc., Holliston, USA).  
NuPAGE ® LDS Sample Buffer (4x), SeeBlue plus 2 pre-stained protein 
markers (Invitrogen Ltd., Paisley, UK).  
10×TAE buffer, G418, Trizol, Optimem, Hygromycin B, Lipofectamine 
transfection reagent (Invitrogen Ltd., Paisley, UK).  
Nalgene Cryoware™ Cryogenic vials (Labware, Roskilde, Denmark).  
Marvel dried milk (Marvel, Dublin, Ireland).  
10, 25, 50 and 100 ml tubes (Merck Sharp & Dohme (MDS) Ltd., Hertfordshire, 
UK). 
AccuGel 40% (19:1 acrylamide:bis), Running buffer (10X, contains distilled 
H2O, Tris/Glycine/SDS) (National Diagnostics, Yorkshire, UK).  
BamH I and Hind III enzymes and associated buffers (New England Biolabs, 
Hitchin, UK).  
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Restriction enzymes and associated buffers, pfu polymerase, Luciferase 
assay kit, Gel shifting assay kit, 1Kb DNA ladder, 100Kb DNA ladder, Dual 
Luciferase Assay reagents, Access RT-PCR system (Promega UK Ltd., 
Southampton, UK).  
Qiaquik gel extraction kit, Qiafilter maxiprep kit, Qiafilter miniprep kit (Qiagen, 
West Sussex, UK).  
RNase A (100 mg/ml) (Qiagen Ltd., West Sussex, UK).  
Complete EDTA free protease inhibitor tablets, Rapid Ligation kit (Roche 
Diagnostics Ltd., East Sussex, UK).  
Complete easy packs-Protease inhibitor cocktail tablets (Roche Diagnostics 
Ltd., West Sussex, UK)  
96-well flat-bottom tissue culture plates with lids, Tissue culture Cell+ flasks 
with PE flat-bottom tissue culture plates with lids, Tissue culture Cell+ flasks 
with PE (Sarstedt Ltd., Leicester, UK). 
Disulfiram, Copper Chloride (CuCl2), minisapt plus (0.20 μm) filter, cisplatin 
(CDDP), paclitaxel (PTX) , doxorubicin (Dox) , gemcitabine (dFdC), 99.9% 
Dimethylsulfoxide (DMSO), Tris HCl, Tris Base, Tween 20, EDTA, Ammonium 
persulfate (APS), Sodium Dodecyl Sulfate (SDS, 98.5% GC grade), Methanol, 
Isopropanol, Glycine, HEPES, Sodium Chloride (NaCl), Thymidine, KH2PO4, 
Sodium hydroxide (NAOH), Nonident p40, Ethidium Bromide, LB broth, 
polydIdC (PdIdC), Triton X-100, Agarose, 3MM paper, Propidium iodide 
(powder), Tetramethylethylenediamine (TEMED), fixer/replenisher, 
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developer/replenisher, DL-dithiothreitol (DTT) solution (1 M in H2O) (Sigma 
Aldrich Company Ltd., Dorset, UK). 
ε-caprolactone (CL) and methoxy-poly(ethylene glycol) (mPEG-OH, Mn=2000 
g/mol) were purchased from Sigma-Aldrich Co. (Steinheim, Germany) and 
used as received. Chrysin(CHR) was purchased from Aladdin Co. (Aladdin, 
China) and used as received. Methylbenzenesulfonyl (TsCl) and triethylamine 
(TEA) were purchased from Asta Tech Pharmaceutical (Chengdu, China).  
Multiskan Ascent and Multidrop 384 (Thermo Fisher Scientific Inc., 
Leicestershire, UK).  
2.1.2. Antibodies  
p-p65 (S276) antibody (ab106129, Abcam, Cambridge, UK) . 
Sox2 (3578), Oct4 (2890) and Nanog (3580)(Cell Signalling, Herts, UK). 
Enhanced ChemiLuminescence (ECL) ™ anti-mouse antibody (RPN2232), 
ECL ™ anti-rabbit antibody (RPN2232) (GE Healthcare, Buckinghamshire, 
UK).  
HIF1α (NB100-479) and HIF2α antibody (NB100-122) (Novus Biologicals, CO, 
USA).  
Anti-vinculin monoclonal antibody (V9130), Anti-tubulin monoclonal antibody 
(T9026), FITC-conjugated anti-mouse IgG antibody (Sigma Aldrich Company 
Ltd., Dorset, UK).  
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2.1.3. Cell lines  
Human breast cancer cell lines: MDA-MB-231, MCF7, T47D, and BT 549. 
Human normal breast epithelial cell line: MCF10A （American Tissue Culture 
Collection, Rockville, USA).  
The normal human vascular endothelial cells, HeCV （Prof Wenguo Jiang, 
University of Cardiff, UK). 
Human endothelial cell line: EAhy926 （Prof. Angel Armesilla, University of 
Wolverhampton, UK). 
NFB p65 transfected (C1, C6) and mock transfected MDA-MB 231 triple 
negative breast cancer cell line （Prof.  Weiguang Wang, University of 
Wolverhampton, UK). 
HIF 1α transfected (C3, C4) and mock transfected MDA-MB 231 triple 
negative breast cancer cell line （Prof.  Weiguang Wang, University of 
Wolverhampton, UK). 
HIF 2α transfected (C4, C6) and mock transfected MDA-MB 231 triple 
negative breast cancer cell line (Prof.  Weiguang Wang, University of 
Wolverhampton, UK).  
Resistant cell lines (MDA-MB 231Gem 100nM and T47Ddox 100nM) (Prof. 
Weiguang Wang, University of Wolverhampton, UK).  
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2.1.4. Buffers  
Complete protease inhibitor  
A (25x) complete protease inhibitor (Roche Diagnostics Limited, West Sussex, 
UK) was prepared by dissolving 1 tablet of complete protease inhibitor in 25 
ml of distilled water, and stored at -20°C until use.  
Glycine Buffer  
Glycine buffer solution (500 ml) was prepared by dissolving 3.75 g glycine and 
2.92 g NaCl in distilled water. The pH of the glycine buffer was adjusted to pH 
10.5 using 5 M NaOH. The glycine buffer solution was stored at room 
temperature until use.  
RIPA Buffer for Whole Protein Extraction  
10x RIPA Buffer was prepared as follows stored at -20°C until use.  
Tris HCL 25 g/l 
Sodium dodecyl sulphate 0.1% per ml  
Triton-X 100 1%  
NaCl 0.15 M  
EDTA 1 mM  
Protease inhibitor 0.001% per ml  
 
Buffer A for Nuclear Protein Extraction  
Lysis buffer (buffer A) was prepared by mixing 200 μl 500 mM HEPES, 50 μl 
2 M KCl, 2 μl 500 mM EGTA (pH 8.0), 2 μl 500 mM EDTA (pH 8.0), 20 μl 0.5 
M DTT, and 500 μl (25X) protease inhibitor in 9.2 ml water. Buffer A was stored 
at -20°C until use.  
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Buffer C for Nuclear Protein Extraction  
Nuclear extraction buffer (Buffer C) was prepared by mixing 60 μl 500 mM 
HEPES, 120 μl 5M NaCl, 3 μl 500 mM EGTA, 3 μl 500 mM EDTA, 3 μl 0.5 M 
DTT, 75 μl (25X) protease inhibitor, and 75 μl 100% glycerol in 1161 μl water, 
and stored at -20°C.   
Separating buffer 
Separating buffer was prepared by mixing 90.8 g Tris base and 2g SDS in 500 
ml of distilled water. The pH of the solution was then adjusted to pH 8.8 using 
HCl. The separating buffer was stored at room temperature until use.  
 
Stacking buffer  
Stacking buffer was prepared by mixing 30 g Tris base and 2 g SDS in 500 ml 
of distilled water. The pH of the solution was then adjusted to pH 6.8 using 
HCl. The stacking buffer was stored at room temperature until use.  
Tris-buffered saline Tween-20 (TBS-T)  
A stock (10x) TBS-T solution was prepared by dissolving 12.11 g Tris base 
and 81.8 g NaCl in 1 litre of distilled water. The (1x) TBS-T buffer was then 
prepared by mixing100 ml (10x) TBS-T, 900 ml distilled water and 500 μl of 
Tween-20.  
Blocking buffer  
Blocking buffer was prepared by dissolving 5 g Marvel milk powder in 100 ml 
of (1x) TBS-T.  
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Transfer Buffer 
Transfer buffer was prepared by mixing 100 ml of 10 x stock solution, 200 ml 
of methanol and 700 ml distilled water. This solution was stored at room 
temperature until use.  
Running buffer  
Running buffer was prepared by mixing 100 ml of 10X stock solution with 900 
ml distilled water.  
2.2. Methods  
2.2.1. Cell culture  
Serum-containing medium  
Serum-containing medium consists of DMEM medium containing 1% (v/v) L-
glutamate, 1% (v/v) penicillin-streptomycin and 10% Foetal Calf Serum 
(BioWhittaker® Lonza, Walkersville, USA).  
Serum-free medium  
Serum-free medium consists of DMEM medium containing 1% (v/v) L-
glutamate, 1% (v/v) penicillin-streptomycin (BioWhittaker® Lonza, 
Walkersville, USA). 
Trypsin  
Working solution of trypsin (1x) was prepared by diluting stock solution of 
trypsin (10x) in sterile PBS (BioWhittaker® Lonza, Walkersville, USA). 
Freezing Medium for cryogenic storage of cell samples  
Freezing medium was prepared by mixing 90% foetal calf serum with 10% 
DMSO (Sigma Aldrich Company Ltd., Dorset, UK), and stored at 4°C until use.  
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Preparing Cell Lines for Liquid Nitrogen Storage  
Cells were trypsinised, spun for 3minutes at 1200rpm and the cell pellet 
collected. The cell pellet was then re-suspended in freezing medium and 
aliquot into 1 ml/labelled-cryovial. Each cryovial was then wrapped in tissue 
paper, put into a disposable labelled-glove and placed at -80°C overnight. The 
following day, the cryovials were removed from the gloves and tissue papers, 
and transferred into liquid nitrogen (-180°C) for long-term storage. The 
locations of the samples stored in liquid nitrogen are recorded in the liquid 
nitrogen storage log.  
Recovering Cell Lines from Liquid Nitrogen Storage  
A 75 cm2 tissue culture flask (Sarstedt Ltd., Leicester, UK) was prepared by 
adding 19 ml of serum-containing medium. Cells were recovered from liquid 
nitrogen storage, rapidly defrosted at 37°C water bath, and transferring the 1 
ml content of the cryovial into the prepared 75 cm2 tissue culture flask. The 
recovered sample was stored in an incubator, in 37°C with 5% CO2.  
Trypsinization of Adherent Cell Lines  
Cell culture medium was removed from the tissue culture flask, rinsed with 5 
ml of sterile phosphate buffered saline (PBS), and 3 ml of trypsin added to the 
adherent cells and spread evenly. The flask was placed in the incubator and 
checked regularly, under the microscope and by gentle tapping of the flask, to 
determine that the cells were no longer adhered to the tissue flask. When the 
cells were no longer adhered to the tissue flask, 3ml of serum-containing 
medium were added to the cell and were re-suspended thoroughly by pipetting 
the 6ml volume up and down. 
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2.2.1.1. General Cell Line Maintenance 
Cell cultures were regularly checked under the microscope (2-3 times a week) 
for cell density defined as percentage confluence, and changes in the colour 
of the medium. When there is a change in the colour of the medium but the 
cell density is low (less than 60% confluence) in which adhered cells are 
spread out and very few cells are touching each other, the medium is removed 
and replaced with fresh serum-containing medium. When there was a change 
in the colour of the medium and the cell density is high (greater than 80% 
confluence), and cells were overgrown leading to some cells no longer being 
adhered to the tissue culture flask and were in suspension, cells are sub-
cultured. Sub-culturing was done by trypsinizing the cells. The 4 ml of cells 
were collected into a 15 ml falcon tube. In the case when cells were not 
needed, half of the cells (2 ml) were disposed of. In the case when cells were 
needed, the cells where centrifuged at 1200rpm for 3 minutes. The medium 
was removed and cell pellet was re-suspended in 2 ml of fresh serum-
containing medium. Two 75 cm2 tissue culture flasks were then prepared by 
adding 19 ml of serum-containing medium, and to this 1 ml of the cell 
suspension was then added. The cells were stored in an incubator at 37oC 
with 5% CO2 with the tissue culture flask lying down. 
2.2.1.2. Culturing cells under hypoxic conditions 
Monolayer breast cancer cell lines MDA-MB 231 and BT 549 were grown 
under hypoxic conditions using STEMCELL Technologies Hypoxia incubator 
chamber gassed with mixture of 1%O2, 5%CO2 and remaining N2 from a 
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custom made BOC gas cylinder. Cells were seeded in T75 flasks and placed 
into the chamber and sealed after purging O2 into the chamber with the above 
mentioned low O2 gas for 4 minutes. Cultured cells were placed in an incubator 
and grown for 5 days before any experiment was done with the cells. The cells 
were fed with fresh media every 2-3 days to make sure the residual O2 in the 
media did not affect the experiment, the media in the flask was gassed before 
closing and then placed in the chamber to continue hypoxic conditions. An O2 
meter was also placed inside the chamber to monitor any leaks or increase in 
O2 levels during the process. 
2.2.1.3. Cell culture of resistant cell lines 
The MDA-MB 231GEM100nM and T47DDox100nM resistant cell lines were 
generated by from MDA-MB-231 and T47D (purchased from ATCC) by 
continuous culturing in medium containing gemcitabine (dFdC) and 
doxorubicin (Dox) respectively (Sigma, Dorset, UK) in a stepwise 
concentration-increasing procedure. The cell lines MDA-MB-231 and T47D 
were cultured with low concentration of drugs dFdC (20nM) and Dox (20nM) 
for 4 weeks and increased gradually to 50nM in time interval of 8 weeks, after 
which they were maintained in DMEM medium supplemented with 10% FCS, 
50 μg/ml penicillin, and 50 μg/ml streptomycin containing 100nM dFdC for 
MDA-MB 231 cell line and 100nM Dox for T47D cell line.  
2.3. Cytotoxicity assay  
Stock MTT solution 5 mg/ml MTT solution (500 ml) (Sigma Aldrich Company 
Ltd., Dorset, UK) was prepared by adding 2.5 g of 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide in 500 ml of sterile PBS, mixed to dissolve 
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using a magnetic stirrer, with the bottle wrapped in foil to protect the 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) from direct light. 
This MTT mixture was filtered using a vacuum filter connected to a pump. This 
filtered MTT solution, wrapped in foil, was stored at 4°C until use. 
MTT assay is one of the widely used methods to evaluate the effect of anti-
cancer drugs on cell viability. Cells were cultured in 96-well plates (5 × 
104/well) and left overnight to allow the cells attached to the bottom in the 
incubator at 37°C. Cells were exposed to different concentrations of anti-
cancer drug prepared by a two-fold serial dilution using medium i.e. 10 μM, 5 
μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM. There was also a negative control 
of cells which was untreated. After removing the spent media from the wells, 
the medium (200 μl) with different concentrations of drug was distributed in 
each well. Normally there are 3 wells with the same drug concentration and 
cell type in each plate at the same time to calculate the standard deviation. 
After incubation at 37°C for 72 hours, 50 μl of MTT (5 mg/ml) was added to 
the wells and the plates were wrapped in the aluminium foil to prevent the 
deterioration of MTT by light. The solution was removed after incubation for 4 
hours at 37°C, and 80 μl of 99.9% DMSO and 20 μl glycine buffer were added. 
The readings were tabulated and half maximal inhibitory concentration (IC50) 
values which indicates how much of the anticancer drug is needed to inhibit 
cell growth expressed as cell viability of the cell lines was calculated from the 
graph after reading the plates by a spectrophotometer at a wavelength of 540 
nm.  
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Cells treated with PTX, VCR, DOX were exposed for 3 days while cells treated 
with CDDP and dFdC were exposed for 5 days. 
2.3.1. Time dependent Cytotoxicity of DDC-Cu and DS plus Cu 
(DS/Cu)  
MCF 7 breast cancer were cultured overnight in flat bottomed 96 well 
plates at a cell density of 5000 cells/well in triplicates and were exposed to 
equal molar ratio of DS (Sigma, Dorset UK) in DMSO and CuCl2 in H2O 
(DS/Cu) or DDC-Cu (TCI, Merseyside UK) in DMSO. The cells were 
treated for 72 hours and subjected to in vitro MTT analysis. The percentage 
cell viability at different concentrations was calculated and the 
corresponding IC50 values were calculated. 
To determine the time-dependent cytotoxicity of DS/Cu reaction and DDC-
Cu. MCF 7 breast cancer cells were plated on 96-wellplates and exposed 
to DDC-Cu or DS/Cu (1:1 molar ratio). After 30 minutes, 60minutes, 
180minutes, 360 minutes, 12 hours and 24 hours drug exposure, the drug-
containing medium was discarded and the cells were cultured for another 
72 hours in drug-free medium and then subjected to MTT assay. 
2.4. Western Blot 
10% Ammonium Persulphate (APS)  
10% Ammonium Persulfate (APS) (Sigma Aldrich Company Ltd., Dorset, UK) 
was prepared by dissolving 0.1 g APS in 1 ml of distilled water. This was 
prepared fresh before use.  
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Preparation of Separating Gel  
Separating gel was prepared by adding 5.5 ml of separating buffer to 6.5 ml of 
distilled water. To this mixture, 4.4 ml of 40% (19:1) acrylamide:bis (AccuGel) 
(Sigma Aldrich Company Ltd., Dorset, UK) was added, followed by 120 μl of 
10% APS and 15 μl Tetramethylethylenediamine (TEMED) (Sigma Aldrich 
Company Ltd., Dorset, UK). 4 ml of this separating gel solution was added to 
the glass gel rack. A small amount of isopropanol, just enough to cover the top 
of the separating gel solution, was added on top of the separating gel. The gel 
was left to set.  
Preparation of Stacking Gel  
Stacking gel was prepared by adding 4.2 ml of stacking buffer to 6.6 ml of 
distilled water. To this mixture, 1.2 ml of AccuGel was added. The isopropanol 
(Sigma Aldrich Company Ltd., Dorset, UK) from the separating gel was 
removed and rinsed with distilled water when the gel was set. To the stacking 
gel mix, 250 μl of 10% APS and 20 μl TEMED was added. The final stacking 
gel mix was added on top of the separating gel. A comb was immediately 
placed on the top layer of the stacking gel, to form the protein loading wells, 
while avoiding bubbles. The gel was left to set before removing the comb. 
Cytoplasmic and Nuclear Protein Extraction  
Nuclear protein extracts were prepared by washing the cells in PBS, 
suspended in lysis buffer A and left on ice for 15 minutes, to which, 5 μl 10% 
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NP-40 (Sigma Aldrich Company Ltd., Dorset, UK) was added and then 
centrifuged for 5 minutes at 800 g. The supernatant was collected (cytoplasmic 
protein) and the pellet was re-suspended in 500 μl lysis buffer A, centrifuged 
for 5 minutes at 800 g, and the supernatant removed. The pellet was re-
suspended in 100 μl of nuclear extraction buffer C, left to spin on a rotator at 
4°C for 1 hour, centrifuged for 5 minutes at 12,000 g and the supernatant 
collected (nuclear protein).  
Protein samples were diluted to a 1:10 or 1:5 ratio in distilled water depending 
on the size of the cell pellet when preparing the protein sample. 5 μl of the 
BSA standards (duplicates) and the diluted protein samples were pipetted into 
a 96-well flat-bottomed plate, in triplicates, to which 25 μl of reagent A/S was 
added. 200 μl of reagent B was then added, incubated at room temperature 
for 10 minutes and the absorbance read at 650 nm. The protein concentration 
of the samples was calculated from plotting the absorbance versus protein 
concentration of the Bovine serum albumin serial standard. 
Protein Concentration Measurement  
A BSA protein serial standard was prepared by serially diluting the 3.0 mg/ml 
BSA solution in RIPA buffer to the following concentrations: 3.0 mg/ml, 1.5 
mg/ml, 1.0 mg/ml, 0.75 mg/ml, 0.50 mg/ml, 0.25 mg/ml and 0 mg/ml (30 μl 
RIPA buffer). The BioRad reagent A/S was prepared by adding 20 μl of 
reagent S to every ml of reagent A and mixed by vortex. 
SDS-PAGE Electrophoresis  
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The prepared SDS-PAGE gels were assembled into the electrophoresis tank 
loaded with 1 x running buffer. The protein samples were prepared by mixing 
0.5 ml of 16 μl of loading buffer (4x), 1 μl of 1 M DTT, 50 μg of protein sample 
and distilled water to make up a final volume of 64 μl in an eppendorf tube. 
This mixture was heated using a PCR block heater at 90°C for 10 minutes, 
then centrifuged at 10,000 g for 30 seconds and stored on ice until use. 10 μl 
of pre-stained protein markers and 30 μl of each protein mixture were loaded 
into the loading wells using a pipette. The gel was ran at 200 amperes of 
current for 1 hour.  
Blotting 
3MM paper (Sigma Aldrich Company Ltd., Dorset, UK) was cut into 12 x 12 
cm size and wet with transfer buffer. PVDF membrane was cut into 7 x 9 cm 
size and wet with methanol. A semi-dry transferring unit was setup by placing 
the SDS-PAGE gel (Sigma Aldrich Company Ltd., Dorset, UK) on top of the 
PVDF membrane, which is sandwiched by 2 layers of 3 x 3 MM paper. Protein 
was transferred from the SDS-PAGE gel to the PVDF membrane by applying 
current for 1 hour and 20 minutes.  
Blocking of the membrane  
The TBS-T(1x) working solution supplemented with 5% fat-free milk was used 
to block the protein-containing PVDF membrane (Sigma Aldrich Company 
Ltd., Dorset, UK) for 1 hour along with agitation in order to prevent non-specific 
binding of primary and secondary antibodies.  
Antibody Staining  
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5 ml of primary antibody (Table 2.1, for catalogue numbers refer to page 63) 
was prepared as described in the blocking buffer. After shaking the PVDF 
membrane in the blocking buffer for at least 1 hour, the membrane was placed 
in a plastic bag with the primary antibody, sealed, and left overnight at 4°C on 
a shaker. On the following day, the PVDF membrane was washed twice with 
TBS-T (1x) for 10 minutes. The PVDF membrane was then soaked in the 
secondary antibody at room temperature for at least 1 hour on a shaker. The 
PVDF membrane was washed twice with TBS-T (1x) for 10 minutes. 
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Table 2.1 Primary Antibodies 
Target Molecule  Dilution   Source 
p-p65 (S276)  1:1000  Abcam, Cambridge, 
UK  
Sox2  1:1000  Cell Signalling, Herts, 
UK  
Oct4  1:1000  Cell Signalling, Herts, 
UK  
Nanog  1:1000  Cell Signalling, Herts, 
UK  
HIF2α  1:1000  Novus Biologicals, 
CO, USA  
HIF1α  1:1000  Novus Biologicals, 
CO, USA  
p65  1:1000  Santa Cruz, 
Heidelberg, Germany  
Nucleolin  1:1000  Santa Cruz, 
Heidelberg, Germany  
IκBα  1:1000  Santa Cruz, 
Heidelberg, Germany  
Tubulin  1:8000  Sigma Aldrich, 
Dorset, UK  
 
Signal detection  
In the dark room, 2 ml prepared EZ-ECL solution (Thermo Fisher Scientific 
Inc., Leicestershire, UK) which was a mixture of solution A and solution B at a 
1:1 ratio was added to PVDF membrane. The PVDF membrane in the A/B 
mixture solution was left for 3-5 minute and the excess solution was removed 
by pouring onto a tissue paper. The PVDF membrane was then wrapped in 
cling film and exposed to a Fuji film. The length of exposure depends on the 
strength of the signal.  
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2.5. Flow Cytometry  
Preparation of Ethanol  
70% ethanol (Thermo Fisher Scientific Inc., Leicestershire, UK) was prepared 
by diluting in PBS from ethanol stock solution to improve the storage ability of 
ethanol.  
 
After 72 hours incubation of cell cultures with the appropriate test drugs, the 
supernatant containing cells in suspension was collected into a 25 ml tube. In 
addition, adhered cells were trypsinised and also collected into the same 25 
ml tube. The cells were pelleted by centrifugation at 800 g for 5 minutes. The 
supernatant was removed and the cells washed twice with 5 ml of sterile PBS. 
The final cell pellet was re-suspended in 0.5 ml of sterile PBS. Using a vortex 
mixing the 0.5 ml cell suspension, 2 ml of 70% ethanol was slowly added and 
left for 10 minutes. After 10 minutes have passed, the cell was pelleted by 
centrifugation at 800 g for 5 minutes, the ethanol was removed and the cell 
pellet re-suspended in 1 ml of sterile PBS. To this cell suspension, 1 μl of 100 
mg/ml RNaseA was added followed by 50 μl of 1 mg/ml propidium iodide and 
incubation for 30 minutes at room temperature wrapped in foil. Samples were 
stored at 4°C until they were analysed by flow cytometry. 
2.5.1.  Stem cell marker determination  
The ALDH positive population in breast cancer cell lines were detected by 
ALDEFLUOR kit (StemCell Tech., Durham, NC, USA) following the supplier’s 
instruction. The cells (2.5×105) were analyzed after being stained in ALDH 
substrate containing assay buffer for 30 min at 37°C. The negative control was 
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treated with diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. For 
CD133 detection cells were incubated with PE 133 antibodie (BD Pharmingen, 
Oxford, UK) for 20 minutes at 4°C. Unbound antibodies were washed off with 
PBS (Sigma). For the determination of embryonic markers Sox2, Oct4 and 
Nanog, after trysinization the cells fixed by acetone/methanol and 
permeabilized by 0.1% triton-X100 and then blocked with 3% BSA for 1 hour 
the cells were stained with primary (1:50 dilution) and FITC-conjugated 
secondary antibodies respectively for 1 hour at RT. The positively stained 
population was detected using a FACS Calibur flow. 
2.5.2. Detection of hypoxia in hypoxic cell cultures 
The hypoxic status of cells grown in hypoxic conditions was determined using 
HypoxyprobeTM-1 plus Kit supplied by Hypoxyprobe Inc (Burlington, MA, 
USA) following the supplier’s instruction. Flow cytometry was used for the 
analysis; the cells were cultured in 25cm2 flasks in both normoxia (NOR) and 
hypoxia (HYP), after treatment with HP reagent they were trypsinized, 
counted, fixed with methanol and stained with the FITC anti-HP antibody. The 
hypoxic population was detected using a FACS Calibur flow cytometer with 
488 nm blue laser and standard FITC 530/30 nm bandpass filter. 
 
2.6. Electrophoretic mobility shift assay (EMSA)  
Gel preparation  
10 x TAE-10 ml of 50 x TAE + 40 ml of dH2O (Invitrogen Ltd., Paisley, UK)  
 
 
80 
 
30% polyacrylamide Protogel, TEMED 10% Ammonium persulfate (APS)-1 g 
of APS + 1 ml of dH2O (10% APS) (Thermo Fisher Scientific Inc., 
Leicestershire, UK).  
Sample preparation 
10 x Binding Buffer, 1 μg/μl Poly (dI-dC), 50% Glycerol, Biotin End-Labelled 
Target DNA, 5 x Loading Buffer (Thermo Fisher Scientific Inc., Leicestershire, 
UK). 
Probes Preparation  
Wild Type (WT) Unlabelled Target DNA (sense and anti-sense probes) 40 μm. 
Mutant (MUT) Unlabelled Target DNA (sense and anti-sense probes) 40 μm. 
The probes were heated at 100ºC for 10 minutes and were cooled down to 
room temperature.  
Samples Preparation  
10 x Binding Buffer, 1 μg/μl Poly (dI-dC), 50% Glycerol, wild type (WT) 
unlabeled target DNA, mutant unlabeled target DNA, and Biotin End-Labelled 
target DNA were thawed on ice. Nuclear proteins from samples were added 
to biotin-labeled oligonucleotide binding buffer consisting of 10 mM Tris at pH 
7.5, 50 mM KCl, 1 mM DTT, 2.5% glycerol, 5 mM MgCl2, and 50 ng of poly (dI-
dC). The samples incubated on ice for 15 minutes and then 10 minutes at 
room temperature. The other samples were prepared without Biotin End-
Labelled Target DNA. 1 μl of Biotin End-Labelled Target DNA of added to all 
samples and incubated on ice for 15 minutes followed by 10 minutes 
incubation at room temperature. 5 μl of 5 x Loading Buffer were added into 
each sample. 
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Electrophoresis  
All samples (23 μl/well) were loaded into their designated wells respectively, 
and then the gel was run for 45 minutes at 120 voltage on ice.  
Blotting  
The nylon membranes (Amersham Hybond TM-N+, GE Healthcare, UK) and 
3MM papers were soaked in 1 xTAE for a minimum of 5-10 minutes. The 
probes were transfered from the gel to the nylon membrane using wet or semi-
dry units following manufacture protocol at 200 amperes of current for 1 hour.  
Cross-link  
The membranes were wrapped in cling film and were exposed for 10-15 
minutes on a trans-illuminator equipped with a 312 nm bulb (Ingenious 
Syngene Bio-Imaging).  
Blocking  
The blocking buffer and the 4 x wash buffer (Thermo Fisher Scientific Inc., 
Leicestershire, UK) were pre-warmed to 37-50°C to dissolve any precipitation, 
then the membranes were soaked in blocking buffer for 15 minutes at room 
temperature on a shaker. At the same time, 30 μl Stabilized Streptavidin-
Horseradish Peroxidase Conjugate were added to 10 ml Blocking Buffer. The 
membranes were soaked in the blocking buffer for 15 minutes at room 
temperature on a shaker.  
Washing  
1 x wash solution (40-60 ml) (Thermo Fisher Scientific Inc., Leicestershire, UK) 
were prepared for washing the membranes for 10 minutes twice in a clean 
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tray, then the membranes were transferred to a new container adding 10 ml 
Equilibration Buffer for 5 minutes at room temperature on a shaker.  
Signal detection  
(Luminol/Enhancer Solution): (Stable Peroxide Solution) (Thermo Fisher 
Scientific Inc., Leicestershire, UK) were mixed in 1:1 ratio and were evenly 
spread on the membranes, for 5 minutes. The membranes were exposed to 
film in the dark room.  
2.7. Luciferase reporter gene assay 
Cell culture  
Different cell lines were harvested by trypsinisation. Plate 5 x 104/100 μl of 
medium/well on to 96 well plates and allowed them to grow overnight at 37°C.  
Lipofectamine Transfections  
On the following day, the transfection solution I and II were prepared first, then 
the pGL3-Basic and other luciferase vectors (0.2 μg of each vector/well) in 
triplicate and internal control pRL-SV40 (0.002 μg/well) were co-transfected 
by using Lipofectamine 2000.  
Solution I: 0.2 μg of each Luciferase reporter plasmid DNA and 0.002 μg pRL-
SV40 (Renilla) DNA was diluted in 25 μl of opti-MEM medium without serum.  
Solution II: 0.5 μl of lipofectamine 2000 was diluted in 250 μl of opti-MEM for 
each DNA samples and incubated at room temperature for 5 minutes.  
The equal amount of solution I and solution II were mixed for 20 minutes at 
room temperature and then were added to the cell culture. The cells were 
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incubated at 37°C, 5% CO2 for 24 hours and were fed with fresh medium for 
further 24 hours incubation prior to luciferase assay test. 
Luciferase assay test & analysis  
The growth medium was removed after 48 hours, and the wells were washed 
with 1 x PBS. 100 μl of 1 x lysate buffer was added to each well and incubated 
at room temperature for 10 minutes with agitation. 20 μl of each lysate sample 
was transferred into a polypropylene plate to test. 30 μl of Luciferase assay 
reagent II was added and read in a luminometer. The reading corresponds to 
firefly luciferase activity. 30 μl Stop & Glo reagent was added and the reading 
was taken which corresponds to renilla activity. The process was repeated for 
each sample in a fresh plate each time. The luciferase activity of each well 
was normalized by the pRL-SV40 Renilla value using the formula: Ln = L/R 
(Ln: normalised luciferase activity; L: luciferase activity reading and R: Renilla 
activity reading). Transcriptional activity of the control, pGL3-Basic, was used 
to further standardize Ln using the formula: RLU = Ln/pGL3-basic (RLU: 
relative luciferase unit) (Promega UK Ltd., Southampton, UK). 
2.8. Stable transfection  
About 0.5-1 million cells/well were cultured in 6 well-plates with 2 ml medium 
overnight to about 70-80% confluence.  
2.8.1 Stable transfection of NFBp65 subunits 
4µg of empty vector cDNA3.1 and recombinant vector with cDNA NFBp65 
were introduced into the cells separately using LipofectamineTM 2000 reagent. 
The transfected cells were incubated at 370C for 24 hours selected for 7-10 
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days in a selective medium containing hygromycin 150µg/mL. Colonies of cells 
were picked up, enlarged and screened for over-expression of target gene in 
comparison with mock transfected clones using western blot. Confirmation of 
the overexpression of NFBp65 was done by analysing the nuclear 
translocation of NFB using western blot from nuclear extract of transfected 
cells. At least two positive clones with high nuclear translocation of NFB were 
selected for each gene and subjected to further analysis. The mock 
transfected cells containing empty vector was grown in parallel for all 
experiments and used as controls for NFB expression. All cells were grown 
under the selecting medium containing hygromycin throughout culturing time. 
2.8.2 Stable transfection of HIF proteins  
MDA-MB 231 cells were cultured (1x106 cells/well) in 6 well plates without 
antibiotics overnight. 4µg of empty vector pcMV6 and recombinant vector with 
HIF1α and HIF2α were introduced into the cells separately using 
LipofectamineTM 2000 reagent. The transfected cells were incubated at 370C 
for 24 hours selected for 7-10 days in a selective medium containing G418 
150ug/mL for HIF1α culture and 200ug/mL for HIF2α cultured cells. Colonies 
of cells were picked up, enlarged and screened for over-expression of target 
gene in comparison with mock transfected clones using western blot. 
Confirmation for the overexpression of HIF1α and HIF2α was done by 
analysing the nuclear translocation of HIF1α and HIF2α respectively using 
western blot from nuclear extract of transfected cells. At least two positive 
clones with high nuclear translocation of both HIF1α and HIF2α were selected 
for each gene and subjected to further analysis. 
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2.9. Migration assay 
Scratch or wound healing assay is a popular cheap assay that can be used to 
study migration of cells. A confluent plate generated from initial seeding of 
0.5x106 cells in  6 well plates of any type of attached cells control or test is 
‘‘wounded’’ by scraping off a thin straight line area of cells using a 200ul plastic 
pipette tip. Pictures of the scratch area were taken at 0hr, 24hrs and 48 hrs. 
Cell migration can be monitored microscopically, as cells travel from the 
undamaged regions into the scratched region. %migration can be calculated 
by measuring the decrease of the uncovered region at different time points 
until the ‘‘wound’’ is closed using the image J software. Cell migration can be 
observed as single cells or loosely connected population (mesenchymal cells) 
or as sheets of cells (epithelial cells). 
2.10. Invasion assay 
300 µl of warm, serum-free media was added to the cell culture inserts and 
incubated at room temperature for 1 hour in order to rehydrate the basement 
membrane layer of the insert. The media was carefully removed after the 
incubation period. 300 µl of cell suspension with 0.5-1x106 cells/ml in serum-
free media was added to the inside of each insert. 500 µl of media with 10% 
fetal bovine serum was added to the lower well of the plate. After incubation 
for 48 hours, media was carefully aspirated from the insert. Using wet cotton-
tipped swabs, cells were removed from the interior of the insert. The insert was 
then dipped in a well containing 400 µl of cell stain solution and incubated for 
10 minutes at room temperature. After several gentle washes in a beaker of 
water, the inserts were allowed to air dry. The inserts were then transferred to 
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a well with 200 µl of Extraction Solution and incubated for 10 minutes in an 
orbital shaker. 100 µl from each sample was transferred to a 96-well plate and 
the optical density was measured at 560nm. 
2.11.  Growth curves and doubling time analysis  
The cells (3×103/well) were cultured in 24-well plates in triplicate. The cells 
were collected by trypsinization and cell numbers in each of three wells were 
counted every 24 hours for 148 hours. The cell doubling time was calculated 
using the program from the Doubling Time Online Calculator 
http://www.doubling-time.com/compute.php. 
2.12.  Confocal microscopy and image analysis  
Cell culture  
Cells were harvested by trypsinisation.5x104 cells were plated on a sterile 8-
well chamber slide over night at 37°C for immumofluorencence experiment. 
Dose-dependent drug treatment or time-dependent treatment was conducted 
on the following day.  
Fluorescence labelling of cells  
The cells were washed twice with PBS gently to avoid the cells detachment 
from the surface of the chamber slide, and then the cells were fixed by adding 
500 μl of methanol/acetone (Volume Ratio 1:1) for 5 minutes. The fixed cells 
were washed twice with PBS, then the cells were blocked with 5% BSA for 30 
minutes at room temperature to block non-specific binding of immunoglobulin. 
The cells were incubated with the primary antibodies for 1 hour at room 
temperature, washed three times with PBS and then labelled with the 
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secondary antibodies for 1 hour in the dark, then the cells were washed three 
times in PBS. Coverslips were mounted onto slides using anti-fade mounting 
medium. Images were captured using laser-scanning microscope (Carl Zeiss 
Laser Scanning Systems LSM 510). 
2.13. RNA extraction  
1 x 106 cells were harvested and washed once with cold 1 x PBS, cell pellets 
were lysed in trizol in 1.5 ml eppendorf for 5 minutes at room temperature. The 
samples were mixed with chloroform and incubated for 5 minutes at room 
temperature. After centrifuge the samples at 10,000 g for 5 minutes, the 
aqueous phase was carefully pipetted off to another 1.5 ml eppendorf. The 
aqueous phase and 550 μl of isopropanol were mixed gently for 5 minutes at 
room temperature, and mixtures were centrifuged again at maximal speed 
(14,000g) for 20 minutes. The isopropanol was discarded from mixtures and 1 
ml of 75% ethanol in diethylpyrocarbonate (DEPC) treated H2O was added for 
washing the pellet barely visible at the base of tube. The pellets were re-
centrifuged at 8,000 g for 5 minutes and air-dried. Finally, the RNA pellets 
were dissolved by adding 30-50 μl (depending on yield) of either DEPC treated 
TE buffer or water. RNA concentration was determined spectrophotometrically 
by measuring absorbance at 260 nm (1 absorbance = 40 ng/ml RNA). The 
260/280 ratio should be greater than 1.8. If less than 1.5-1.6 or so, the RNA is 
partially degraded. Lower ratios also suggest DNA or thiocyanate 
contamination. The concentration is essentially the equivalent of the OD at 
260 nm (in μg/μl). 
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2.14. Reverse transcriptase polymerase chain reaction  
In this study, a promega access real time-polymerase chain reaction (RT-
PCR) system kit was used to perform the experiment. This system is one step 
RT-PCR in a single tube in which a reverse transcriptase produces first a 
strand of cDNA from RNA, then a thermostable DNA polymerase produces a 
second strand of DNA and amplifies the specific DNA of interest. A ratio of 1:2 
oligodT primers: RNA template was used in a volume of 25 μl containing 5 μl 
of 5 x AMV/Tfl reaction buffer, 1 μl of TAMV-reverse transcriptase, 1 μl of Tfl 
DNA polymerase, 2 μl of 25 mM MgSO4, 1 μl of dNTPs (10 mM of ATP, CTP, 
GTP and GTP) and nuclease free water up to 25 μl. Reverse transcripton was 
performed at 45°C for 45 minutes, following inactivation of AMV RT and 
denaturation of the RNA/cDNA hybrid by incubation at 94°C for 2 minutes. The 
human housekeeping gene GAPDH was used as the RNA loading control, 
which was amplified by the same RT-PCR system. The table 2.2 shows the 
primers, which was used in RT-PCR in this study. Amplification was performed 
using standard cycling parameters: 94°C 30 seconds for denaturation, 58°C 1 
minute for annealing and 68°C 1 minute for extension. After the final PCR cycle 
the final extension was at 68°C for 5 minutes and then kept at 4°C until further 
analysis. The room temperature-polymerase chain reaction products were 
separated on a 1% agarose gel and the bands visualized and photographed 
under UV light. 
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Table 2.2.  Primers Target 
Primer  Product Size  Forward primer 5' -
3'  
Reverse primers 5' 
-3'  
GAPDH  226bp  GAAGGTGAAGGT
CGGAGTC  
GAAGATGGTGAT
GGGATTTC  
ALDH1A1  154bp  TGTTAGCTGATGC
CGACTTG  
TTCTTAGCCCGCT
CAACACT  
ALDH1A3  150bp  TCTCGACAAAGC
CCTGAAGT  
TATTCGGCCAAAG
CGTATTC  
ALDH2  193bp  AACCAGCAGCCC
GAGGTCTT  
AAGGTGAGCCCA
GCTGGAAG  
ALDH3A1  229bp  TGTTCTCCAGCAA
CGACAAG  
CTGACCTTCAGGC
CTTCATC  
 
2.15. Purification of PCR products  
Polymerase chain reaction (PCR) products were purified using a StrataPrep® 
PCR Purification kit. An equal volume of DNA-binding solution was added to 
the aqueous portion of the PCR products. Transfer PCR product-DNA-binding-
solution mixture to a micro-spin cup and spin at 12,000 g for 30 seconds. The 
PCR products remaining in the fibre matrix of the micro-spin were washed with 
1× washing buffer then eluted using 50 μl of elution buffer.  
2.16.  Molecular Biology Protocols 
Preparation of LB plates  
LB medium was prepared by dissolving 25 g LB broth powder and 20 g agar 
into 1 L of deioned water. This was autoclaved and allowed to cool to 50°C 
prior to the addition of ampicillin (50 μg/ml) or kanamycin (50 μg/ml). The 
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medium was mixed to ensure equal distribution of antibiotic and approximately 
15 ml poured per 10cm2 Petri dish. The plates were left to set at room 
temperature before being stored at 4°C.  
Transformation of competent bacterial cells  
Competent bacteria DH5α was purchased from invitrogen and kept at -80°C. 
An aliquot of 50μl competent bacteria DH5α was allowed to thaw on ice. 10 ng 
of DNA was added and incubated on ice for 15 minutes. The cells were 
subjected to a heat shock at for 42°C 90 seconds and returned to ice for 2 
minutes. Added 1 ml of SOC medium to the cells and incubated at 37°C for 1 
hour in a shaking incubator. One hundred microliters of the reaction was 
spread onto a LB plate containing the appropriate antibiotic and incubated 
overnight at 37°C.  
Preparation of plasmid DNA  
Mini-preps  
Mini-prep purification was carried out using Qifilter miniprep kit following the 
manufactures instructions. Cells were harvested by centrifugation at 12,000 g 
for 5 minutes and re-suspended by pipetting in 100μl of re-suspension buffer 
I (50 mM Tris-HCl, 10 mM EDTA, pH 8.0 containing 100 μg/ml RNase A). Cells 
were treated with 100μl of lysis buffer II (200 mM NaOH, 1% (w/v) SDS), mixed 
and incubated for 5 minutes with gently up and down. Lysis was terminated by 
the addition of 100μl of neutralisation buffer III (3 mM potassium acetate, pH 
5.5). After centrifuging for 10 minutes at 12,000 g, the supernatants of cell 
lysates were transferred to mini-prep columns. The columns were centrifuged 
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for 1 minute at 12,000 g and washed twice with 750 μl wash buffer (1.0 mM 
NaCl, 50 mM Tris-HCl, pH 7.0, 15% (v/v) isopropanol). After washing, bound 
DNA was eluted into a clean 1.5 ml eppendorf tube with 100 μl DNase, RNase-
free H2O. 
Maxi-preps  
The Qiagen Qiafilter kit was used to produce larger scale DNA samples. 
Purification of DNA was carried out according to the manufactures instructions 
(Qiagen Ltd., Manchester, UK). A 350 ml culture of transformed bacteria was 
pelleted by centrifugation for 15 minutes at 6,000 g at 4°C. The cell pellet was 
re-suspended in 10 ml of pre-cold buffer P1 (50 mM Tris-HCL pH 8.0, 10mM 
EDTA, 100 μg/μl Rnase A). 10 ml buffer P2 (200 mM NaOH, 1% (w/v) SDS) 
was added to the cells with gently up and down for incubating 10 minutes at 
room temperature. Neutralized the reaction by adding 10 ml of buffer P3 (3.0 
M potassium acetate pH 5.5) and the solution was immediately applied to a 
QIAfilter cartridge and left for 10 minutes at room temperature to settle. 
Meanwhile, a Qiagen tip 500 was equilibrated by the addition of buffer QBT 
(750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol). After 10 
minutes, the lysed cells were added onto the equilibrated tip and allowed to 
filter through. The column was washed with 60 ml of buffer QC (1.0 M NaCl, 
50 mM MOPS pH 7.0, 15% (v/v) isopropanol). The DNA was eluted by the 
addition of 15 ml of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) 
isopropanol) to the tip. After adding 10.5 ml isopropanol, the DNA was 
precipitated by centrifuging at 12,000 g for 30 minutes at 4°C. The DNA pellet 
was washed with 5 ml of room temperature 70% (volume ratio) ethanol and 
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then centrifuged for 15 minutes at 12,000 g at 4°C. The supernatant was 
carefully removed and the pellet allowed to air dry prior to re-suspension in 
0.5-1 ml of DNase, RNase-free H2O. 
Quantification of DNA  
DNA measurement was performed by examining the absorbance of a 1:40 
dilution of the sample at 260 nm. An optical density of 1 unit was taken to 
correspond to 50 μg/ml of double stranded DNA. The sample concentration 
could be determined using the following formula.  
Sample concentration = OD 260 x dilution factor (40) x 50 μg/ml  
Digestion of DNA with restriction endonucleases  
One unit of restriction endonuclease activity was capable of completely 
digesting 1 μg of DNA depending on the manufacturer. 1 μg of DNA digests 
were prepared using the appropriate restriction enzyme (1-2 units) with a 
specified buffer providing by the manufacturer provided in a final volume of 20 
μl. Reactions were incubated at 37°C for a minimum of 2 hours.  
Agarose gel electrophoresis of DNA  
Digested DNA samples or PCR reactions were examined using gel 
electrophoresis. Samples were diluted in 5 × DNA loading buffer. 1.0% (w/v) 
agarose gel was prepared by mixing agarose with 1 × TAE and 2.5 mg/ml 
ethidium bromide. The gels were set in a horizontal gel tank and once set 
immersed in 1 × TAE. Samples were loaded and the gels run at 100V for 1 
hour. The DNA fragments were visualized under ultraviolet light. The size of 
each fragment was assessed by comparison with DNA molecular markers.  
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DNA Purification from agarose gels 
The required DNA fragments were excised from the gel with a sterile 
disposable scalpel blade inside the UV transilluminator hood. Excised gel 
fragments were transferred to a sterile tube. The fragments were purified using 
the QiaQuick gel extraction according to the manufacturer’s instructions. 
Excised DNA fragments were dissolved in buffer QG followed by the addition 
of isopropanol at 37°C. The solution was loaded onto a purification column. 
After centrifugation, DNA was eluted from the purification column using 30 μl 
of sterile water.  
Ligation of DNA  
When plasmid DNA and/or PCR fragments had been digested and purified as 
described above, ligation of digested PCR or DNA fragments to the digested 
vector DNA was achieved using a Rapid DNA ligation kit. A molar ratio of 1:3 
to 1:8 vector, PCR product/DNA fragment was used in a volume of 10 μl 
containing 1 unit of ligase and the supplied buffer. The reaction was incubated 
at room temperature for 1 hour or at 4°C overnight.  
2.17. Reactive Oxygen Species activity detection 
The extracellular ROS levels were determined using Fc OxyBURST dihydro-
2’, 4, 5, 6, 7, 7’-hexafluorofluorescein (H2HFF) probe (Invitrogen, Paisley, UK). 
60 µl of Fc oxyBurst dye was added to 3ml of serum free medium and 100 µl 
aliquoted into 96 well plate. 20µM of H2O2 was prepared in PBS and 100 µl 
added to 3 wells in the 96 well plate. Equal molar concentration (10 μM or 10 
mM) of DS and CuCl2 was mixed in culture medium. Fluorescence was 
measured in 96-well plates at excitation 490 nm and emission 520 nm using a 
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Fluoroskan Ascent UV fluorometer (Thermo Scientific, Northumberland, UK) 
at different time intervals. 
2.18. Determination of metabolic kinetics of DS/Cu and DDC-Cu 
MCF7 cells were treated with equal molar ratio of DS and CuCl2 or DDC-
Cu at a final concentration of 2μM. The medium and cells were separately 
collected after 30, 180 and 360 min. The reaction products in the whole 
cell lysate and medium were extracted in 0.25 and 1ml chloroform 
respectively and subjected to HPLC analysis. The separation was 
achieved using a C18 reverse-phase column at an injection volume of 20μl 
and a flow rate of 1ml/min. The wave length of 435nm and 275nm, mobile 
phase of 10:90% and 30:70% (water: methanol, v/v) were used for DDC-
Cu and DS analysis respectively.  
2.19. Encapsulation of DS in polymeric micelles 
Preparation of DS loaded Polymeric micelles Nanoparticles 
The DS loaded micelles is formed by solvent evaporation method. A dispersion 
of 100 mg of F127 micelles was made in 20ml of purified water under magnetic 
stirring and 50 mg DS dissolved in 20ml of absolute ethanol was slowly added 
to the aqueous dispersion of micelles. The mixture was kept under magnetic 
stirring for 24 hours (covered with parafilm). After the 24 hours incubation 20ml 
of ethanol was evaporated by rotary evaporation (temperature <40oC) and the 
aqueous dispersion containing the DS loaded micelles was filtered through a 
0.20µm filter to eliminate the non-encapsulated DS. Sucrose (5%) was added 
to the micellar dispersion which was then frozen for subsequent lyophilization. 
 
 
95 
 
Empty polymeric micelles were also prepared using similar technique. 
2.19.1. Characterization of Disulfiram loaded Polymeric Micelle 
The mean particle size and size distribution of the PMDS were determined by 
dynamic light scattering (DLS) (Brookhaven Instruments Corporation, USA).  
Zeta potential was measured by the Laser Doppler Anemometry (LDA) on 
ZetaPlus Zeta Potential Analyzer (Brookhaven Instruments Corporation, 
USA). Samples were dispersed in distilled water and the lyophilized DS-
micelles were reconstituted in water, and were analyzed for size by DLS, for 
drug loading by spectrophotometry. All measurements were performed at 25 
°C. Experimental values were calculated from the measurements performed 
at least in triplicate. 
2.19.2. Measurement of encapsulation efficiency (EE) and drug loading 
content (DLC) of DS loaded PM 
The content of encapsulated DS was determined by HPLC Agilent 1260 in 
methanol using calibration curve obtained from DS/methnol solutions with 
different DS concentrations. C18 column (250 mm×4.6 mm, 5 μm) was used 
with a mobile phase of methanol-water (70:30) and the flow rate was 1.0 
mL/min. The detection wavelength was 275nm and column temperature was 
25℃. Drug loading content (DLC) and drug loading efficiency (DLE) were 
calculated according to the following formulae:   
 
 
 
D L C ( w t % ) = 
m a s s o f D S  i n m i c e l l e s 
m a s s o f D S  
 
l o a d e d m i c e l l e s 
1 0 0 % 
D L E ( w t % ) = 
m a s s o f D S  i n m i c e l l e s 
m a s s o f D S  i n f e e d 
1 0 0 % 
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The amount of non-entrapped DS was determined by HPLC by UV detection 
set at 275 nm (SHIMADZU LC-20). The mobile phase was a mixture of 
methanol:water (70:30%) and the flow rate was set at 1 ml/min. Separation 
was achieved using a Phenomenex C18 column (250mm  4.6 mm, 5m). The 
amount of DS entrapped in the nanoparticles was determined after their 
dissolution in dichloromethane. After evaporation of dichloromethane at room 
temperature, DS was dissolved in pure ethanol. The supernatants were 
passed through a membrane filter (pore size 0.22 m, Millipore) before HPLC 
measurements. 
2.19.3. Measurement of the half-life of DS in vitro 
Free DS or PM-DS (100 l at a concentration of 3 mg/ml) was added into an 
eppendoff tube containing 300 l of horse serum with shaking at 37°C. The 
eppendoff tubes were collected and protein precipitated by adding 300 l of 
absolute methanol at different time intervals. The supernatant was subjected 
to HPLC measurement. 
2.19.4. Cumulative release of Disulfiram from Polymeric Micelle 
In vitro cumulative release of DS for the polymeric micelles were carried out in 
0.1 M phosphate buffer solution (PBS) at pH 5 and 7.4 containing 0.5% Tween 
80 (w/v) to enhance the solubility of DS, using the dialysis bag diffusion 
technique. A known amount of disulfiram loaded micelles was dispersed in 4ml 
phosphate- buffered saline (PBS) containing 0.5% Tween 80 (w/v). The 
mixture (2ml) was placed in a dialysis bag (MWCO 6000-8000, Sigma-Aldrich). 
The end-sealed bag was immersed in 50ml PBS (pH 7.4 and 5) containing 
0.5% Tween 80 (w/v). Sample were maintained at 37oC and shaken at 
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100rpm. At appropriate intervals, 2ml of sample was collected from the 
medium and an equal volume of fresh medium was added to the release 
medium. The concentration of disulfiram in each sample was measured by 
ultraviolet- visible spectrophotometry at 275nm. Data obtained in triplicate 
were analysed graphically (the percent accumulative amount of DS released 
from micelles versus time plotted). 
2.20. Statistical Analysis  
All statistics used in analysing the data were conducted using Graphpad Prism 
(version 6.01; GraphPad Software, Inc) and Microsoft Excel 2010 data 
analysis tools. The cut-off for statistical significance between samples was set 
to p=0.05. Any statistical tests with p<0.05 defines ‘‘the results between the 
samples are statistically different’’, p<0.001 ‘‘the results between the samples 
are statistically very different’’, and p≥0.05 defines ‘‘there are no statistical 
significance between the samples’’. The statistical Mann-Whitney U test: was 
used to determine the statistical significance between Breast Cancer (BC) cell 
lines that were tested under the exact same conditions. Two-sample assuming 
unequal variance’ was used to determine the statistical significance of the 
same BC cell line that was tested under different conditions. The statistical test 
“Kruskal-Wallis, Mood’s median test’’ was used to determine the statistical 
significance of the same BC cell lines that were tested under different 
condition. 
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Chapter Three 
Hypoxia induces CSC, chemoresistance and migration/invasion traits in 
TNBC cell lines. 
3.1 Introduction 
Triple negative breast cancer (TNBC) is the subtype of breast cancer that does 
not express genes for oestrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2) (Curigliano and 
Goldhirsch, 2011; Penault-Llorca and Viale, 2012). Scientific advancement in 
BC research have improved BC management with resultant increase in 
survival rate, however TNBC is still a difficult cancer to treat because of the 
lack of targetable receptors and is an assemblage of different breast cancer 
subtypes.  
Stem cell ‘’niche’’ a specialized microenvironment within tumours maintains 
the properties of cancer stem cells (CSCs) self-renewal and multipotency 
(Keith and Simon, 2007; Hill et al., 2009). The cells, blood vessel, matrix 
glucoproteins and three-dimensional space form the stem cell niche (Scadden, 
2006). The stem cell niche contains CSCs and these cells are mostly in a 
hypoxic state. Reports by Ezashi et al., (2005) showed that the low O2 tension 
(1%) in the niche decreased cell proliferation and maintained pluripotency 
while higher oxygen tension (3-5%) maintained pluripotentency of cells but 
had no effect on their proliferation rate. These results suggest that the hypoxic 
niche maintains slow-cycling proliferative rate and quiescence in relation to the 
oxygen tension within tumours. HIF protein activated under hypoxia also 
regulates signalling pathways that maintain stem cell self-renewal and 
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multipotency. CD133+ CSCs from gliomas were found to overexpresses HIF2α 
and other HIF regulated genes compared to non-stem cells or normal neural 
progenitor cells, inhibition of HIF2α reduced self-renewal, proliferation and 
survival in vivo with diminished tumour initiation potential of glioma CSCs (Li 
et al., 2009). This finding was also confirmed by Franovic et al. (2009) in which 
inhibition of HIF2α in colorectal, non-small cell lung cancer and gliobastoma 
that harboured CSCs population prevents in vivo growth and tumourigenesis 
irrespective of the mutational status and tissue origin (Franovic et al., 2009). 
3.1.2. Hypoxia induced EMT 
High invasion and metastasis are the principal factors causing poor prognosis 
of patients with TNBC. Approximately 90% of cancer related death results from 
the metastatic spread of primary tumours (Christofori, 2006). Hypoxic 
response regulated by the HIF protein particularly HIF1α activation correlates 
with tumour metastasis by promoting tumour cell metastatic potential. HIF1α 
is suggested to meditate the repression of E-cadherin as overexpression of 
HIF1α upregulates repression of E-cadherin repressors twist, Snail and SIP1 
with associated loss of E-cadherin and overexpression of N-cadherin and 
Vimentin which promotes epithelial to mesenchymal transition (EMT) and 
metastatic phenotypes in human cancer cells (Evans et al., 2007).  
CSCs are widely accepted to be responsible for multidrug resistance in cancer 
cell and are believed to be one of the reasons for chemotherapeutic failure 
and cancer relapse. Previous studies have shown that hypoxia play key role 
in the induction and maintenance of CSCs traits, chemoresistance and 
metastasis in cancer cells (Li et al., 2009, Franovic et al., 2009). 
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3.1.3  Rationale and aims of the study 
This study was carried out to confirm if hypoxia is able to induce CSCs traits 
in triple negative breast cancer (TNBC) cell lines, and to examine the response 
of these cells to conventional anticancer drugs. Hypoxia induced EMT was 
also examined to determine the process of cell metastasis.  
3.2. Experimental design 
General materials, products, labwares, manufacturers and methodologies 
used for the entire study have been described in details in chapter 2. Specific 
materials, methods and experimental design used for this part of this study are 
stated below. 
3.2.1. Culturing cells under hypoxic conditions 
Monolayer TNBC breast cancer cell lines MDA-MB 231 and BT 549 were 
grown under hypoxic conditions using STEMCELL Technologies Hypoxia 
incubator chamber (refer to Chapter 2, page 69).  
3.2.2. Detection of hypoxia in hypoxic cell cultures 
The hypoxic status of MDA-MB 231 and BT 549 cells grown in hypoxic 
conditions was determined using HypoxyprobeTM-1 plus Kit (refer to Chapter 
2, page 79).  Additional confirmation of the hypoxia status was done by 
western blot analysis of hypoxia-inducible factors (HIFs) (refer to Chapter 2, 
page 72).   
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3.2.3. Determination of EMT properties of cells 
Hypoxia is believed to induce epithelial to mesenchymal transition (EMT).  In 
vitro wound healing assay (scratch assay) for migration and transwell invasion 
assay (Boyden chamber assay) were performed in hypoxic and normoxic 
cultures to determine the invasive and migratory properties of the cells (refer 
to Chapter 2, page 85 and 86). 
3.2.4. CSC markers determination in hypoxic cells 
Increase in markers such as ALDH+, CD 133 and embryonic markers Sox2, 
Oct4 and Nanog are common feature of CSCs. If hypoxia induces EMT in 
cells, it was hypothesized that these markers would also be increased. These 
CSC markers were examined using immunofluorescence protocol for FACS 
where an increase in fluorescence indicates an increase in the expression of 
these markers (refer to Chapter 2, page 78).   
3.2.5.   MTT cytotoxicity assay for hypoxic cell cultures 
Chemoresistance is a feature of CSCs and a major problem for chemotherapy. 
If cells under hypoxia show increase in CSC markers, it was hypothesized that 
hypoxic cells would show resistance to an ample range of anticancer drugs. 
To assess the effect of hypoxia on drug sensitivity cells, MTT cytotoxicity 
assay was performed in hypoxic and normoxic cultures after exposure to 
various anticancer drugs (refer to Chapter 2, page 70 and 71). 
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3.3.6.  Growth curves and doubling time analysis  
To examine the growth profile and proliferative rates of hypoxic cells, growth 
curve and doubling time analysis was performed on MDA-MB 231 and BT 549 
cell lines (refer to Chapter 2, page 86). 
3.3. RESULTS 
3.3.1.  Increase proportion of hypoxic cells in hypoxic culture 
Monolayer breast cancer (BC) cells lines grown in hypoxic culture were 
compared with those grown under normoxia using hypoxyprobe. The results 
obtained from FACS analysis showed that a substantial number of cells grown 
in hypoxic culture had an increase in proportion of hypoxic cell (%) compared 
to those cultured in normoxia (Figure 3.1A and B). Further analysis for the 
confirmation of hypoxia was done by western blot and the results show an 
increase and nuclear translocation in HIFs in the hypoxic culture when 
compared to the normoxia culture of BC cell lines (Figure 3.2). 
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Figure 3.1(A) Representative FACS Plots of expression of hypoxic population 
in BC cell lines: Fluorescence Activated Cell Sorting (FACS) analysis using 
Hypoxyprobe kit staining shows increase in population of hypoxic cells in hypoxic 
culture compared to normoxic culture. This indicates the successful induction of 
hypoxia in our hypoxic culture system. 
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Figure 3.1B Bar chart representation of hypoxic and normoxic populations in 
BC cell lines. Histograms (Median ± interquartile range) displayed an increase hypoxic 
cell population in cell lines grown under hypoxia in comparison to their respective 
normoxic cultures (Mann and Whitney U test, **p=<0.05, n=9). 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Representative Western blots of hypoxia-inducible factors (HIFs) in 
BC cell lines: Western blot analysis of nuclear extracts from NOR and HYP cells of 
MDA-MB 231 and BT 549 cell line shows that the hypoxic cultures have increased 
expression and nuclear translocation of HIF1α and HIF2α in comparison to the normoxic 
cells.  Nucleolin was used as loading control. (NOR: normoxic culture, HYP: hypoxic 
culture, HIF: hypoxia-inducible factor). 
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3.3.2.  Hypoxic cells significantly resistant to anticancer drugs 
To study the effect of hypoxia in the induction of chemoresistance, cisplatin 
(CDDP), a first line drug for TNBC and four conventional anticancer drugs 
paclitaxel (PTX), doxorubicin (Dox), vincristine (VCR) and gemcitabine (dFdC) 
were tested on cells cultured in both hypoxic and normoxic conditions. MTT 
cytotoxicity results showed that the cells grown in hypoxic conditions were 
resistant to all five anticancer drugs tested, while the cells cultured in normoxic 
conditions were killed at low concentrations of the drugs. The hypoxic cells 
were able to survive at even high concentrations of anticancer drugs used. 
The half maximal inhibitory concentration (IC50) values indicates how much of 
the anticancer drug is needed to inhibit cell growth expressed as cell viability. 
Figure 3.3 (A) and (B) shows that cell viability curves and bar charts (IC50 
values) for MDA-MB 231 and BT 549 breast cell lines respectively grown in 
hypoxia were significantly higher than their normoxic culture.  
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Figure 3.3(A1). Representative Drug Concentration Response Curves of MDA-MB 231 in normoxic and hypoxic culture. Cell viability curve 
shows difference in dose response between normoxia and hypoxia cultures. The hypoxic cells were highly resistant to the CDDP, DOX, PTX, dFdC 
and VCR while cell death was induced in the normoxic cells at much lower concentrations of these anticancer drugs. (MDA: MDA-MB 231 cell line, 
Cisplatin (CDDP), paclitaxel (PTX), doxorubicin (Dox), vincristine (VCR) and gemcitabine (dFdC)) 
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Figure 3.3(A2). Bar chart representative of IC50 values of normoxic and hypoxic cells treated with anticancer drugs. The 
histograms (median ± interquartile range) shows the elevated half maximal inhibitory concentration (IC50) values for hypoxic cells indicating 
increased drug to 5 anticancer drug tested cisplatin (CDDP), paclitaxel (PTX), doxorubicin (Dox), vincristine (VCR) and gemcitabine (dFdC), 
(Mann and Whitney U test, **p=<0.001, n=9). 
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Figure 3.3(B1). Representative Drug Concentration Response Curves of BT 549 in normoxic and hypoxic culture. Cell viability curve shows 
difference in dose response between normoxia and hypoxia cultures. The hypoxic cells were highly resistant to the CDDP, DOX, PTX, dFdC and VCR 
while cell death was induced in the normoxic cells at much lower concentrations of these anticancer drugs. (BT: BT 549 cell line, Cisplatin (CDDP), 
paclitaxel (PTX), doxorubicin (Dox), vincristine (VCR) and gemcitabine (dFdC)). 
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Figure 3.3(B2) Bar chart representative of IC50 values of normoxic and hypoxic cells treated with anticancer drugs. Histogram 
(median ± interquartile range) shows elevated half maximal inhibitory concentration  (IC50) values for hypoxic cells indicating increased drug 
resistance to 5 anticancer drug cisplatin (CDDP), paclitaxel (PTX), doxorubicin (Dox), vincristine (VCR) and gemcitabine (dFdC) (Mann and 
Whitney U test, resistance, **p=<0.001, n=9). 
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3.3.3.  Hypoxic cells express high CSCs markers  
Fluorescence-activated cell sorting (FASC) analysis showed that BC cells grown 
under hypoxia had higher expression of CSC markers (ALDH+, CD133) (Figure 
3.4 A and B) and embryonic markers (Nanog, Sox2, Oct4) when compared to 
cells cultured in normoxic conditions. The expression of embryonic stem cell 
proteins Sox2, Oct4 and Nanog regulates stemness, self-renewal and 
pluripotency of cells and are were found to be significantly increased in hypoxia 
in both MDA-MB 231 (Figure 3.5) and BT 549 (Figure 3.6). Growth curve 
experiments were also conducted and the results (Figure 3.7) obtained 
demonstrated that hypoxic cells had a significant decrease in growth rate and 
doubling time indicating quiescence which is an important stem cell feature.  
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Figure 3.4(A1). Representative FASC Plots of ALDH expression in normoxic and 
hypoxic cultures measured by ALDEFLUOR assay. FASC results shows ALDH activity 
in hypoxic and normoxia cells with and without treatment with DEAB (30µM). Breast cancer 
cell line cultured under hypoxia expressed high percentage of ALDH+ compared to their 
respective normoxic cultures. (Abbreviations: DEAB: Diethylaminobenzaldehyde; ALDH: 
Aldehyde dehydrogenase activity, FASC: Fluorescence Activated Cell Sorting).  
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Figure 3.4(A2). Bar chart representation of ALDH+ cells in hypoxic and normoxic 
populations in BC cell lines. Histograms (median ± interquartile range) displays statistically 
significant increase in the ALDH+ activity in hypoxic cultures in comparison to their respective 
normoxic cultures (Mann and Whitney U test, **p=<0.0001, n=9).  After treatment with DEAB, 
there was no statistical difference in ALDH+ cell from both cultures (Mann and Whitney U test, 
p>0.05). (Abbreviations ALDH: aldehyde dehydrogenase, DEAB: diethylaminobenzaldehyde).   
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Figure 3.4 (B) Representative FASC Plots of CD133 expression in normoxic and 
hypoxic cultures measured using CD133-PE conjugated antibody. FASC data shows 
that higher expression of CD133 was observed in hypoxic culture compared to normoxic 
culture. Histograms (median ± interquartile range) displays statistically significant increase in 
CD133 expression in Hypoxic cultures in comparison to their respective normoxic cultures. 
(Mann and Whitney U test, **p=<0.001, n=9). (Abbreviations FASC: Fluorescence Activated 
Cell Sorting). 
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Figure 3.5. Representative FASC Plots of Embryonic CSC markers Expression in 
normoxic and hypoxic cultures of MDA-MB 231 cell line. FASC data shows that higher 
expression of embryonic stem cell markers (Nanog, Sox2 and Oct4) were displayed in MBA-
MB231 hypoxic culture compared to normoxic culture. Histograms (median ± interquartile 
range) above displays statistically significant increase in all three embryonic CSC markers in 
hypoxic cultures in comparison to normoxic culture. (Mann and Whitney U test, **p=<0.001, 
n=9). Abbreviation; FASC: Fluorescence Activated Cell Sorting expression  
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Figure 3.6. Representative FASC Plots of Embryonic CSC markers Expression in 
normoxic and hypoxic cultures of BT 549 cell line.  FASC data shows that higher 
expression of embryonic stem cell markers (Nanog, Sox2 and Oct4) were displayed in BT 
549 hypoxic culture compared to normoxic culture. Histograms (median ± interquartile range) 
above displays statistically significant increase in all three embryonic CSC markers in hypoxic 
cultures compared to normoxic cultures. (Mann and Whitney U test, **p=<0.001, n=9). 
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Figure 3.7. Representative Growth curves of MDA-MB 231 and BT549 cancer cell 
lines cultured in normoxia and hypoxia. Cells growth rate under hypoxia was slower 
than those grown in normoxia. This could be due to the acquisition of CSC characteristics 
leading to quiescence (Mean± SD, n=6).  
3.3.4 Hypoxia induces EMT in BC cell lines 
Results from western blot protein analysis showed that cells grown in hypoxia 
were found to have higher expression of EMT markers such as increase in N-
cadherin and decrease in E-cadherin expressions, this switch indicates the cells 
obtained a more mesenchymal characteristic. Vimentin expression was also 
increased. Whereas in cells grown under normoxia there was no loss of E-
cadherin and hence they remain epithelial in nature. These results suggest that 
hypoxia can transform the cells into a more mesenchymal phenotype and can be 
reversed to epithelial nature if the cells were to return to normoxia.  
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Figure 3.8. Representative Western Blots of EMT markers in hypoxic cells using 
whole cell lysates of NOR and HYP cultures of breast cell lines. The results shows 
that cells under hypoxia have decreased expression of epithelial marker E-cadherin and 
increased expression of mesenchymal markers (N-cadherin and vimentin) in comparison 
to that of normoxic cells indicating EMT activation in the HYP cells.  Tubulin was used 
as loading control. (NOR-normoxic culture, HYP: hypoxic culture). 
3.3.5. Hypoxic cells display increase migration and invasive potential 
Further confirmation of hypoxia-induced EMT and transformation of cells into 
mesenchymal phenotype was done by analysing the migratory potential of cells 
under hypoxia. The images taken using the inverted microscope for Boyden 
chamber migration assay and the optical density (OD) measured from the 
experiment enabled determination of percentage migration between normoxic 
and hypoxic cell cultures. Results from the analysis (Figure 3.9) showed 
significant increase in the migratory potential of cells grown under hypoxic 
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conditions. Mesenchymal phenotypes are also known to have increased invasion 
potential that can be measured by transwell matrigel invasion assay. Cells with 
mesenchymal characteristics have the potential to produce matrix 
metalloproteinases that can digest the extracellular membrane or substance like 
matrigel that enables them to invade the gel and move out of the matrix towards 
chemoattractants like serum or growth factors. Images taken from the above 
experiment shown in Figure 3.10 indicate a remarkable increase in the invasion 
potential of cells grown under hypoxia. The results given as invasion index (%) 
confirm the increased invasion potential of hypoxic cell cultures which is 
statistically significant.   
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Figure 3.9. Representative Matrigel Invasion assay of TNBC hypoxic cells. Images 
(Magnification 20X) shows that the cells grown under hypoxic conditions are highly invasive 
in comparison to that of normoxic cells indicating EMT activation and mesenchymal 
characteristic of the hypoxic cells. Histograms (median ± interquartile range) shows 
statistically significant invasive rate of hypoxic cells (Mann and Whitney U test, **p=<0.0001, 
n=6). (Abbreviations Triple negative breast cancer (TNBC). Epithelial to mesenchymal 
transition (EMT)). 
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Figure 3.10. Representative Matrigel Migration assay of TNBC hypoxic cells. 
Images (Magnification 20X) shows that the cells grown under hypoxic conditions have 
increase migration in comparison to that of normoxic cells. The histograms (median ± 
interquartile range) displayed statistically significant migratory potential of hypoxic cells 
indicating EMT activation and mesenchymal characteristic of the hypoxic cells (Mann and 
Whitney U test, **p=<0.0001, n=6). (Abbreviations Triple negative breast cancer (TNBC). 
Epithelial to mesenchymal transition (EMT)). 
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3.4. Discussion 
Hypoxia, a reduction in tissue oxygen tension is a common feature associated 
with solid tumours (Vaupel and Mayer, 2007). Tumours adapt to these hypoxic 
changes by switching on genetic pathways that promote tumour aggressiveness, 
metastasis and chemoresistance; patients with hypoxic tumours generally have 
a poorer prognosis (Semenza, 2007; Keith and Simon, 2007). Increasing 
evidence show that cancer is a disease that involves stem cells as cells with stem-
like features have been isolated from many solid tumours including the breast, 
brain, colon, liver and pancreatic cancers (Al-Hajj et al., 2003; Singh et al., 2004; 
Li et al., 2007; O’Brien et al., 2007; Prince et al., 2007). Increased expression of 
certain cancer stem cell markers (CSC) markers such as ALDH+ and 
overexpression of embryonic stem markers (Sox2, Oct4, Nanog) have been used 
to identify stemness in BC cells (Tirino et al., 2013).   
Das et al., (2008) reported that hypoxic tumour cells are poorly differentiated and 
express stem cell markers. Other studies also postulate that hypoxia may be 
responsible for the persistence of CSCs in tumours and the hypoxic niche 
provides a suitable microenvironment for the maintenance of these CSCs which 
are involved in promoting therapeutic failure and tumour relapse (Rosen and 
Jordan, 2009; Lin and Yun, 2010). With these facts in mind, it was hypothesized 
that hypoxia may be involved in the induction of CSCs traits and maintenance of 
CSCs in cancer cells. Breast cancer cell lines MDA-MB 231 and BT549 cultured 
in hypoxic chamber were observed to have higher population of hypoxic cells 
compared to those cells cultured in normoxia. HIF nuclear translocation was also 
increased in the hypoxic cultured cells (Figure 3.1 and 3.2). Data from this study 
(Figure 3.4 A and B) also showed that monolayer TNBC cells grown under 
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hypoxia had higher expression of CSCs markers (ALDH+, CD133) and embryonic 
markers (Sox2, Oct4, Nanog) compared to cells grown in normoxia, suggestive 
that hypoxia induces these CSC traits.  
Breast cancer metastasis is one of the primary cause for cancer related deaths 
in TNBC patients (Gupta and Massagu, 2006; Steeg, 2006). Patients with primary 
tumours that contain high population of hypoxic cells have been reported to have 
a reduction in overall survival rate after surgical resection of the primary tumour 
(Vergis et al., 2008), these suggests that hypoxia is able to promote a more 
aggressive tumour with metastatic phenotype. According to the report by Badve 
and Nakshatri, (2012) CSC phenotype represents tumours that are aggressive 
with inherent ability to adapt, lie dormant or rapidly proliferate and these CSC 
phenotype represents the plasticity of tumours to undergo EMT giving rise to 
metastasis. The results from this study shows that cells under hypoxia displayed 
an increase in vimentin and N-cadherin expression indicating a switching to a 
mesenchymal phenotype while losing E-cadherin which is the trademark of 
epithelial phenotype (Figure 3.8). Further confirmation from the invasion and 
migration assay (Figure 3.9 and 3.10) also demonstrated that cells cultured under 
hypoxia have significant increased migratory and invasion potentials compared 
to cells in normoxic culture indicating that there is a close relationship between 
stem cell induction and EMT phenotype in cancer cell lines. 
Exposure of cells and tissues to hypoxia stimulates stress response pathways 
that enable self-preservation and anti-apoptotic phenotype in cells. There is 
strong association between tumour hypoxia and poor prognosis and resistance 
to therapies (De Milito and Fais, 2005; Li et al., 2009). Data from MTT analysis 
reveal that cells grown under hypoxia were significantly resistant to the 5 
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conventional anticancer drugs (Cisplatin, vincristine, paclitaxel, Doxorubicin and 
gemcitabine) tested suggestive that hypoxia may be involved in the induction of 
these drug resistance indicative that hypoxia induces stemness of cells with 
resultant drug resistance. 
Conclusion 
Even with the advancement in treatment and outcome of patients in recent times, 
drug resistance of tumour cells is a major factor limiting the effectiveness of 
chemotherapeutic treatment in most human tumours. Hypoxia induces CSC-like 
characteristics in breast cancer cell line. The hypoxic cells show slow proliferation 
rate but displayed high migratory and invasive potentials. It is concluded that 
hypoxia induces these CSC-like phenotype leading to chemoresistance, 
therefore further understanding of the mechanisms of hypoxia-induced EMT will 
be beneficial in targeting these hypoxic stem cell. 
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Chapter Four 
NFB: A key factor involved in hypoxia-induced chemoresistance and 
stemness of breast cancer cells 
4.1 Introduction 
NFB is a family of transcription factors important for the regulation of the immune 
and inflammatory responses, developmental processes, cellular growth and 
apoptosis (Li and Verma, 2002; Bonizzi and Karin, 2004). NFB is expressed in 
virtually all cell types and sequestered in cytoplasm by the inhibitor of NF-kappa 
B (IK) (Hayden and Ghosh, 2004). External stimuli such as oxidative stress, 
hypoxia, inflammatory cytokines, viral infections activates IB kinase (IKK) which 
triggers the phosphorylation of IBα with resultant proteasomal degradation of 
IBα, releasing NFB dimer form which then translocates to the nucleus where 
the NFB proteins bind to B sites as dimers, either homodimers or heterodimers, 
and exerts both positive and negative effects on target gene transcription (Liang 
et al., 2004). 
The inactive NFB-IB complex can directly or indirectly be activated by hypoxia 
which results in an increase in its expression. There is constitutive NFB in many 
solid tumours contributing to cancer cell survival and reduced sensitivity to 
anticancer drugs (Arlt and Schafer, 2002). Several reports have shown that NFB 
is activated in human breast cancer cell lines as well as in primary breast tumours 
(Cogswell et al., 2000; Nakshatri and Goulet, 2002). Other studies also 
demonstrated that NFB activation results in tumour chemoresistance by 
exerting antiapoptotic effects by the up-regulation antiapoptotic genes in BC cells 
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resulting in cell survival mechanisms and resistance to therapeutic regimens (Arlt 
and Schafer, 2002; Montagut et al., 2003).  
Hypoxia induced NFB promotes signalling pathways involved in the 
inflammatory response through the regulation of gene expression of 
proinflammatory cytokines, adhesion molecules, enzymes, and pro-inflammatory 
enzymes.  NFB activates the antiapoptotic process which inhibits apoptosis 
enabling survival of hypoxic insult in cancer cells (Taylor et al., 2008). Hypoxia 
induced NFactivation is also believed to contribute to the maintenance of 
CSCs during the development and progression of tumours (Nakshatri and Goulet, 
2002). 
Result data from Chapter 3 revealed that hypoxia induced the overexpression of 
NFin monolayer TNBC cultured under hypoxia with resultant stemness of 
cells. 
4.1.1  Rationale and aims of this study 
This study was therefore carried out to confirm if the overexpression of 
NFinduced CSCs traits in TNBC cell lines cultured in normoxia and to 
examine the link between hypoxia and NF signalling pathway in 
chemoresistance and therapy failure. The effects of NFin BC metastasis was 
also examined to reveal if overexpression of NFincreases the migratory and 
invasiveness of TNBC cells. 
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4.2 Experimental Design  
General materials, products, labwares, manufacturers and methodologies used 
for the entire study have been described in details in chapter 2. Specific materials, 
methods and experimental design used for this part of this study are stated below.  
4.2.1.  Stable transfection of MDA-MB 231 cells with NFB p65 subunits 
To determine the effects of NFB in maintenance of stem-like cell characteristics 
and chemoresistance, MDA-MB 231 cells were transfected with cDNA NFBp65 
vector and empty vector following the protocols for transfection as reported in 
Chapter two (page 84). 
4.2.2.  MTT cytotoxicity assay in NFB transfected cells 
There is established proof that hypoxia induced chemoresistance in breast 
cancer cell as shown in chapter 3, to test if overexpression of NFB can also 
induce drug resistance, Mock and NFB transfected cells were exposed to 
anticancer drugs paclitaxel (PTX), vincristine (VCR), doxorubicin (DOX), cisplatin 
(CDDP) and gemcitabine (dFdC) and MTT assay performed (refer to Chapter 2, 
page 71).  
4.2.3. Determination of CSC markers in NFB transfected cells 
CSC markers ALDH, CD133, Sox2, Oct4 and Nanog were determined using 
immuno-fluoresecence protocol for FACS. Over expression of the NFB protein 
should induce an increase in these CSC markers which was quantified by 
measuring increase in fluorescence (refer to Chapter 2, page 78).  
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4.2.4. Determination of EMT characteristics in NFB transfected cells 
To examine the epithelial to mesenchymal transition (EMT) in NFB transfected 
cells, EMT markers vimentin, E-Cadherin and N-cadherin were determined by 
western blot (refer to Chapter 2, page 72). In vitro wound healing assay (scratch 
assay) for migration and transwell invasion assay (Boyden chamber assay) were 
also performed to determine the invasive and migratory properties of the cells 
(refer to Chapter 2, page 85 and 86). 
4.3. Results  
4.3.1. Stable transfection of NFB p65 subunit in MDA-MB 231 BC cell line  
MDA-MB 231 cells were transfected with cDNA incorporating the NFBp65 vector 
or the empty vectors in media containing hygromycin 150µg/mL. Two clones C1 
and C6 with the highest expression of NFBp65 were chosen for further testing. 
Western blot results (Figure 4.1) shows that clones C1 and C6 expressed higher 
levels of NFBp65 from both nuclear and whole cell lysate extracts.  
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Figure 4.1. Representative Western Blots of NFBp65 transfected cells using 
whole cell lysates and nuclear extracts of MDA-MB 231 cell line transfected with 
NFBp65 subunit. The result shows that NFBp65 overexpressing clones C1 and C6 had 
higher p65 expression and higher nuclear translocation of p65 in comparison to the mock.  
Tubulin and nucleolin were used as loading control. 
4.3.2 Hypoxia may be involved in NFB activation  
BC cells cultured under hypoxia had higher of p65 expression and nuclear 
translocation of p65 from nuclear protein extracts (Figure 4.2).   
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Figure 4.2. Representative Western Blots of NFBp65 in hypoxic cells using whole 
cell lysate and nuclear extracts of normoxic and hypoxic cultures of breast cell 
lines. The results shows that cells cultured under hypoxia had increase of NFBp65 and 
higher nuclear translocation of p65 in comparison to that of normoxic cells.  Tubulin and 
nucleolin were used as loading control. (NOR- normoxia, HYP: hypoxia, WP – whole 
protein; NuP – nuclear protein) 
4.3.3. Cells overexpressing NFBp65 were highly resistant to anticancer 
drugs 
Results from MTT cytotoxicity analysis show that NFBp65 (C1 and C6) 
overexpressing cells were significantly resistant to 5 anticancer drugs tested 
(cisplatin, paclitaxel, doxorubicin, vincristine and gemcitabine) when compared to 
the Mock which were killed at lower concentrations of the drugs. The IC50 (refer 
to chapter 2, page 71) of the NFBp65 overexpressing cells were much higher 
than that obtained for the mock transfected cells (Figure 4.3). 
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Figure 4.3 Representative Drug Concentration Response Curves of Mock and 
NFB p65 transfected cells. Cell viability curve from MTT analysis shows difference in 
dose response between cells overexpressing NFB p65 and the mock cells. The NFB p65 
overexpressing cells C1 and C6 were highly resistant to the CDDP, DOX, PTX, dFdC and 
VCR. Histograms (median ± interquartile range) shows elevated half maximal inhibitory 
concentration (IC50) values for NFB p65 overexpressing cells compared to mock cells 
indicating increased drug resistance. (Kruskal-Wallis test, **p=<0.0001, n=9) (Abbreviations; 
Cisplatin: CDDP, doxorubicin: DOX, paclitaxel (PTX), gemcitabine (dFdC) and vincristine 
(VCR) 
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4.3.4. Overexpression of NFBp65 in BC cells induces CSC traits  
Data from FACS analysis showed that the NFBp65 over expressing positive 
clones (C1 and C6) had significantly higher expression of CSC markers (ALDH 
and CD 133) when compared to the Mock cells (Figure 4.4A and 4.4B). The 
expression of embryonic stem cell markers Sox2, Oct4 and Nanog were also 
increased in the NFBp65 overexpressing clones compared to the mock cells 
(Figure 4.5 A and B).  
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Figure 4.4.(A). Representative FASC Plots of ALDH expression in MDA-MB 231 
NFBp65 transfected cells measured by ALDEFLUOR assay. FASC data shows ALDH 
activity in mock and NFBp65 transfected clones (C1 and C6) with and without treatment 
with DEAB (30µM). NFBp65 transfected clones (C1 and C6) expressed high percentage of 
ALDH+ compared to the mock cells before treatment with DEAB. Histograms (median ± 
interquartile range) displays the statistically significant increase in the ALDH+ activity in 
NFBp65 transfected clones (C1 and C6) in comparison to mock cells (Kruskal-Wallis test, 
**p=<0.0001, n=9).  After treatment with DEAB, there was no statistical difference in ALDH+ 
cell from both cultures (Kruskal-Wallis test, p>0.05). (Abbreviations: DEAB: 
Diethylaminobenzaldehyde;  ALDH: Aldehyde dehydrogenase active). 
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Figure 4.4B. Representative FASC Plots of CD133 expression in MDA-MB 231 
NFBp65 cell line measured using CD133-PE conjugated antibody. FASC data 
shows that CD133 expression was significantly higher in the transfected cells (C1 and C6) 
when compared to the Mock cells. Histograms (median ± interquartile range) above displays 
statistically significant increase in CD133 expression in transfected cells (C1 and C6) 
compared to the mock (Kruskal-Wallis test, **p=<0.001 n=9). 
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Figure 4.5(A). Representative FASC Plots of Embryonic Stem cell markers 
Expression in MDA-MB 231 NFBp65 BC cell line.  FASC data shows that higher 
expression of embryonic stem cell markers (Nanog, Sox2 and Oct4) were displayed in the 
NFBp65 overexpressing clones (C1 and C6) compared to Mock cells.  
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Figure 4.5B Bar Chart Representative of Expression of Embryonic markers in 
MDA-MB 231 NFBp65 cell line. Histograms (median ± interquartile range) above 
displays significant increase in all three embryonic markers (Nanog, OCT4 and Sox2) 
markers in transfected cells (C1 and C6) compared to the Mock cells (Kruskal-Wallis 
test,**p=<0.001 n=9). 
 
4.3.5. NFBp65 overexpression induced EMT in MDA-MB 231 cell line 
Results from Chapter 3 showed that EMT is induced under hypoxic conditions. 
Overexpression of NFBp65 in TNBC cell line MDA-MB 231 also induced higher 
expression of EMT markers Vimentin and N-cadherin with accompanying 
decrease in E-cadherin expressions (Figure 4.6), this cadherin switch indicates 
the cells acquired a more mesenchymal characteristic.  
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Figure 4.6. Representative Western Blots of EMT markers in Mock and NFBp65 
transfected cell. NFBp65 overexpressing cells C1 and C6 exhibits EMT features 
displayed as decreased expression of epithelial marker E-cadherin and increased 
expression of mesenchymal markers (N-cadherin and vimentin) in comparison to Mock 
cells indicating EMT is induced by increase in NFBp65 activity. Tubulin was used as 
loading control. 
4.3.6. Increase in NFBp65 expression induced higher migration and 
invasion 
Further confirmation of hypoxia-induced EMT and transformation of cells into 
mesenchymal phenotype was done by analysing the migratory potential of cells 
under hypoxia. NFBp65 overexpressing cells (C1 and C6) showed significant 
increase in migratory and invasive potentials compared to the Mock cells (Figure 
4.7 and 4.8).  
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Figure 4.7 Representative Migration (wound healing) assay Images of Mock and 
NFBp65 transfected cells. Images (Magnification 10X) taken shows that the cells 
overexpressing NFBp65 are highly migratory compared to Mock cells. Images after 48 
hours showed that NFBp65 overexpressing cells (C1 and C6) had a higher migratory 
potential than Mock cells.   
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Figure 4.8 Representative Matrigel Invasion assay Images of Mock and NFBp65 
transfected cells. Images (Magnification 20X) taken after 3 days shows that the cells 
overexpressing NFBp65 have high invasive properties in comparison to that of mock cells 
indicating EMT activation in these cells. 
 
4.3.7. Inhibition of NFBp65 decreased the migratory and invasive potential 
in MDA-MB231 cell line  
Increase in NFBp65 activity in BC cell line induced increase in migration and 
invasion potential as shown from our results above. Inhibition of NFBp65 with 
an inhibitor resulted in a decrease in migratory potential of cells (Figure 4.9 A and 
B). 
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Figure 4.9. Representative Migration assay Images of Mock and NFBp65 
transfected cells inhibited with small molecules and DS/Cu. Images (Magnification 
10X) taken shows that inhibition NFBp65 subunit by p65 inhibitor or DS/Cu decreased the 
migration of NFBp65 transfected cells even after 48 hours.(DS: disulfiram, Cu: copper). 
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Figure 4.9B. Representative Matrigel Invasion assay Image of Mock and NFBp65 
transfected cells inhibited with small molecules and DS/Cu. Images (Magnification 
20X) taken shows that inhibition of NFp65 decreased the invasiveness of NFp65 
transfected cells after treated of cells with DS plus copper and p65 inhibitor (DS: 
disulfiram, Cu:copper). 
 
4.3.8 NFBp65 transfection induced HIF activity 
Scortegagna et al., (2008) reported that loss of HIF1α activity decreased NFB 
activation and p65 expression while increase in HIF1α expression resulted in 
hyperphosphorylation of IB and phosphorylation of p65 at Ser276 in 
keratinocytes. NFB also induces HIF2α by the interaction between IKK and 
CBP/p300 (Tian et al., 2012). Results from western blot analysis showed that HIF 
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proteins were overexpressed in the NFBp65 positive clones C1 and C6 (Figure 
4.10). 
 
 
 
 
 
 
Figure 4.10. Representative Western Blots of HIF1α and HIF2α expression in 
NFBp65 MDA-MB 231 transfected cell. Nuclear translocation of HIF1α and HIF2α 
was displayed in NFBp65 overexpressing cells C1 and C6. Nucleolin was used as 
loading control (Abbreviation; HIF: hypoxia-inducible factor). 
4.4.  Discussion  
Breast cancer stem cells (BCSCs) play pivotal role in the propagation of tumour 
existence, treatment resistance and cancer relapse (Kakarala and Wicha, 2008; 
Coker and Allan, 2008). Several reports revealed that hypoxia is crucial for 
stemness of cells as it provides a conducive environment ‘Stem cell niche’ for the 
maintenance of these self-renewing cells (Rosen and Jordan 2009; Lin and Yun, 
2010). This is in line with my results as hypoxia induced a stem cell-like 
phenotype in triple negative breast cancer (TNBC). NFB, a family of transcription 
factors is one of the many transcription factors activated during hypoxia to ensure 
the survival of cells during hypoxic insults. Dysregulation of NFB activation 
results in persistent nuclear translocation of proteins such as p50, p52, p65, cRel 
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and RelB, which disrupts the balance between cell proliferation and death through 
the upregulation of anti-apoptotic proteins (Karin and Lin, 2002). NFB is widely 
overexpressed in many cancers such as pancreatic cancers, breast cancer, brain 
cancer, colon cancer (Biswas et al., 2004).  
Resistance in breast cancer (BC) is a complex process and several studies have 
revealed that BC cells with stem cell-like properties are highly resistant to cancer 
drugs (Al-Hajj et al., 2003; Hambardzumyan et al., 2006; Dave and Chang, 2009). 
These BC stem cells with stem cell phenotype are defined by expression of 
surface markers such as ESA+, CD44+, CD24- (Clarke and Fuller, 2006; Lynch 
et al., 2006; Polyak and Hahn, 2006). Data from this study reveal that that hypoxia 
induced the activation and expression of NFB in monolayer cells cultured under 
hypoxia (Figure 4.2).  Flow cytometry analysis of my data showed that the 
transfected cells (C1 and C6) displayed higher expression of stem cell markers 
ALDH, CD133 and embryonic stem cell markers (Nanog, Oct4 and Sox2) 
compared with mock cells. These results suggest that NFB activation can induce 
stem-like features in cancer cells which is consistent with the report by Takase et 
al., (2013) which demonstrated that NFκB, especially p65, play crucial role in the 
maintenance of pluripotency of cells. 
NFB is the main chemoresistant anti-cancer factor activated during 
chemoresistance in many human tumours. Constitutively elevated NFB levels 
have been reported in oestrogen receptor negative primary tumours which can 
be further increased by chemotherapy (Biswas et al., 2000). A studies by Wang 
et al., (2003) demonstrated that high NFB activity is linked with chemoresistance 
as it triggers the upregulations of antiapoptotic genes that block the induced 
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apoptosis by anticancer drugs. Results from my study showed that NFB induced 
resistance to anticancer drugs (Figure 4.3), which is consistent with other studies 
(Guo et al, 2009; Wang et al., 2003). This elevated NFB activity in TNBC has 
been suggested to be responsible for chemoresistance and metastatic growth.  
Metastasis the spread of primary tumours to secondary organs and sites 
contributes to over 90% of cancer mortality (Christofori, 2006).  EMT features 
induces the loss of epithelial markers (E-cadherin and α and  catenin), with 
associated gain in mesenchymal cell markers (fibronectin, vimentin, and N-
cadherin), leading to the acquisition of migratory and invasive properties (Huber 
et al., 2005). NFB signalling has been associated with EMT as evidence show 
that activation of NFB pathway is required for the induction and maintenance of 
Ras and transforming growth factor (TGF) β-dependent EMT. Furthermore, NFB 
binds to a promoter in E-cadherin repressor ZEB-1/2 resulting in regulation of the 
EMT phenotype (Chua et al., 2007). The NFB transfected cells were observed 
to have higher migratory and invasive potential indicating that NFB may indeed 
be essential for metastasis (Figure 4.6, 4.7 and 4.8). This hypothesis was further 
confirmed as inhibition of NFB with small molecule inhibitor and DS reduced the 
invasive and migratory potentials in the transfected cell lines (Figure 4.9 A and 
B). This is consistent with the reports by Huber et al., (2004) as blocking of NFB 
activity revoked the metastatic potential of mammary epithelial cells in a mouse 
model system.  
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Conclusion 
NFB promotes expression of antiapoptotic proteins protecting cells from 
apoptosis induced by chemotherapeutic agents contributing to chemoresistance 
of tumours. Hypoxia induced NFB activation may be important for the 
maintenance of CSCs during the development and progression of tumours. 
TNBC lacks targetable receptors, NFB may be considered as a potential 
therapeutic target for TNBC as inhibition of NFB increases the sensitivity of 
cancer cells to chemotherapeutic drugs. 
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Chapter Five 
The role of hypoxia inducible factors in hypoxia induced EMT and 
chemoresistance in breast cancer 
5.1 Introduction  
Many human cancers have significantly lower O2 concentration when compared 
to surrounding normal tissues. This persistent reduction in O2 availability induces 
the HIFs, HGF, ‘SNAIL’, ‘TWIST’, Notch and NFB pathways which regulates 
several cancer biological processes such as cell immortalization and stem cell 
maintenance, glucose and energy metabolism, vascularization, genetic 
instability, invasion and metastasis and resistance to therapy (Xia et al., 2009; 
Semenza, 2010). A study reported that there are regions of hypoxia or anoxia 
within sold tumours caused by poor or altered vascularization and deterioration 
of diffusion geometry which results in limited oxygen diffusion and delivery 
(Vaupel and Mayer, 2007). This decrease in oxygen tension may be detrimental 
to some tumour cells however hypoxia can contribute to a selection of cells that 
are more aggressive and promote tumour growth (Semenza, 2000; Harris, 2002), 
leading to poor prognostic outcome and an increased risk for metastasis that may 
escape therapy (Tatum et al., 2006). Neoplastic cells surviving in hypoxia display 
increased invasive tendency suggesting that hypoxia may favour cancer 
progression (Semenza, 2002; Le et al., 2004).  
Under hypoxia, several transcription factors are activated, one of such is the 
hypoxia-inducible factors (HIF-1 and HIF-2) referred to as the master regulators 
for hypoxia. HIF1α and HIF2α are commonly over expressed in malignant cells 
and is greatly associated with poor prognosis in many breast cancers (Schindl et 
al., 2002; Bos et al., 2003). 
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5.1.3 Rationale and aims of this study 
This study was carried out to investigate the role of HIF1α and HIF2α in hypoxia 
induced EMT and related stemness and to find out if HIF1α or HIF2α functions 
as the driving force behind chemoresistant CSCs in TNBC. 
5.2 Experimental Design  
General materials, products, labwares, manufacturers and methodologies used 
for the entire study have been described in details in chapter 2. Specific materials, 
methods and experimental design used for this part of this study are stated below.  
5.3.1 Stable transfection of MDA-MB 231 cell line with HIF1α and HIF2α 
HIF1α and HIF2α were overexpressed in breast cancer cell line after transfection 
with HIF1α and HIF2α pCMV6 subunits respectively. The mock transfected cells 
containing empty pCMV6 vector were controls for HIF expression (refer to 
Chapter 2, page 84).  
5.3.2 Determination of CSC markers in HIF transfected cells 
Over expression of the HIF protein should induce an increase in CSC markers 
which were measured by flow cytometry (refer to Chapter 2, page 78).  
5.3.3 Determination of EMT characteristics in HIF transfected cells 
Pervious results from chapter 3 show that EMT features were induced in cells 
grown under hypoxia. I expect the HIF transfected cells to also follow the same 
trend with cells overexpressing both HIF1α and HIF2α displaying mesenchymal 
characteristics. EMT markers were determined by western blot, in vitro wound 
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healing assay and transwell invasion assay were performed (refer to Chapter 2, 
page 85 and 86). 
5.3.3 MTT cytotoxicity assay for HIF transfected cells 
The drug sensitivity of Mock and HIF transfected celled were determined by MTT 
assay (refer to Chapter 2, page 71).  
5.4 Results  
5.4.1 Stable transfection HIF1α in MDA-MB 231BC cell line  
Mock cells and two clones (C3 and 4) with the highest expression of HIF1α 
cultured in media containing 150µg/ml of G418 were chosen for further testing. 
Western blot results (Figure 5.1) show that clones 3 and 4 expressed higher 
levels of HIF1α. 
 
 
 
 
 
 
Figure 5.1. Representative Western Blots of Mock and HIF1 transfection cells: 
MDA-MB 231 cell line was successfully transfected with pCMV6-HIF1 to increase the 
expression of HIF1 protein. Western blot analysis of whole cell lysates and nuclear protein 
from mock transfected cells and two clones (C-3 and C-4) revealed an increased expression 
and nuclear translocation of HIF1 in the positive clones in comparison to that of Mock cells. 
Tubulin and Nucleolin were used as loading control. 
MOCK C3      C4 
HIF1α nuclear protein 
α  tubulin 
Nucleolin 
HIF1α whole protein 
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5.4.2 Overexpression HIF1α in breast cancer cells induces higher 
expression of CSC markers.  
Data from FACS analysis (Figure 5.2 and 5.3) showed that the HIF1α over 
expressing clones C3 and C4 had significantly higher expression of CSC markers 
(ALDH and CD 133) and embryonic stem cell markers (Sox2, Oct4 and Nanog) 
when compared to the mock (Figure 5.4).  
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Figure 5.2. Representative FASC Plots of ALDH expression in MDA-MB 231 HIF1 
transfected cells measured by ALDEFLUOR assay. FASC results shows ALDH 
expression in Mock and HIF1α transfected clones (C3 and C4) with and without treatment 
with DEAB (30µM). HIF1α transfected clones (C3 and C4) expressed high percentage of 
ALDH+ compared to the mock cells before treatment with DEAB. Histogram (median ± 
interquartile range) displays the statistically significant increase in the ALDH+ activity in HIF1α 
transfected clones (C3 and C4) in comparison to mock cells (Kruskal-Wallis test, 
**p=<0.0001, n=9).  After treatment with DEAB, there was no statistical difference in ALDH+ 
cell from both cultures (Kruskal-Wallis test, p>0.05). (Abbreviations: DEAB: 
Diethylaminobenzaldehyde;  ALDH: Aldehyde dehydrogenase active) 
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Figure 5.2. Representative FASC Plots of CD133 expression in MDA-MB 231 mock 
and HIF1 transfected cells measured by PE-CD133 immunostaining assay. FASC 
data shows CD133 expression in mock and HIF1α transfected clones (C3 and C4). There 
was an increase in the expression of CD133 in the HIF1α overexpressing clones (C3 and 
C4) compared to mock cells. Histograms (median ± interquartile range) displays the 
statistically significant increase in the CD133 expression in HIF1α positive clones C3 and C4 
in comparison to mock transfected cells (Kruskal-Wallis test, **p=<0.05 n=9). 
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Figure 5.3. Representative FASC Plots of Embryonic Stem cell markers expression in 
MDA-MB 231 HIF1α transfected cell.  Fluorescence Activated Cell Sorting (FASC) data 
shows data shows that higher expression of embryonic stem cell markers nanog, Sox2 and 
Oct4 were displayed in HIF1α transfected clones (C3 and C4) compared to mock cells. 
Histograms (median ± interquartile range) above displays statistically significant increase in 
all three embryonic markers (Nanog, Oct4 and Sox2) markers in transfected transformed 
cells (C3 and 4) when compared to the mock (Kruskal-Wallis test, **p=<0.05 n=9). 
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5.3.3 Increase in HIF1α activity induces resistance to anticancer drugs 
Results from chapter 3 and 4 already show that both hypoxia and NFBp65 
overexpression induce chemoresistance to anticancer drugs. MTT cytotoxicity 
results showed that HIF1α positive clones C3 and C4 were extremely resistant to 
all five anticancer drugs (cisplatin, doxorubicin, vincristine, paclitaxel and 
gemcitabine) tested compared to the Mock cells. Figure 5.4 shows the cell 
viability curves and bar charts for the IC50 values for the five anticancer drugs 
indicating that increase HIF1α protein is able to drug resistance in cells. 
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Figure 5.4. Representative Drug Concentration Response Curves of Mock and 
HIF1 transfected cells after treatment with anticancer drugs CDDP, VCR, PTX, 
dFdC and DOX. The cell viability curves from MTT analysis shows the dose response 
of mock and HIF transfected cells (C3 and C4) to conventional anticancer drugs CDDP, 
VCR, PTX, dFdC and DOX. (Abbreviations; CDDP: cisplatin, VCR: vincristine, PTX 
paclitaxel, dFdC: gemciatbine and Dox: doxorubicin). 
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Table 5.1 IC50 values of some Anticancer Drugs in Mock and HIF1α 
Transfected Cells 
Anti -cancer 
drug 
IC50 Mock IC50 HIF1α 
C3 
IC50 HIF1α 
C4 
H- value p-value 
Cisplatin (µM) 201± 20.61 > 500 > 500 19.53 0.002** 
Paclitaxel (nM) 20.56 ± 10.67 > 200 > 200 26.32 0.0001** 
Vincristine (nM) 16.89 ± 5.33 > 150 >150 22.67 0.0001** 
Gemcitabine (nM) 30.49 ± 9.81 > 500 > 500 38.78 0.0001** 
Doxorubicin (nM) 300.11 ± 8.73 > 1000 > 1000 27.10 0.0001** 
 
Table 5.1 displays the results (median ± interquartile range) of half maximum inhibitory 
concentration (IC50) values of HIF1 transfected cells and mock cells. The HIF1 
transfected cells were found to have higher IC50 and were significantly resistant to these 
conventional anticancer drugs compared to the mock cells. (Kruskal-Wallis test, ** 
p<0.05, n=9). 
5.3.4 Cells with increase HIF1α activity displayed mesenchymal 
properties. 
Expression of mesenchymal proteins vimentin and N-cadherin in HIF1α positive 
clones were observed as shown from western blot analysis in Figure 5.5, with a 
loss of the epithelial marker E-cadherin. In the mock cells the E-cadherin 
expression was high with decreased expression of vimentin and N-cadherin 
suggesting an epithelial phenotype in these cells.  
Images taken from wound healing scratch assay and matrigel invasion assay in 
HIF1α transfect clones and mock cells showed that the HIF1α clones C3 and C4 
have increased invasive potential when compared to the mock transfected cells 
 
 
156 
 
(Figures 5.6 and 5. 7). These results show that HIF1α overexpression in cells is 
able to induce a more mesenchymal phenotype. 
 
 
 
 
 
 
 
Figure 5.5. Representative Western Blots of EMT markers in Mock and HIF1α 
transfected cells using whole cell lysates. The results shows that expression of E-
cadherin was decreased in HIF1α transfection clones and increased expression of 
mesenchymal markers (N-cadherin and vimentin) in comparison to that of Mock cells 
indicating epithelial to mesenchymal transition (EMT) activation in the these cells.  
Tubulin was used as loading control. 
 
 
 
 
 
Figure 5.6. Representative Matrigel Invasion assay Images of Mock and HIF1α 
transfected cells. Images (Magnification 20X) taken by light microscope after 3 days show 
that increase in HIF1α activity increased invasive properties of HIF1α positive clones C3 and 
C4 in comparison to Mock cells indicating EMT activation and mesenchymal properties  
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Figure 5.7. Representative Migration (wound healing) assay Images of Mock and 
HIF1α transfected cells. Images (Magnification 10X) shows that increase in HIF1α activity 
increased migratory properties of HIF1α positive clones C3 and C4 in comparison to Mock cells 
after 48 hours indicating EMT activation and mesenchymal phenotype.  
5.4.1 Stable transfection of HIF2α in MDA-MB 231BC cell line  
Mock cells and two clones (C4 and 6) with the highest expression of HIF1α 
cultured in media containing 200µg/ml of G418 were chosen for further testing. 
Western blot results (Figure 5.8) show that clones 4 and 6 expressed higher 
levels of HIF1α.  
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Figure 5.8. Representative Western Blots of Mock and HIF2 transfection cells: 
MDA-MB 231 cell line was successfully transfected with pCMV6-HIF2 to increase the 
expression of HIF2 protein. Western blot analysis of whole cell lysates and nuclear protein 
from mock transfected cells and clones (C-4 and C-6) revealed an increase in expression 
and nuclear translocation of HIF2 in the positive clones (C4 and C6) in comparison to that 
of Mock cells. Tubulin and Nucleolin was used as loading control. 
5.4.2 Overexpression of HIF2α in breast cancer cells induces higher 
expression of CSC markers.  
Data from FACS analysis (Figure 5.9 and 5.10) showed that the HIF2α 
overexpressing clones C4 and C6 have significantly higher expression of CSC 
markers (ALDH and CD 133) when compared to the mock similar to the finding 
for HIF1α. The expression of embryonic stem cell markers Sox2, Oct4 and Nanog 
were also increased in the HIF2 overexpressing clones compared to the mock 
cells (Figure 5.11). 
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Figure 5.9. Representative FASC Plots of ALDH expression mock and HIF2 
transfected cells measured by ALDEFLUOR assay.  FASC results shows ALDH 
expression in mock and HIF2α transfected clones (C4 and C6) with and without treatment 
with DEAB (30µM). HIF2α transfected clones (C4 and C6) expressed high percentage of 
ALDH+ compared to the mock cells before treatment with DEAB. Histograms (median ± 
interquartile range) displays the statistically significant increase in the ALDH+ activity in HIF2α 
transfected clones (C4 and C6) in comparison to mock cells (Kruskal-Wallis test, 
**p=<0.0001, n=9).  After treatment with DEAB, there was no statistical difference in ALDH+ 
cell from mock and HIF2α transfected clones (Kruskal-Wallis test, p>0.05). (Abbreviations: 
DEAB: Diethylaminobenzaldehyde;  ALDH: Aldehyde dehydrogenase). 
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Figure 5.10. Representative FASC Plots of CD133 expression in MDA-MB 231 in 
mock and HIF2 transfected cells measured by PE-CD133 immunostaining assay.  
Fluorescence Activated Cell Sorting (FASC) data shows CD133 expression in mock and 
HIF2α transfected clones (C4 and C6). There was an increase in the expression of CD133 
in the HIF2α overexpressing clones (C4 and C6) compared to mock cells. Histograms 
(median ± interquartile range) displays the statistically significant increase in the CD133 
expression in HIF2α positive clones C4 and C6 in comparison to mock transfected cells 
(Kruskal-Wallis test, **p=<0.05 n=9). 
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Figure 5.11. Representative FASC Plots of Embryonic Stem cell markers expression 
in MDA-MB 231 mock and HIF2α transfected cell.  FASC data shows data shows that 
higher expression of embryonic stem cell markers (Nanog, Sox2 and Oct4) were displayed 
in HIF2α transfected clones (C4 and C6) compared to mock cells. Histograms (median ± 
interquartile range) above displays statistically significant increase in all three embryonic 
markers (Nanog, Oct4 and Sox2) markers in transfected transformed cells (4 and 6) when 
compared to the mock (Kruskal-Wallis test, **p=<0.05 n=9). 
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5.4.3 Increase HIF2α expression induces resistance to anticancer drugs 
Drug sensitivity of HIF2α clones to CDDP, a first line drug for TNBC and four 
other conventional anticancer drugs PTX, DOX, VCR and dFdC were tested. MTT 
cytotoxicity results showed that HIF2α positive clones C4 and C6 were extremely 
resistant to all five anticancer drugs tested compared to the Mock cells. Figure 
5.12 shows the cell viability curves for the IC50 values for the five anticancer drugs 
indicating that increase HIF2α protein is able to induce drug resistance in cells. 
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Figure 5.12 Representative Drug Concentration Response Curves of Mock and 
HIF2 transfected cells after treatment with CDDP, VCR, PTX, dFdC and DOX. The 
cell viability curves show that HIF2 transfected cells were highly resistant to these 
anticancer drugs. The transfected cells survived at higher concentrations of drugs compared 
to mock cells (Cisplatin: CDDP, vincristine: VCR, paclitaxel: PTX, gemcitabine (dFdC) and 
doxorubicin (DOX). 
Table 5.2 IC50 values of 5 Anticancer Drugs in Mock and HIF2α Transfected 
cells 
Anti -cancer 
drug 
IC50 Mock IC50 HIF2α 
C4 
IC50 HIF2α 
C6 
H- 
value 
p-value 
Cisplatin (µM) 201 ± 40.32 > 500 > 500 17.83 0.001** 
Paclitaxel (nM) 20.56 ± 10.67 > 200 > 200 24.42 0.0001** 
Vincristine (nM) 16.89 ± 5.33 > 150 >150 27.57 0.0001** 
Gemcitabine (nM) 30.49 ± 9.81 > 500 > 500 36.18 0.0001** 
Doxorubicin (nM) 300.11 ± 8.73 > 1000 > 1000 29.90 0.0001** 
 
Table 5.2 displays the results (median ± interquartile range) of half maximum inhibitory 
concentration (IC50) values of HIF2 transfected cells (C3 and C4) and mock cells. The 
HIF2 transfected cells were found to have higher IC50 and were significantly resistant to 
these conventional anticancer drugs compared to the mock cells. (Kruskal-Wallis test, ** 
p<0.05, n=9). 
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5.4.3 Increase HIF2α activity show mesenchymal properties. 
Similar to the results for HIF1α overexpressing cells, HIF2α clones (C4 and C6) 
also expressed higher mesenchymal proteins vimentin and N-cadherin with a 
loss of the epithelial marker E-cadherin as seen from western blot analysis 
(Figure 5.13). In the mock cells the E-cadherin expression was high with 
decreased expression of vimentin and N-cadherin suggesting an epithelial 
phenotype in these cells.  
Migration and invasion assay (Figure 5.14 and 5.15) further confirmed the 
increased migratory and invasiveness of HIF2α overexpressing cells.  
 
 
 
 
 
 
 
 
Figure 5.13. Representative Western Blots of EMT markers in Mock and HIF2α 
transfected cells using whole cell lysates. The results show that HIF2α transfection 
decreased expression of epithelial marker E-cadherin and increased expression of 
mesenchymal markers (N-cadherin and vimentin) in comparison to that of Mock cells 
indicating EMT activation in the hypoxic cells.  Tubulin was used as loading control. 
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Figure 5.14. Representative Matrigel Invasion assay Images of Mock and HIF1α 
transfected cells. Images (Magnification 20X) taken shows  that increase in HIF2α 
activity enhanced the invasive properties of HIF2α positive clones C4 and C6 in 
comparison to Mock cells after 3 days indicating EMT activation and mesenchymal 
phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15. Representative Migration (wound healing) assay Images of Mock and 
HIF2α transfected cells. Images properties (Magnification 10X) shows  that increase in 
HIF2α activity increased migratory properties of HIF2α positive clones C4 and C6 in 
comparison to Mock cells even after 48 hours indicating EMT activation and 
mesenchymal.  
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5.5. Discussion  
Cellular adaptation to environmental stresses such as hypoxia promotes the 
activation of several signalling pathways to ensure survival. Primary mediators of 
the hypoxic response of cells HIF1α and 2α are activated under hypoxic stress. 
Results from previous chapter (Chapter 3) show that both HIF1α and 2α nuclear 
translocation increased in BC cells cultured under hypoxia. It was hypothesized 
that either HIF1α or 2α may be responsible for the hypoxia-induced epithelial to 
mesenchymal transition (EMT) and resultant chemoresistance in BC cells. To this 
effect, the EMT and cancer stem cell (CSC) abilities of HIF1α and 2α were studied 
through over expression by stable transfection in MDA-MB 231 BC cell line. After 
successful transfection, several clones were picked and screened two clones with 
the highest expression and nuclear translocation of HIF were selected. These two 
positive clones and one mock transfected clone (control) was analysed for both 
HIF1α and 2α proteins using western blot.  
HIF the master regulator of hypoxia is not normally expressed in breast tissues 
but is highly expressed in malignant breast cancer (Wang et al., 2006). Hypoxia 
promotes EMT in BC cells via the induction of notch and twist pathways which 
are direct transcription target of HIF1α (Higgins et al., 2007). HIF2α was shown 
to induce EMT by overexpression of ‘snail’ and ‘vimentin’ in mouse lung model 
(Li et al., 2009). My results show that both HIF1α and 2α overexpressing clones 
have higher expression of vimentin and N-cadherin indicating a mesenchymal 
phenotype with associated loss of E-cadherin a hallmark of epithelial phenotypes. 
The migratory and invasive potential from these HIF overexpressing clones were 
also increased. It was hypothesized that the induction of CSCs-like traits by HIF 
may be responsible for this drug resistance. Multiple recent studies in CSC 
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isolated from GBM, neuroblastoma, renal cancer and non-small lung cancer 
show that HIF2α is required for the maintenance of the CSC phenotype and its 
functions (Li et al., 2009). Heddleston et al., (2010) reported that HIF2α activation 
increased expression of CSC factors like cMyc, Nanog and Oct4. Similar to the 
findings of these reports the HIF1α and 2α overexpressing cells also had higher 
expression of CSC markers ALDH a universal marker for stemness of cells, CD 
133 and CD44 with accompanying low expression of CD24 all suggestive of CSC-
like cell phenotype when compared to the mock. The expression of embryonic 
stem cell markers Sox2, Oct4 and Nanog were also increased in the HIF1α and 
2α transfected cells when compared to the mock cells. The results from this study 
suggest that both HIF1α and 2α play important role in the activation of EMT and 
consequent maintenance of CSC phenotype. 
Study by Teicher et al., (2003) demonstrated that BC cells acquire resistance to 
doxorubicin under low-oxygen-induced hypoxia and CoCl2-induced chemical 
hypoxia indicative that HIF play significant role in hypoxia induced 
chemoresistance. The focus of this study was to examine the effects HIF1α and 
2α overexpression on chemoresistance and possibility understand the 
mechanism involved in this drug resistance. The results showed that both HIF1α 
and 2α overexpressing cells were significantly resistant to the 5 conventional 
anticancer drugs tested (cisplatin, paclitaxel, doxorubicin, vincristine and 
gemcitabine) which is in line with previously published study (Sullivan and 
Graham, 2009). Recent studies show that cancer stem-like cells play key roles in 
TNBC chemoresistance (Bhola et al., 2013 and Samanta et al., 2014). Bhola et 
al., (2013) demonstrated that HIF-1α is a central determinant of triple negative 
cancer stem-like cell chemo-resistance. These finding along with results obtained 
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from this study strongly suggest that HIF are important for induction of CSC traits 
in BC with associated EMT and chemoresistance. 
Conclusion 
The main aim of this study was to examine the role of HIF1α and 2α proteins in 
hypoxia-induced EMT and consequent chemoresistance. Data from my results 
show that both HIF1α and 2α can induce EMT and CSC traits. Therefore, 
development of pharmacological agents to inhibit these factors may hold promise 
for patients with TNBC as they lack targetable receptors. 
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Chapter Six 
The cytotoxic mechanisms of Disulfiram in pan-chemoresistant breast 
cancer cell lines 
6.0 Characterization of resistant breast cancer cell lines (T47DDox100nM 
and MDA-MB 231Gem 100nM). 
6.1. Introduction 
Primary and acquired resistance represents a major challenge for the 
effectiveness of chemotherapeutic agents in breast cancer management. 
Doxorubicin (Dox) an anthracycline antibiotic is one of the most widely used 
chemotherapuetic agents for BC and is a prefered single agent as well as used 
in combination regimens for recurrent and metastatic BC (Gluck, 2005). 
Resistance to Dox can occur  through several mechanisms such as decreased 
drug accumulation in which there is an increase drug efflux due to overexpression 
of multidrug resistance protein P-glycoprotein, alteration in drug targets proteins 
via cellular downregulation of topoisomerase II expression,  cellular suppression 
of apoptosis by upregulation of GST and by enhanced capacity of drug-induced 
DNA repair (Nielsen et al., 1996; Tubbs et al., 2009). 
Gemcitabine (dFdC) can be used as a single agent for advanced BC or in 
combination therapy with other chemotherapeutic drugs such as CDDP and PTX 
with even higher response rates. It is a first line drug for the treatment of BC and 
has a high initial activity against tumours but is prone to induce acquired 
resistance in cancer cells. Metabolism and chemoresitance mechanisms of dFdC 
have been discussed in detailed in chapter 1.  
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Many current cancer therapies are limited by the severity and frequency of 
adverse side effects associated with such treatments which has led to a search 
and high demand for non-toxic alternatives. One source of new therapies may be 
through repurposing of clinically approved drugs, where safety in patients has 
already been established. Disulfiram (DS) an anti-alcoholism drug used in clinic 
for over 60 years (Eneanya et al., 1981) demonstrates anti-cancer effects in 
cancer cell lines (Cen et al., 2004) as well as in a range of solid and 
haematological malignancies (Wickstrom et al., 2007). The clinical use of DS over 
a long period of time has shown it to be a very safe drug with minimal and 
manageable toxic effects, even at fairly high doses of 300 to 500 milligrams daily 
(Sauna et al., 2005).  
The biological activity of disulfiram is attributed to its ability to bind divalent cations 
and consequently disrupt metal dependent processes, principally those involving 
copper (Cu) and zinc (Zn) (Marikovsky et. al., 2002; Shiah et. al., 2003). Several 
in vitro experiments indicate that the cytotoxicity of DS is entirely dependent on 
copper(II) (Cu) or some other transition bivalent metal ions in the culture medium 
(Cen et. al., 2004; Iljin  et. al., 2009; Liu et. al., 2012).  
Acquired resistance of initially senstive cancer cells to chemotherapeutic drugs 
is a major challenge for successful treatment of BC cells. Previous chapters 3, 4 
and 5 have revealed that CSCs, NFB and HIFs play vital roles in conferring 
resistance to BC cell. Therefore, it is necessary for development of drugs that 
counter these resistance in BC. However, no positive data has been published 
by clinical trials using oral version of DS plus copper gluconate in cancer 
treatment even with the promising laboratory data obtained from the in vitro and 
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in vivo experiments in cancer cell lines and animals respectively. Therefore, 
elucidating the disparity between the anticancer cytotoxicity of DS in laboratory 
and clinic is of great importance. 
6.1.2. Rationale for the study 
This study evaluates the drug sensitivity of MDA-MB 231GEM100nM and 
T47DDox100nM to a number of conventional anticancer drugs and the possible 
mechanisms for drug resistance. 
A recent study by Lewis et al., (2014) proposed that the in vitro cytotoxicity of DS 
in cancer cells occurs by ROS generated from the reaction of DS and Cu rather 
than the final product, DDC-Cu. If this is the case, then DS and Cu may not be 
able to react near the cancer cells to execute anticancer cytotoxic action in vivo 
since the half-life of ROS is very short (D'Autreaux and Toledano 2007). Thus it 
will be virtual impossible to translate the in vitro anticancer cytotoxic effect of DS 
into clinic. Furthermore, if ROS generated by the reaction of DS and Cu is the 
major mechanism by which DS carries out its anticancer effect, then DDC-Cu will 
have no significant cytotoxic effect on cancer cells. The study was performed to 
examine the effect of DS-Cu induced ROS and to determine if DDC-Cu has any 
cytotoxic effects on cancer cells. 
6.2. Experimental Design 
General materials, products, labwares, manufacturers and methodologies used 
for the entire study have been described in details in chapter 2. Specific materials, 
methods and experimental design used for this part of this study are stated below. 
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6.2.1. MTT cytotoxicity assay in resistant cell lines 
Drug sensitivity of the resistant cells lines (MDA-MB-231GEM100nM and 
T47DDox100nM) and parental cell line (MDA-MB-231 and T47D) were analysed 
using MTT assays (refer to Chapter 2, page 71).  
6.2.2. Time dependent Cytotoxicity of DDC-Cu and DS plus Cu (DS/Cu)  
To examine the time-dependent cytotoxicity of DS/Cu reaction and DDC-Cu. 
MCF 7 breast cancer cells were exposed to DDC-Cu or DS/Cu (1:1 molar 
ratio) in a time dependent manner and then subjected to MTT assay (refer to 
Chapter 2, 72). 
6.2.3. Determination of CSC markers in resistant cell lines 
CSC markers ALDH, CD133, Sox2, Oct4 and Nanog were detected in the 
resistant and parental cell lines by flow cytometry (refer to Chapter 2, page 78). 
6.2.4. Reactive Oxygen Species activity detection 
To examine the effects of reactive oxygen species (ROS) generated by DS plus 
Cu reaction, extracellular ROS levels at different time intervals were determined 
in culture medium (refer to Chapter 2, page 93).  
6.2.5. Determination of metabolic kinetics of DS/Cu and DDC-Cu 
To examine the metabolic kinetics of DS plus Cu and DDC-Cu, medium and 
MCF7 cells lysate were subjected HPLC analysis after treated with equal 
molar ratio of DS and CuCl2 or DDC-Cu (refer to Chapter 2, page 94).  
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6.3. Results  
6.3.1. Morphological features  
The drug resistance cells were observed to have a different phenotype than the 
wild type (WT) parental cells. The resistant cells were smaller and with less 
defined irregular multiple nuclei.  
    
 
 
 
 
 
 
Figure 6.1 Representative Images of Morphology of wild type and resistant cells. 
Images taken by light microscopy shows the morphology of parental and resistant cells 
(Magnification 20X) after culturing in normoxia. The resistant cells were smaller in size when 
compared to the parental cell lines (Abbreviations WT: wide type; MDA-MB-231GEM100nM: 
MDA-MB231 gemcitabine resistant cell. 
6.3.2. Resistant cell lines show cross and pan-resistance to anticancer 
drugs 
Data from MTT cytotoxicity analysis showed that apart from being highly resistant 
to dFdC (Figure 6.3A), the MDA-MB 231Gem100nM cell line is also cross resistant 
to other anticancer drugs e.g. CDDP, Dox, VCR and PTX (Figure 6.3B). The 
parental cell line has a much lower IC50s compared to that of the resistant cell line 
T47D WT  T47D Dox100nM 
MDA-MB 231 
WT 
MDA-MB 231 Gem100nM 
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MDA-MB 231Gem100nM (Table 6.1). Similar results were also obtained for the 
T47DDox100nM cell line, in which resistance to Dox was observed and cross 
resistance to other anticancer drug with various mechanism of action (Figure 6.4 
A and B).  
 
 
 
 
 
 
 
 
Figure 6.2(A). Representative Drug Concentration Response Curve of MDA-MB 
231 and MDA-MB 231Gem100nM cell line. Cell viability curve from MTT analysis shows 
difference in dose response between resistant cell (MDA GEM) and parental cell (MDA WT). 
The resistant cell displayed significant resistance to dFdC. Histogram (median ± interquartile 
range) shows elevated half maximal inhibitory concentration (IC50) values indicating 
increased drug resistance to gemcitabine (Mann and Whitney U test, resistance, **p=<0.001, 
n=9). (Abbreviations; MDA-WT: MDA-MB 231 wild type cell line, MDA GEM: MDA-MB 231 
gemcitabine resistant cell line, dFdC: gemcitabine). 
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Figure 6.2(B). Representative Drug Concentration Response Curves of MDA-MB 
231 and MDA-MB 231Gem100nM cell line. Cell viability curve shows difference in dose 
response between resistant cell and parental cell lines. The resistant cell MDA-MB 
231Gem100nM displayed significant cross resistance to anticancer drugs (VCR, Dox, CDDP and 
PTX). Histogram (median ± interquartile range) shows elevated half maximal inhibitory 
concentration (IC50) values indicating increased drug resistance (MDA WT: MDA-MB 231 
wild type cell line, MDA GEM: MDA-MB 231 gemcitabine resistance cell line, VCR: 
vincristine, Dox: doxorubicin, CDDP: cisplatin and PTX: paclitaxel). 
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Figure 6.3. Representative Drug Concentration Response Curve of T47D and 
T47DDox100nM cell line. Cell viability curve from MTT analysis shows difference in dose 
response between resistant cell (T47DDox100nM) and parental cell (T47D WT). The resistant 
cell displayed significant resistance to Dox. Histogram (median ± interquartile range) shows 
elevated half maximal inhibitory concentration (IC50) values indicating increased drug 
resistance to doxorubicin (Mann and Whitney U test, resistance, **p=<0.001, n=9). 
(Abbreviations; T47D-WT: T47D wild type cell line, T47D DOX: T47D doxorubicin resistant 
cell line, Dox: doxorubicin). 
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Figure 6.3.B Representative Drug Concentration Response Curves of T47D and 
T47DDox100nM cell line to conventional anticancer drugs. Cell viability curve shows 
difference in dose response between resistant cell (T47DDox100nM) and parental cell (T47D WT). 
The resistant cell T47DDox100nM displayed significant cross resistance to anticancer drugs (VCR, 
dFdC, CDDP and PTX). Histogram (median ± interquartile range) shows elevated half maximal 
inhibitory concentration (IC50) values indicating increased drug resistance in T47DDox100nM cell 
lines  (Mann and Whitney U test, resistance, **p=<0.001, n=9). (Abbreviations; T47D-WT: T47D 
wild type cell line, T47D DOX: T47D doxorubicin resistant cell line, cisplatin (CDDP), paclitaxel 
(PTX), vincristine (VCR) and gemcitabine (dFdC)). 
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Table 6.1 IC50 Value from cell viability curve in Resistant Cell Line T47DDox 
100nM and Sensitive Cell Line T47D WT 
Anti-cancer 
drug/ IC50 
T47D WT T47D Dox100nM U- value p-value 
Cisplatin (µM) 198.01 ± 5.89 > 600 17.12 0.0002** 
Paclitaxel (nM) 7.69± 0.26 > 200 36.29 0.0001** 
Vincristine (nM) 4.81 ± 3.56 > 250 31.97 0.0001** 
Gemcitabine (nM) 224.54 ± 4.81 > 600 23.45 0.0001** 
Doxorubicin (nM) 365.78 ± 108.73 > 1000 29.32 0.0001** 
 
Table 6.1 displays the results (median ± interquartile range) of half maximum inhibitory 
concentration (IC50) values of T47D wild type and T47DDox 100nM resistant cell line. The 
resistant cell line T47DDox 100nM were found to have higher IC50 and were significantly 
resistant to these conventional anticancer drugs compared to the mock cells. (Mann and 
Whitney U test ** p<0.05, n=9). (Abbreviations: WT: wild type, IC50: half maximum inhibitory 
concentration) 
6.3.3. Resistant cell lines displayed an increase in CSC markers 
Data from FACS analysis show that the resistant cell lines MDA-MB-231GEM100nM 
(Figure 6.4 A and B) have higher expression of CSC markers (ALDH, CD 133) 
compared to the sensitive parental cell line MDA-MB 231 WT. Similar results 
were also obtained for T47DDox100nM resistant cells (Figure 6.5 A and B). 
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Figure 6.4(A) Representative FASCS Plots of ALDH expression in MDA-MB 231 WT 
and MDA-MB 231GEM100nM BC cell line. FASC results shows ALDH activity in MDA-MB 231 
WT and MDA-MB 231GEM100nM BC cells with and without treatment with DEAB (30µM). MDA-MB 
231GEM100nM expressed high percentage of ALDH+ compared to the mock cells before treatment 
with DEAB. Histogram (median ± interquartile range) displays the statistically significant increase 
in the ALDH+ activity in MDA-MB 231GEM100nM in comparison to MDA-MB 231 WT (Mann and 
Whitney U test, **p=<0.0001, n=9).  After treatment with DEAB, there was no statistical difference 
in ALDH+ cell from both cultures (p>0.05).  (Abbreviations WT: wild type, GEM100nM: 
gemcitabine resistance cell line, DEAB: Diethylaminobenzaldehyde;  ALDH: Aldehyde 
dehydrogenase active). 
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Figure 6.4(B). Representative FASC Plots of CD133 expression in MDA-MB 231 WT 
and MDA-MB 231GEM100nM BC cell line by PE-CD133 immunostaining assay. 
FASC data shows CD133 expression in MDA-MB 231 WT and MDA-MB 231GEM100nM cell 
lines. There was an increase in the expression of CD133 in the MDA-MB 231GEM100nM 
compared to parental cell line MDA-MB 231 WT. Histograms (median ± interquartile range) 
displays the statistically significant increase in the CD133 expression in MDA-MB 
231GEM100nM in comparison to sensitive MDA-MB 231 WT cell line (Mann and Whitney U test, 
**p=<0.0001, n=9) (Abbreviations: WT: wide type; GEM100nM: gemcitabine resistance cell). 
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Figure 6.5(A). Representative FASC Plots of ALDH expression in T47D WT and 
T47DDox100nM BC cell line measured by ALDEFLUOR assay. FASC results shows ALDH 
expression in T47D WT and T47DDOX100nM BC cells with and without treatment with DEAB 
(30µM). T47DDOX100nM expressed high percentage of ALDH+ compared to the mock cells 
before treatment with DEAB. Histogram (median ± interquartile range) displays the 
statistically significant increase in the ALDH+ activity in T47DDOX100nM in comparison to T47D 
WT (Mann and Whitney U test, **p=<0.0001, n=9).  After treatment with DEAB, there was no 
statistical difference in ALDH+ cell from sensitive and resistant cell lines (Mann and Whitney 
U test, p>0.05).  (Abbreviations WT: wild type, Dox100nM: doxorubicin resistance cell, DEAB: 
Diethylaminobenzaldehyde; ALDH: Aldehyde dehydrogenase active). 
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Figure 6.5B. Representative FASC Plots of CD133 expression in T47D WT and 
T47DDox100nM BC cell line measured by PE-CD133 immunostaining assay. FASC data 
shows CD133 expression in T47D WT and T47DDox100nM cell lines. T47DDox100nM cells 
displayed increase in CDD 133 expression compared to parental cell line T47D WT.  
Histogram (median ± interquartile range) above displays statistically significant increase in 
CD133 in T47DDox100nM cells compared to the sensitive parental cell T47D WT (Mann and 
Whitney U test, **p=<0.0001, n=9). (Abbreviations: WT: wide type; Dox100nM: doxorubicin 
resistance cell, ALDH: aldehyde dehydrogenase).  
 
S
id
e
 S
c
a
tt
e
r 
CD133 expression 
T47D WT T47DDox100nM 
0.0
3.0
6.0
9.0
T47D WT  T47D DOX 100
+
v
e
 c
e
ll
s
 (
%
)
CD133 expression
** 
 
 
184 
 
6.3.4. Resistant cell lines displayed an increase in embryonic stem cell 
markers 
The embryonic stem cells (Nanog, Sox2, Oct4) important for maintenance of stem 
cell, renewal and pluripotency were also significantly increased in the resistant 
cell lines MDA-MB-231GEM100nM and T47DDox100nM in comparison to the parental 
cell MDA-MB-231and T47D respectively. (Figure 6.6 (A)(B) and 6.7).  
 
 
 
 
 
 
 
 
 
Figure 6.6(A). Representative FASC Plots of Embryonic Stem cell markers expression 
in MDA-MB 231 MDA-MB 231 Wild Type and MDA-MB 231GEM100nM cell line.  
Fluorescence Activated Cell Sorting (FASC) data shows that higher expression of embryonic 
stem cell markers (nanog, Sox2 and Oct4) were displayed in MDA-MB 231GEM100nM 
compared to parental cell MDA-MB 231.   
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Figure 6.6B Bar chart Representation of embryonic stem cell markers expression 
in MDA-MB 231 WT and MDA-MB 231GEM100nM BC cell line. Histograms (median ± 
interquartile range) above displays statistically significant increase in all three embryonic 
markers (Nanog, Oct4 and Sox2) markers in MDA-MB 231 GEM100nM cells compared to the 
sensitive parent cell MDA-MB 231 WT (Mann and Whitney U test, **p=<0.05, n=9). 
(Abbreviations: WT: wide type; GEM100nM: gemcitabine resistance cell). 
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Figure 6.7. Representative FASC Plots of Embryonic Stem cell markers expression in 
T47D WT and T47DDox100nM cell line.  Fluorescence Activated Cell Sorting (FASC) data shows 
that higher expression of embryonic stem cell markers (Nanog, Sox2 and Oct4) were displayed 
in T47DDox100nM compared to parental cell T47D.  Histograms (median ± interquartile range) above 
displays statistically significant increase in all three embryonic markers (Nanog, Oct4 and Sox2) 
markers in T47DDox100nM cells compared to the sensitive parent cell T47D wild type (Mann and 
Whitney U test, **p=<0.05, n=9). (Abbreviations: WT: wide type; Dox100nM: doxorubicin 
resistance cell). 
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6.3.5. Resistant cell lines have longer doubling time 
Quiescence is a common feature of drug resistant cancer cell lines. The cell 
growth of resistant cells MDA-MB-231GEM100nM and T47DDox100nM were 
significantly slower compared to the parental wide type cells MDA-MB-231 and 
T47D respectively.  Growth curves show that the resistant cells have a longer 
doubling time as shown in Figure 6.8.  
 
 
 
 
 
 
 
 
Figure 6.8. Representative Growth curves of MDA-MB-231 and MDA-MB-
231GEM100nM cells and T47D and T47DDOX100nM cell lines. The figure shows the growth 
curve (Mean ± SD) for wide type cells and resistant cells, MDA-MB-231GEM100nM and 
T47DDOX100nM cell lines proliferates slower than their respective wide type cells. 
(Abbreviations: WT: wide type; Dox100nM: doxorubicin resistance cell, ALDH: aldehyde 
dehydrogenase) 
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6.3.6. Western blot analysis of antiapoptotic proteins 
Western blot analysis performed on whole cell lysate of T47DDox100nM resistant 
cell line show that expression of P-gp may be a major factor contributing to drug 
resistance in these cells. 
 
   
 
 
 
 
 
Figure 6.9. Representative Western Blot of MDR1 P-pg expression in T47D wild 
type and T47DDox100nM. Western blotting on whole cell lysates shows that T47DDox100nM 
resistant cell overexpresses multiple drug resistance1 (MDR1) P-glycoprotein compared 
to sensitive T47D wild type cell line. 
6.3.7. Resistant cells exhibit reduce cytotoxic apoptotic induced death 
Several morphological changes were observed in the resistant cell lines. Images 
captured using light microscope show that the MDA-MB 231GEM100nM cells were 
smaller than the parental cell MDA-MB 231 cells. The T47DDox100nM appeared to 
have multiple nuclei, spindle like with elongated pseudopodia and have a less 
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cohesive appearance while parental T47D cells have a cobblestone appearance 
with single nuclei.  
Cell death was observed in the parental cells MDA-MB 231 and T47D cells after 
exposure to 200nM and 700nM of dFdC and Dox respectively, while the resistant 
cells were tolerant to the anticancer drugs. Treatment of cells with Ds/Cu induced 
massive cell death.  
 
 
 
 
 
 
 
 
 
 
Figure 6.10.A. Representative Images of MDA-MB-231GEM100nM cell line resistance 
to gemcitabine-induced apoptosis. Images shows the morphology (× 20 magnification) of 
MDA-231 WT and MDA-MB231GEM100nM cells before and after treatment with dFdC (200nM). After 
72 hours, cell death was observed in the MDA-MB 231 treated parental cells while the resistant 
cells survived. Treatment of MDA-231 WT and MDA-MB231GEM100nM cell lines with DS plus Cu for 
4 hours induced cell death in both resistant and sensitive cell lines. (Abbreviations: dFdC: 
gemcitabine, WT: wild type, GEM100nM: gemcitabine resistance cell, DS: disulfiram, Cu: copper).  
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Figure 6.10B. Representative Images of T47DDox100 cell line resistance to 
doxorubicin-induced apoptosis. Images shows the morphology (×20 magnification) of 
T47D wild type and T47DDox100nM cells before and after treatment with Dox (700nM). After 72 
hours, cell death was observed in the MDA-MB 231 treated parental cells while the resistant 
cells survived. Treatment of T47D wild type and T47DDox100nM cell lines with DS plus Cu for 
4 hours induced cell death in both resistant and sensitive cell lines. (Abbreviations: Dox: 
doxorubicin, WT: wild type, DOX100nM: doxorubicin resistance cell, DS: disulfiram, Cu: 
copper). 
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6.4.1 Cytotoxicity of DDC-Cu and DS plus Cu (DS/Cu) was observed in 
cancer cell lines. 
After 72 hours exposure of DDC-Cu and DS/Cu, both showed high cytotoxic 
to MCF7 breast cancer cell line. The IC50 of DS/Cu was 449nM while that of 
DDC-Cu which was 238nM.  Our results showed that DDC-Cu exhibited 
higher cytotoxicity than DS/Cu (Figure 6.11). This may indicate that the 
cytotoxicity of DS/Cu may not be solely due by the reaction between DS and 
Cu but DDC-Cu the final product of the reaction may play critical role in DS/Cu 
induced cell death. 
 
Figure 6.11. Representative Drug Concentration Response Curve of MCF7 
cells treated with DS/Cu and DDC-Cu. Viability curve from the MTT analysis show 
that both DS/Cu and DDC-Cu are toxic to cancer cells. DDC-Cu complex induced more 
cell death in than DS plus Cu treated MCF 7 cell line (DS: disulfiram, Cu: copper, DDC-
Cu: diethyldithiocarbamic copper complex). 
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6.4.2 Time dependent cytotoxicity of DDC-Cu and DS plus Cu (DS/Cu) in 
BC cancer cell lines. 
The time dependent cytotoxicity of DS/Cu reaction and DDC-Cu was studied 
at different time interval. Viability curve from MTT analysis showed that there 
was massive cell death in cells exposed to DS/Cu after 30 minutes with more 
cell death detected at 60 minutes but levelled off after 180 minutes. This was 
in contrast to cell killing observed for DDC-Cu, at 30 and 60 minutes no 
significant cell death was observed until about 180 minutes (Figure 6.12).  
The viability curves for both DS/Cu and DDC-Cu was similar until after 72 
hours where more killing was observed for DDC-Cu (Figure 6.11A). This 
results suggest that the DS is able to exhibit a rapid cytotoxic effect on cancer 
cells, followed a delayed cell killing by DDC-Cu.          
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Figure 6.12. Representative Drug Concentration Response Curves of DS/Cu and DDC-Cu at different time points (30min, 60min, 
180min, 360 min, 12 hours and 24 hours). Cell viability curve from MTT analysis for DS/Cu and DDC-Cu at different time interval show 
that both DS/Cu and DDC-Cu are toxic to cancer cells. DS plus Cu and DDC-Cu were both toxic to cancer cells in a time dependent trend.
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6.4.3 ROS was responsible for the cytotoxic killing of DS/Cu 
MTT analysis data show that DS/Cu and DDC-Cu are both toxic to cancer. 
According to a recent report by (Lewis et al., 2014) the cytotoxic effect of DS in 
association with Cu was attributed to the generation of ROS. Extracellular ROS 
generation in medium was examined from the reaction of DS/Cu, DDC-Cu, DS 
alone, Cu alone and H2O2. The results showed that higher levels of ROS was 
detected at ordinary working concentration of DS at 10µM, the reaction between 
Ds/Cu generated significantly higher ROS that 20µM H2O2 and plateaued at 
about 3 hours. Lower levels of ROS were detected from 10mM of DS/Cu probably 
due to instant crystallization of DS and Cu at higher concentrations. No significant 
ROS was detected in DDC-Cu and DS only containing mediums (Figure 6.13), 
indicating that ROS may be responsible for the cytotoxicity of DS/Cu but not DDC-
Cu. 
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Figure 6.13. Representative Plots of ROS activity detected in DS, Cu, DS/Cu, 
DD-Cu and H2O2 containing cell culture medium. Extracellular ROS in medium 
containing DS/Cu and H2O2 generated higher ROS than medium containing DDC-Cu, 
DS alone, Cu alone suggestive that ROS generated by DS plus Cu reactive could be 
responsible for the rapid cell death. The intensity of the fluorescence represents the 
intensity of the ROS in the medium (ROS: reactive oxygen species, DS: disulfiram, Cu: 
copper, DDC-Cu: diethyldithiocarbamic copper complex). 
6.4.4 DS/Cu is unstable in medium 
The stability of DS/Cu and the metabolic kinetics of DS/Cu and DDC-Cu in MCF7 
cell cultured was evaluated. Peak for pure standard DDC-Cu and DS were 
detected at retention time of 4.15 and 7.07 minutes respectively (Figure 6.14). 
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DDC-Cu was detected in both medium and cell lysate extracts from DS/Cu 
containing medium with a steady increase in concentration (Figure 6.15). Stable 
levels of DDC-Cu was detected in medium and cell lysate when pure DDC-Cu 
was added to culture medium( Figure 6.16), DS was detected in DS/Cu cultured 
medium but rapidly plunged to undetectable levels after 30 minutes while no DS 
was detected in cell lysate. 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14(A). Representative HPLC Peaks DS and DDC-Cu in cell medium. Peaks 
for retention time of pure standards of DS and DDC-Cu measured by HPLC (DS: 
disulfiram, Cu: copper, DDC-Cu: diethyldithiocarbamic-copper complex, mAU: 
milliabsorbance unit). 
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Figure 6.14(B). Representative Calibration Curves of DS and DDC-Cu in cell 
medium. The figure displays the standard calibration curve of Area (mAU) of pure standards 
of DS and DDC-Cu measured by HPLC (DS: disulfiram, DDC-Cu: diethyldithiocarbamic-
copper complex, mAU: milliabsorbance unit). 
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Figure 6.15 Representative HPLC profile Plots of DS/Cu and DDC-Cu. DS/Cu and 
DDC-DC detected from cell lysate of MCF7 cell line. The graph (median ± interquartile 
range, n=6) show the HPLC profiles of DS and DDC-Cu in the time-dependent trend of DDC-Cu 
in the cell lysate. DS plus Cu was converted to DDC-Cu in cell lysate in a time dependent trend 
and DDC-Cu complex in cell lysate steadily increased. 
   
 
 
 
 
 
 
 
 
 
 
Figure 6.16. Represenatative Plots on Time dependent trend of DS-Cu and DDC-
Cu in culture medium. The graph (median ± interquartile range, n=6) shows the HPLC 
profiles of DS and DDC-Cu in the time-dependent trend of DDC-Cu in the culture medium. 
In cell culture DS rapidly degraded forming DDC-Cu complex (DS: disulfiram, Cu: copper, 
DDC-Cu: diethyldithiocarbamic-copper complex).  
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6.5. Discussion 
Chemotherapy the use of cytotoxic drugs is one of the standard methods of 
treatment for many cancers. Chemotherapy induces cell death in tumours 
reducing the tumour bulk however many patients experience tumour recurrence 
and ultimately death. Resistance to these therapeutic drugs remains a major 
hurdle in the treatment and management of BC. In this study, two resistant cell 
lines MDA-MB-231GEM100nM and T47DDox100nM were characterized for better 
understanding on the mechanisms of chemoresistance involved in resistance to 
dFdC and Dox respectively.  
In this study, in vitro cytotoxicity assay showed that MDA-MB-231GEM100nM cell 
lines were significantly resistant to dFdC-induced cytotoxicity compared to the 
sensitive parental MDA-MB 231 cell line. The resistant cell line was also cross 
resistant to four other conventional anticancer drugs (CDDP, VCR, PTX, Dox) all 
with different mechanism of action (Figure 6.2 A and B), indicative that acquired 
resistance to dFdC can induce pan-resistance to a range of anticancer drugs 
which is in agreement with the report by Faneyte et al., (2001) which 
demonstrated that BC cells initially responsive to anticancer drugs frequently 
relapsed and acquired resistance to a broad spectrum of drugs. 
Previous results show that CSCs play vital roles in the induction of 
chemoresistance in BC cells. To further understand the mechanism of resistance 
of dFdC, flow cytometry assay was performed in the MDA-MB 231 parental cell 
and MDA-MB 231GEM100nM cell line. The resistant cell line MDA-MB 231GEM100nM 
had higher expression of CSC markers suggestive that these cells had a stem-
like phenotype which may be the cause for the chemoresistance.  
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Dox an anthracycline antibiotic is considered to be one of the most effective agent 
in the treatment of BC, however resistance to Dox leads to unsuccessful outcome 
in many patient. MTT cytotoxicity analysis showed that the T47DDox100nM resistant 
cells were also found to be resistance to Dox and other conventional anticancer 
drugs. Similar to the findings in dFdC resistant cells, the Dox resistant cells also 
displayed CSCs like phenotype as stem cell markers ALDH, CD44+/CD24-, CD 
133 and embryonic markers (Nanog, Sox2 and Oct4) were all significantly 
increased in T47DDox100nM cells compared to the parental T47D wild type cell. 
Further confirming the involvement of stem cells in drug resistance.  
Another mechanism of resistance in cancer cell is overexpression of MDR related 
ABC transporters which increase drug efflux from cells. Dox resistance is 
predominantly due to the expression of P-gp (Broxterman et al., 1995). P-gp a 
multidrug efflux pump responsible for drug resistant in a number of cancer 
cancers was also slightly upregulated in the T47D Dox100nM resistant cell line but 
was not detected in MDA-MB-231GEM100nM cells, suggesting that P-gp could be 
responsible for the resistance in Dox resistant cells but was not the case for the 
dFdC resistant cells. 
Several studies have shown that DS induced apoptosis in a number of cell lines 
(Cen et al., 2002; Wang et al., 2003; Brar et al., 2004), others reveal that it has 
antiangiogenic effects on cancer cell (Shain et al., 2003), inhibits DNA 
topoisomerase (Yakisich et al., 2001)  and inhibits NFκB activity.  Cancer cells 
due to their rapid proliferation and metabolic rate possess higher ROS (a group 
of oxygen-containing free radicals with high reactive chemical properties) than 
normal cells but are quite tolerable to this increase in ROS because of their high 
antioxidant capability (Gupte and Mumper, 2009; Sporn and Liby, 2012). Further 
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increases in ROS exposure by ROS-generating agent can overwhelm and 
exhaust this cellular antioxidant capacity protecting cancer cells thus inducing 
apoptosis and ultimately death. Several studies have illustrated that DS facilitates 
the intracellular uptake of Cu in cancer cells and potentiate the cytotoxicity of 
several anticancer drugs in drug resistant and sensitive breast, colon and 
leukaemia cell lines (Wang et al., 2003; Guo et al., 2010; Liu et al., 2014).  
The reaction between DS and Cu is a strong ROS inducer (Nobel et al., 1995). 
According to the report by Conticello et al., (1995), DS in association with heavy 
metal can induce ROS meditated death in cells. Data from my MTT analysis show 
that DS/Cu and DDC-Cu were both significantly cytotoxic to BC cell lines (Figure 
6.11A). I demonstrated that the cytotoxicity of DS may occurs in two phase, firstly 
an instant and short term action (Figure 6.13) in which higher ROS was generated 
from the reaction between DS/Cu. This was further confirmed by MTT results 
analysis in which instantaneous cell death was observed in cells after 30 minutes 
treatment with DS/Cu reaction, further killing also observed but levelled off after 
180 minutes. No significant ROS was detected in DDC-Cu and DS only 
containing mediums, indicative that the cytotoxic effect of DDC-Cu was not 
mediated through ROS. DS can also exert a delayed toxic effect by its end 
product DDC-Cu with a higher cytotoxic effect.  
After absorption of the parent drug DS or its Cu-complex DDC-Cu across the GIT 
mucosa into the blood stream, DS rapidly disappears below its limit of detection 
(Stromme, 1965; Cobby et al., 1977) being reduced to DDC by endogenous thiols 
and glutathione reductase in the erythrocytes. The metabolic stability of free 
DS/Cu and DDC-Cu was examined; my result illustrated that DS was highly 
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unstable in medium and cell lysate while DDC-Cu was detected in both medium 
and cell lysate extracts from DS/Cu containing medium with a steady increase in 
concentration. DS has a very short half-life in serum less than 2 minutes (data 
from chapter 7). Due to this very short half-life of DS in vivo sufficient ROS will 
not be generated if the oral version of DS and Cu is administered to patient 
separately limiting the efficacy of DS as a potential chemotherapeutics. To 
resolve this problem, we recently protected DS from degradation in the 
bloodstream by encapsulation of DS into nanoparticles. 
Conclusion 
These resistant cell lines could be useful model to investigate the mechanisms of 
resistance in BC cells. My data show that the resistant cells were highly resistant 
to a range of anticancer drugs suggestive that acquired resistance can induce 
pan-resistance in BC cells. The resistant cells had slow proliferation rate as 
shown in the growth curve displaying senescence. We believe that the induction 
of stem-like cell features (increased stem cell markers) in these cells together 
with the several antiapoptotic genes were responsible for drug resistance, 
therefore development of drugs that can target these CSCs would be beneficial. 
Cell death induced by DS/Cu may be biphasic via instant and delayed phases, 
with the instant killing caused the ROS generation from the reaction between DS 
and Cu and the delayed killing linked to the effects of DDC-Cu which interfere 
with molecular pathways within cancer cells inducing apoptosis. 
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Chapter Seven 
Encapsulation of DS in Polymeric micelles 
7.1. Introduction  
There is a growing interest in the use of nanotechnology in the prevention, 
diagnosis and treatment of disease. The use of nanocarriers for cancer treatment 
could be quite advantageous the reason being that the encapsulated anticancer 
drug is protected from unfavourable conditions which prevent rapid degradation, 
improve biodistribution and pharmacokinetics and ultimately improving the 
efficacy of the anticancer drugs. The abnormal vasculature and reduced 
lymphatic drainage of tumours results in an increase in selective targeting by 
nanocarriers which can penetrate the leaky blood vessels of cancer cells with 
high local concentration of the encapsulated anticancer drug (Upreti et. al., 2013). 
Nanocarriers used for delivery of chemotherapeutic agents include liposomes (Li 
et al., 2009), polymeric micelles (Kim et al., 2004) and PLGA (Torchilin, 2007). 
Liposomes have been used extensively in the clinic for drug delivery and their 
efficacy has been shown to reduce systematic effects and toxicity as well as 
attenuate drug clearance (Torchilin, 2005). The efficacy of DS encapsulated in 
liposome has been investigated by Prof. Wang Weiguang research group, 
although quite effective as a potential anticancer agent (Liu et al., 2014) 
liposomes are subjected to several limitation such as low encapsulation 
efficiency, poor storage stability, fast burst release of drugs in the presence of 
blood components and lack of tunable trigger for drug release (Mohanraj and 
Chen, 2006).  
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Polymeric micelles are nanoscopic drug carriers with a core/shell structure 
formed by amphiphilic block polymers. The application of micelles as drug 
delivery is due to this unique amphiphilic core-shell architecture in which the 
hydrophobic core serves as a reservoir for the encapsulation of hydrophobic 
drugs and the hydrophilic brush like shell structure protects the hydrophobic part 
from biological invasion and minimizes opsonin adsorption contributing to a 
longer blood circulation time and blood stability of micelles (Gabizon et al., 2003). 
Furthermore, the relatively small size polymeric micelles enables them evade 
scavenging by the mononuclear phagocytic system of the liver and bypass of 
filtration by the inter-endothelial cells of the spleen which increase the 
accumulation of micelles at tissue site with vascular abnormalities (Aliabadi, and 
Lavasanifar, 2006).  
The cytotoxicity of DS in complex with Cu has long been reported in a number of 
breast cancer cells lines (Chen et al., 2006; Yip et al., 2011), however the 
translation of DS into clinical cancer treatment is severely limited because the 
half-life of DS in the blood stream is very short approximately 4 minutes (Cobby 
et al., 1977; Johansson, 1992). The efficacy of liposomal DS has been 
investigated by Prof. Wang Weiguang research group in breast cancer models 
(Liu et al., 2014), although effective liposome was only able to extend the half-life 
of DS to about 30 minutes. 
7.1.2. Rationale and aims of this study 
The objective of this study is to develop a long circulating polymeric micelle 
encapsulated DS all aimed at improving the anticancer efficacy of DS. 
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7.2.  Experimental design 
Detailed information on materials, products, manufacturers and methodologies 
used for the entire study have been described in chapter 2. The following are 
specific experimental designs and methods used for this part of the study.  
7.2.1. Preparation and Characterization of Disulfiram loaded Polymeric 
Micelle 
DS loaded polymeric micelles (PMDS) were prepared and characterized (refer to 
Chapter 2, page 94 and 95).  
7.2.2. Cumulative release of Disulfiram and Measurement of the in vitro 
half-life of Disulfiram in Horse Serum  
Cumulative release profile of free disulfiram (DS) in PBS and in vitro half-life of 
free DS and disulfiram loaded polymeric micelles (PM-DS) in horse serum  were 
examined (refer Chapter 2, page 96).  
7.3. Results 
7.3.1. Physicochemical characterization of DS loaded PM nanoparticles 
Data from pilot study show that PMDS ratio influence encapsulation efficiency 
(EE), drug loading content (DLC) and nanoparticle size (Table 7.1). The PMDS 
ratio of 2:1 (w/w) gave optimum results and was used for further preparations. 
The stabilized micelles have an average size of about 200nm, narrow distribution 
and negative zeta potential values (Table 7.2).  
 
 
 
 
206 
 
Table 7.1: Influence of PMDS ratio on Encapsulation Efficiency and Drug 
Loading Content. 
     
Parameter   Formulation   
PM (mg) 100 100 100 100 
DS (mg) 10 30 50 70 
DLC(%) 4.21±0.34 6.42±1.22 10.69±2.15 7.87±1.49 
EE (%) 91.5±0.56 83.2±2.76 81.8±3.59 60.2±2.4 
Table 7.1 show the encapsulation efficiency (EE) and drug loading content (DLC) of 
different ratio of DS encapsulated in polymeric micelles. The 2:1 ratio was the optimum 
ratio used for preparation for PMDS formulations because of the high DLC and EE 
obtained (DS –disulfiram, PM – polymeric micelles). 
Table 7.2 Size, Polydisperity and Zeta Potential of PMDS 
PM-DS Aqueous dispersion Lyophilized sample 
Size (nm) 192 ± 8 223 ± 5 
Polydispersity 0.25 ±0.01 0.30 ±0.02 
Zeta potential (mV) -17.2 ± 1.2 -20.4 ± 1.6 
Table 7.2 show the size, polydisperity and zeta potential of dried and wet sample of 
PMDS. (DS –disulfiram, PM – polymeric micelles). The PMDS formulation were of 
uniform distribution and size. The negative zeta potential show the stability strength of 
PMDS. 
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Figure 7.1. Representative Scan Electron Microscopy (SEM) images of PMDS. SEM 
images show that the PMDS is spherical in shape and have uniform size distribution. 
The empty PM and DS loaded PM were similar in size distribution and uniformity (DS: 
disulfiram, PM: polymeric micelle).  
7.3.2.  In vitro half-life of Disulfiram in Horse Serum 
In vitro release profile of free DS and PMDS dispersed in horse serum showed 
that free DS was quickly degraded to undetectable levels within few minutes, 
while DS was slowly released from micelles with a half-life of approximately 3 
hours (Figure7.2 A and B). 
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Figure 7.2(A). Representative Plots of In vitro half-life of free DS and DS loaded PM 
in horse serum. The half-life of free DS and DS loaded micelles measured at interval 
time points using HPLC. Free DS was rapidly degraded in horse serum, while the release 
of DS from PM was slowly released with a half-life of over 3 hours (DS: disulfiram, PM: 
polymeric micelle)  
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Figure 7.2B. Representative Bar chart of half-life of free DS and DS loaded PM in 
horse serum. In vitro release experiment on horse serum shows that DS is slowly 
released from PM with significant longer half-life whereas free DS was rapidly degraded. 
(n= 4, median ± interquartile range). DS: disulfiram, PM: polymeric micelle. 
7.3.3.  In vitro release studies 
The cumulative release profile of DS from PM in PBS (containing 0.5% Tween 80 
(w/v) at pH 7.4 and 5 reveal that DS can be released from PM nanoparticle 
(Figure 7.3). The release was higher in acidic conditions suggesting that DS 
would be released from PM in higher amounts within the acidic tumour 
microenvironment compared to its release in the blood which is at physiological 
pH of 7.  
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Figure 7.3. Represenative Plots of In vitro cumulative release of DS from PM in 
PBS (containing 0.5% tween 80) at pH 5 and 7.4. DS can be released from PM in both 
acidic and alkaline conditions. Degradation of free DS occurred rapidly, while the release 
of DS from PM was sustained for over 25 hours. (DS –disulfiram, PM – polymeric 
micelles, PBS: phosphate buffer saline). 
7.3.4.  MTT cytotoxicity assay of PMDS in TNBC cell lines 
The cytotoxicity of free DS and PMDS were examined in BC cell lines cultured in 
in hypoxia, transfected cell lines (HIF 1α and HIF2α transfect cells), NFκBp65 
transfected cells and resistant cell lines. MTT assay showed that the in vitro 
cytotoxicity of PMDS supplemented with Cu (1µM) was comparable to that of free 
DS/Cu.  
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Figure 7.4(A). Representative Drug Concentration Response Curves of PMDS and 
Anticancer Drugs on cells in Hypoxic culture. Cell viability curve shows difference in 
dose response of Free DS, PM-DS and a first line anticancer drug (dFdC). Hypoxic cells 
resistant to dFdC were sensitive to DS plus Cu. DS induced cell death in the hypoxic 
cells which were resistant to dFdC. (Abbreviations: DS: disulfiram, PM: polymeric 
micelles, Gem100nM: Gemcitabine resistant cells, dFdC (gemcitabine)). 
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Fig 7.4(B). Representative Drug Concentration Response Curves of PMDS and 
Anticancer Drugs on cells in cells resistant cell lines. Cell viability curve shows 
difference in dose response of Free DS, PM-DS and first line anticancer drugs 
(gemcitabine and Dox). Resistant cell T47DDOX100nM and MDA-MB 231GEM100nM were 
sensitive to DS plus Cu. DS induced cell death in the resistant cell lines. (Abbreviations: 
DS: disulfiram, PM: polymeric micelles, Gem100nM: Gemcitabine resistant cells, 
Dox100nM: doxorubicin resistant cells, Dox: doxorubicin, dFdC: gemcitabine). 
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Table 7.3: IC50 value of Several Resistant BC Cell Lines to First line 
Anticancer drugs 
BC cell line/ 
IC50 
Free 
DS/Cu 
(nM) 
PMDS 
Cu 
(nM) 
CDDP 
(µM) 
Gem 
(nM)  
DOX 
(nM) 
Hypoxic BT 549 141.06 
(4.30) 
249.46 
(35.98) 
826.22 
(189.94) 
600.1 
(26.99) 
1276.54 
(157.01) 
Hypoxia MDA-MB 
231 
111.81 
(0.88) 
149.88 
(40.1) 
993.98 
(152.33) 
> 1000 2405.22 
(2.15.67) 
NFκB p65 
transfected cell 
91.89 
(7.85) 
100.22 
(9.12) 
535.47 
(52.9) 
940.22 
(160.76) 
> 2000 
HIF 1α transfected 
cell 
110.43 
(7.85) 
120.22 
(9.12) 
> 900 > 500 > 1000 
HIF 2α transfected 
cell 
105.19 
(5.47) 
124.77 
(10.99) 
> 900 >500 >1000 
T47DDox 100nM 102.19 
(11.12) 
109.19 
(8.87) 
> 900 771  
(38.81) 
>1000 
MDA-MB 231Gem 
100nM 
102.20 
(15.43) 
140.86 
(9.21) 
> 900 300 
(5.67) 
>1000 
 
Table 7.4 shows the (median ± interquartile range) of half maximum inhibitory 
concentration (IC50) values of cells treated with free DS/Cu, PMDS/Cu and three first line 
anti-breast cancer drugs (dFdC, Dox and CDDP). The resistant cells (hypoxic cells, 
NFκBp65, HIF 1α, HIF 2α, T47DDox 100nM and MDA-MB 231Gem 100nM) were resistant to 
conventional anticancer drugs (dFdC, Dox and CDDP).  Free DS and PMDS induced 
cell death in these resistant cells (Mann and Whitney U test ** p<0.05, n=9). (DS: 
disulfiram, PM: polymeric micelle, dFdC: gemcitabine, DOX: doxorubicin, PTX: 
paclitaxel, CDDP: cisplatin, IC50: half maximum inhibitory concentration). 
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7.4. Discussion 
Numerous anticancer drugs such as Doxorubicin, cisplatin and paclitaxel have 
been encapsulated in nanocarriers and were found to be more effective than the 
free drug (Torchilin, 2005; Zhang et al., 2005). Encapsulation of anticancer drugs 
in nanocarriers circumvents the problem of drug insolubility, increase precision of 
drugs on desired sites, protection against systemic adverse effects, control drug 
release and enhance transportation across barrier. Thereby increasing the 
efficacy, specificity and targeting ability of chemotherapeutic agents (Soppimath 
et al., 2000).  
Polymeric micelles are fast becoming powerful tools in nanomedicine for cancer 
therapeutics due to their small size, in vivo stability, ability to solubilize water 
insoluble anticancer drugs and prolonged blood circulation. Clinical trials with 
micellular formulations have demonstrated that they have numerous 
pharmacological advantages with reduced systemic toxicity and morbidity in 
patients compared to conventional drug formulation (Sutton et al., 2007; 
Matsumura and Kataoka, 2009). Due to their unique size range < 200nm, 
micelles are able to avoid renal clearance and uptake by the liver and spleen thus 
preferentially accumulating in solid tumour via enhanced permeation and 
retention effects (EPR) (Maeda et al., 2001; Torchilin, 2007). Compared with 
other nanocarriers, micelles are much easier to prepare and have a flexible 
structure for manipulation as drug delivery system (Moutinho et al., 2012).   
Liu et al., (2014) have recently investigated the efficacy of a liposomal 
encapsulated DS on cancer cells. Liposome increased the half-life of DS to 30 
minutes in blood, however liposome is subject to degradation in the bloodstream. 
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With these facts in mind, DS was encapsulated in polymeric micelles aimed at 
improving the in vivo efficiency of DS. Free DS is highly toxic to BC cells in vitro 
(Figure 7.5 A and B) having a biphasic cytotoxic effect on cancer cells, with rapid 
cell death caused by the generation of ROS by the interaction between DS and 
Cu and a delayed killing caused by a metabolite of DS DDC-Cu. However 
translation of DS into clinics is hampered due to its short half-life.  
DS was successfully encapsulated in PM with a high encapsulation efficiency of 
over 80% with relatively small size (200nm) and even distribution as shown from 
Scan Electron Microscopy images (Figure 7.3). Cumulative in vitro release study 
performed on PMDS show that DS can be released from PM in both acidic and 
alkaline conditions in a pH dependent manner with higher release occurring in 
acidic pH, indicative that my formulation PMDS can preferentially target tumour 
cells (acidic milieu). Studies with miniature pH electrodes show that the pH within 
tumours varies from those of normal tissues having substantially more acidic 
values (Kallinowski and Vaupel, 1989; Huber et al., 2010).  
The short half-life of free DS in blood stream is the major hindrance preventing 
its clinical translation as an anticancer agent (Johansson, 1992). The result 
shows that free DS was rapidly degraded in horse serum with a half-life of less 
than 2 minutes consistent with the previous report (Cobby et al., 1977). In 
contrast, the half-life of encapsulated DS in the PMDS formulation was markedly 
increased to over 3 hours (Figure 7.3 A and B) indicative that in the bloodstream 
DS can be slowly released from PM and in association with Cu induce cytotoxicity 
in cancer cells. 
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The cytotoxicity of PMDS was examined in several BC cells grown under hypoxia, 
resistant cells (MDA-MB-231GEM100nM and T47DDox100nM) and transfected cells 
(HIF1α, HIF2α and NFBp65 overexpressing cells). Results from MTT 
cytotoxicity assay have shown that cells grown under hypoxia are highly resistant 
to conventional anticancer drugs (CDDP, Dox, dFdC, PTX and VCR), similarly 
overexpression of both HIF 1α and HIF2α confer resistance to these transformed 
cells. NFBp65 activation in cells also induced drug resistance BC cells as shown 
from previous results. The in vitro cytotoxic effect of PMDS was comparable to 
that of the free DS (Table 7.3). The IC50s of PMDS and free DS were found to be 
very similar. DS alone, Cu alone and the empty PM did not induce cell death.  
Conclusion 
The clinical anticancer application of DS is severely limited due to the very short 
half-life as DS is very unstable in the bloodstream and rapidly degraded. 
Polymeric micelles hold great promise as drug delivery agents, DS was 
successfully encapsulated in micelle and this formulation protects DS from 
enzymatic degradation. This new formulation PMDS has a reasonable 
encapsulation efficiency, drug loading content, in vitro controlled release and half-
life. PMDS in combination with Cu was significantly toxic to BC cells. Therefore 
the use of nanotechnology may improve the efficacy of DS as an anticancer agent 
translating it into an effective BC therapeutics.  
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Chapter Eight 
8.1. General Discussion 
In this study, results from growth curve analysis showed that monolayer TNBC 
cells grown under hypoxia have slower rate of proliferation compared to those 
grown in normoxia, indicating that hypoxia can induce quiescence in cells. 
Furthermore data from MTT analysis also show that hypoxia induced resistance 
to anticancer drugs as cells grown under hypoxia were significantly resistant to 
cisplatin (CDDP), gemcitabine (dFdC), vincristine (VCR), doxorubicin (Dox) and 
paclitaxel (PTX) compared to cells cultured in normoxic conditions in which cell 
death was induced at a much lower concentration.  
Recent studies demonstrate that hypoxia induces expression of stem cell 
markers in cancer cells, decreases proliferation and such cells were highly 
resistant to conventional anticancer drugs (Bar et al., 2010; Kolenda et al., 2011). 
The identification of CSCs in BC (Al-Hajj et al., 2003) opened an interest in the 
relevance of CSCs in cancer biology. These cells are believed to reside in the 
hypoxic niche and are mostly in a hypoxic state. Several studies suggest that 
hypoxia may be responsible for the persistence and maintenance of CSCs in 
tumours involved in the promotion of therapeutic failure and tumour relapse 
(Rosen and Jordan, 2009; Lin and Yun, 2010). According to the report by Bao et 
al., (2012), hypoxia was a determinant of stemness in the stem cell niche and 
exposure of cells to hypoxia in vitro enhanced their tumourigenic potential in vivo. 
Hypoxia facilitate the emergence of malignant clones by maintaining cancer cells 
in their undifferentiated stem cell state, permitting self-renewal of cells and the 
accumulation of genetic and epigenetic changes resulting in a more aggressive 
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tumour. One aim of my study was to investigate the relevance of hypoxia in 
chemoresistance, monolayer of TNBC cells cultured in hypoxic condition were 
found to exhibit CSC-like characteristics with increase in CSC markers (ALDH 
and CD133) and embryonic markers (Nanog, Sox2, Oct4) compared to those 
grown in normoxia. These results suggest that hypoxia is able to induce these 
CSCs phenotype which may be responsible for the resistance to therapy.  
Hypoxia can induce stem cell characteristics, however the molecular 
mechanisms and pathways linking hypoxia and CSCs are not fully understood. 
The HIF (HIF1α and HIF2α) are the most prominent and best understood 
hypoxia-induced signalling pathways. Evidence from several reports 
demonstrated that HIF activation is associated with an undifferentiated 
phenotype in several cancers; in primary pancreatic carcinomas, nuclear 
accumulation of HIF1α protein was found mainly in poorly differentiated tumour 
cells (Couvelard et al., 2005). Similar observations were seen in neuroblastomas 
as elevated levels of HIF1α and HIF2α proteins were found in stem cell-like 
populations (Li et al., 2009; Pietras et al., 2009). Covetto et al., (2006) confirmed 
that Oct4, a stem cell transcription factor is a target for HIF2α and HIF2α activated 
Oct4 regulates self-renewal and differentiation in stem cells.  Flow cytometry data 
analysis from my study showed that both HIF1α and HIF2α overexpression 
induced higher expression of CSC marker (ALDH and CD133) compared to the 
mock cells suggesting that HIF protein may induce these stem-like characters in 
cells. Embryonic stem cell markers indicating pluripotent phenotype (Nanog, 
Oct4, Sox2) were also expressed in the HIF transfected cells. These results are 
consistent with other reports which showed that elevated levels of these stem cell 
markers occurs in many somatic carcinomas (Jones et al., 2004;Tai et al., 2005). 
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Cancer with stem cell-like features displays higher resistance than the bulk mass 
of differentiated cancer cells to radiotherapy and chemotherapy. These cells were 
also observed to be significantly resistant to anti-cancer drugs.  
Apart from the HIF activated pathways which play important cellular responses 
during hypoxia, other signalling pathways such as the NFB pathways are also 
activated during hypoxia. In this study, nuclear translocation of HIF1α, HIF2α and 
NFBp65 proteins were detected in hypoxic monolayer cell indicative that NFB 
is activated in hypoxic cells. Evidence has revealed that NFB play pivotal roles 
in maintaining CSCs and chemoresistance in cancer cells (Liu et al., 2010; 
Hinohara et al., 2012; Myant et al., 2013). To evaluate the role of NFB in 
maintenance of stemness and chemosensitivity, MDA-MB 231 cells were 
transfected with NFBp65 subunits. High p65 protein level and transcriptional 
activities were detected in the transformed clones. These transformed cells have 
significantly higher population of CSCs (ALDH+ and CD133) and embryonic stem 
cell (Nanog, Oct4 and Sox2). In comparison to the mock-transfected cells, the 
cells overexpressing p65 were highly resistant to 5 first line anticancer drugs 
tested (CDDP, dFdC, VCR, Dox and PTX). Data from my result is in line with 
reports by Liu et. al., (2014), which showed that NFB plays a key role in hypoxia-
induced CSCs and chemoresistance. The molecular mechanisms of how HIF 
pathway regulates NFB pathway remains unclear, HIF pathway activates NFB 
pathway mainly through the regulation of IK signalling-mediated regulation of 
canonical NFB signalling (Cummins et al., 2006) as HIF1α protein have B site 
in its promoter region.  Several reports have shown that there is a cross-talk 
between HIF and NFB pathways, HIF2α subunits interacts with NFB 
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through IKγ nuclear factor kappa B essential modulator (NEMO) and NEMO is 
reported to shuttle between the nucleus and cytoplasm and compete with IKKα 
and p65 (Bracken et al., 2005). IB kinase B, an upstream activator of NFB has 
been identified as a substrate of prolyl-hydroxylases and its activity was found to 
reduce upon hydroxylation (Cummins et al., 2006). Inhibition of NFB was found 
to reduce the induction of HIF target cells (Fitzpatrick et al., 2011) and the 
expression of HIF was directly regulated by NFB (Bonello et al., 2007, van Uden 
et al., 2008). Data from this study further confirm the existence of this cross-talk 
between NFB and HIF pathways as the HIF transfected cells overexpressed 
NFB and the NFB transfected clones overexpressed HIF1α and HIF2α 
proteins.  Interactions of HIF and NFB pathways contribute to BC metastasis 
through the induction of EMT together with migration through p65-lysine 
acetylation and HDAC dependent epigenetic mechanism leading to the up-
regulation NFB and HIF (Bendinelli et al., 2009). 
Approximately 90% of BC deaths are caused by local invasion and distant 
metastasis of tumours. During epithelial to mesenchymal transition (EMT) 
transformed epithelial cells acquire mesenchymal-like phenotype which enables 
tumour cells to disseminate from the primary tumour and penetrate extracellular 
matrix into the blood and lymphatic vessels to a secondary organ. Expression of 
classic EMT markers (Vimentin, N-cadherin, Twist and snail) is a feature of TNBC 
and is associated with evasion of apoptosis, senescence and resistance to 
chemotherapy (Polyak and Weinberg, 2009; Nieto, 2011). The connection 
between EMT and CSCs was demonstrated by Hollier et al., (2009), they 
observed that EMT facilitated the generation of cancer cells with mesenchymal 
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traits as well as self-renewal of cells required for initiating secondary tumours. In 
this study, hypoxia induced EMT phenotype in BC cells as cells grown under 
hypoxia exhibited higher invasive and migratory potentials. Similarly, NFBp65 
and HIF transfected cells also showed higher migratory and invasive potentials. 
Interestingly these cells were also found to exhibit CSC-like cell features 
suggesting that there may be a link between EMT and stemness of cells. 
Primary and acquired resistance represents a major challenge for the 
effectiveness of chemotherapeutic agents in Breast cancer (BC). Breast cancer 
becomes refractory to cytotoxic drugs and becomes typically incurable resulting 
in tumour relapse (Harris et al., 2000).  Cancer cells with reduced sensitivity to 
drugs after continuous exposure to anticancer drugs become cross resistant to 
other anticancer with different mechanism of action. In this study, two resistant 
cells lines MDA-MB-231GEM100nM and T47DDox100nM were characterized. These 
resistant cells were significantly resistant to anticancer drugs which is in 
agreement with the reports from others studies (Faneyte et al., 2001; 
AbuHammad and Zihlif, 2013). The resistant cell lines were also found to exhibit 
some CSC-like characteristics having higher expression of CSC markers 
suggestive that CSCs play important roles in the biology of BC cells. 
Conventional therapeutic agents eradicate cells of the tumour bulk but spare the 
CSC sub-population. These surviving cells have stem cell-like phenotype and are 
proposed to be the cause for tumour recurrence and chemoresistance. Therefore 
targeting these CSCs may improve the long-term outcome of TNBC patients. The 
demand for an effective anticancer agent against BC especially in patients with 
TNBC is of great importance. Development of new therapies for cancer involves 
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a slow and costly process thus repurposing of old drugs would greatly reduce the 
time and cost for development of new drugs which benefits both the patient and 
the pharmaceutical industries as safety and pharmacokinetic profiles are ready 
well established. DS an anti-alcoholism drug used for the management and 
treatment of alcoholism have been shown to have cytotoxic effects against cancer 
cells (Wickstrom et al., 2007; Cvek, 2011). The metabolism and clinical 
pharmacology of DS is well understood and is shown to have little or no cytotoxic 
effects on normal cell, thus DS can be repurposed as a potential anticancer 
agents. In vitro experiments show that DS is highly toxic to BC cells however its 
in vivo activity is sum worth limited because of its relatively short half-life in the 
blood stream been rapidly degraded and thus cancer cells are not sufficiently 
exposed to the cytotoxic effect of DS. The half-life of DS according to the reports 
by Cobby et al., (1977) was only about 4 minutes, in vitro half-life  experiments in 
horse serum showed a shorter half-life less than 2 minutes (Figure 7.2 A and B). 
The anticancer activity of DS requires the unmodified DS, therefore to translate 
DS into cancer therapeutics an efficacious delivery system to protect DS in the 
blood stream and transport it into cancer cells is necessary.  
Nanotechnology the use of nanocarriers to encapsulate active ingredients may 
be a solution to this hurdle. Nanoparticles (NP) have distinctive advantages in 
delivering anticancer drugs to tumour sites by changing the pharmacokinetics 
and biodistribution of drugs which improves the efficacy and reduces systematic 
adverse effects. It was hypothesized that encapsulation of DS in NP will improve 
its anticancer efficacy and aid in its translation in clinics. To this effect I 
encapsulated DS in polymeric micelles. Polymeric micelles are FDA approved 
excipients for internal use and is considered as one of the most suitable 
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biocompatible polymer carrier for in vivo studies (Sahoo et al., 2007). The 
advantages of micelles as drug carriers are their relative small size, high 
structural stability and low toxicity. I successfully encapsulated DS in polymeric 
micelles. This formulation PMDS was able to increase the half-life of DS to over 
3 hours in horse serum and a sustained release was obtained.  
The cytotoxic effects of DS are dependent on copper (Cu) as shown from my 
results (Chapter 6, Figure 6.12). The unique electronic structure of Cu enables it 
to act as cofactors in a number of redox reactions of enzymes required for normal 
growth and development (Tapiero et al., 2003). Tumour cells accumulate Cu to 
sustain their higher metabolic demand with resultant increase in Cu levels 
compared to non-malignant cells (Gupte and Mumper, 2009). DS is a chelator of 
divalent metallic ions such as Cu and Zn and enables the transportation of Cu 
into cells bypassing the CTr1 regulator inducing a phenomenon known as Cu 
overload which depletes the glutathione antioxidant defences systems of tumour 
cells inducing cell death. In this study, Cu alone did not induce cell death in cancer 
cells. Results from my study indicate the cytotoxicity of Cu on cancer cells occurs 
in two phases. Firstly an instant and short-term action induced by the reaction 
between DS and Cu generating of ROS as shown in Chapter 6 (Figure 6.12 and 
6.13). Secondly, delayed toxic effects induced by DDC-Cu an end product in DS 
metabolism (Figure 6.13). Data from my results reveal that the cytotoxicity of 
DDC-Cu was even higher than that occurring with ROS generation by DS and Cu 
alone (Figure 6.11). 
The most important and novel findings in my study are that DS was successfully 
encapsulated in polymeric micelles, this encapsulated DS is protected from rapid 
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degradation and can target CSCs which are the main reason for 
chemotherapeutic failure and cancer relapse. I was also able to show that the 
cytotoxic effect of DS occurs is in two phases, a rapid ROS induced cell death 
followed by a delayed and more effective cytotoxic effect induced by DDC-Cu. 
8.2. Conclusion 
This study has shown that hypoxia plays fundamental role in Breast Cancer 
biology by inducing stem-like characters in TNBC. It provides a suitable 
environment ‘stem cell niche’ for the maintenance of these CSCs which are 
responsible for therapeutic failure and tumour recurrence. To maintain cellular 
homeostasis during hypoxic insult several signalling pathway such as the HIF 
and NFB pathway are activated during hypoxia, these transcriptional factors 
were also shown to induce stem-like traits and chemoresistance in BC. 
Chemotherapy still remains the gold standard treatment of TNBC as patients with 
this form of BC have the worst prognosis and outcome due to the lack of 
targetable receptors. This study have shown that these CSCs are the key factor 
responsible for chemoresistance as hypoxic cells as well as transfected cells 
were all shown to have high expression of CSC markers. Therefore targeting 
these CSC could improve the prognosis of patients with TNBC. DS shows strong 
anticancer activity in vitro, DS in association with Cu is a strong ROS inducer, it 
is also a potent inhibitor of NFB which is the principle antiapoptotic transcription 
factor activated in many types of tumours. More importantly DS is an inhibitor of 
ALDH a functional marker of CSCs. Therefore combination of DS with Cu will 
induce cell death preferentially in tumour cells while sparing normal tissues, 
because cancer cell with their high metabolic rate already have high Cu, and 
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increase in Cu load will induce more ROS which can be counteracted by the high 
antioxidant capacity of cancer cells. Fortunately DS as an ALDH inhibitor can 
exhaust the antioxidants within cancer cells thus making them vulnerable to ROS 
induced cell death.  DS though effective as an anticancer agent in vitro is highly 
unstable and rapidly degraded in the blood stream. To improve the efficacy of DS 
as a BC therapeutic in vivo. DS was successful encapsulated in polymeric 
micelles and our formulation enhanced the stability and half-life of DS in serum. 
My results show that PMDS was able to induce cell death in hypoxic and 
overexpressing cells, thus reversing the chemoresistance induced the CSCs.  
8.2.3. Recommendation and future work 
As proven in this study, DS in combination with Cu have potent anticancer effects 
in BC cells. The targeted delivery of DS in nanoparticles needs further 
development to speed up the emergence of DS as a chemotherapeutics in clinical 
use for the treatment of TNBC patients.  
Having developed this formulation polymeric micelle enabled disulfiram (PMDS), 
the next phase of this study is to further increase the pharmacodynamic 
properties of this formulation by modifying the ratio of hydrophilic/hydrophobic 
block, improving the stability and drug loading content.  
DS clearly has been shown to be very effective in vitro as an anticancer agent, 
however behaviour of treatment systems differs in in vitro and in vivo studies. 
Therefore, in vivo studies would be carried out for further evaluation of the effects 
of PMDS in tumour mice models. Firstly, tissue distribution studies needs to be 
done in mice to examine the stability of PMDS in vivo. The anticancer efficacy of 
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PMDS in vivo needs to be studied. Xenograft experiments would be carried out 
in nude immunedeficient mice. Resistant cells (5×105) would be subcutaneously 
injected at one front flank of the mice. When the tumour volume (V) reaches 
~200mm3, the tumour bearing mice would be randomly subdivided into 6 groups 
(8 mice/group): control; copper gluconate (CuGlu), empty PMDS i.v.; PMDS 
2.5mg/kg i.v. + CuGlu 6mg/kg; PMDS 5mg/kg i.v. + CuGlu 6mg/kg.; PMDS 
10mg/kg i.v. + CuGlu 6mg/kg. The animals would then be for treated 3 times/week 
for successive 3 weeks. The xenograft size would be monitored weekly and 
tumour volume calculated. The animals would be sacrificed after 3 weeks. The 
tumours removed, photographed and subjected to further analysis. 
Modification of the formulation polymeric enabled disulfiram (PMDS) would also 
be done to improve the drug loading content and to test their effects on other 
cancers especially human brain cancers. Polymeric micelles may be an effective 
drug carrier due to its small size and can target cancer cells. This formulation 
PMDS may be a successful therapy against chemoresistant GBM stem cells 
opening an area for novel effective therapy in brain tumours. 
Flow cytometry results would also be reanalysed to show the cell count versus 
the forward light scatter height showing the degree of increase or decrease in 
fluorescence intensities. Images from western blot, invasive and migratory 
assays would also be quantified using image J software.   
The half maximum inhibitory concentration (IC50) for some of the resistant cells 
were not obtained because the highest concentrations of drug tested did not 
induce cell death in these cells. Higher concentrations of anticancer drugs would 
be used to treat these cells.  
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